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Abstract 
 
Introduction 
Status epilepticus (SE) has confounded clinicians for hundreds of years and remains the 
most common neurological emergency affecting children in emergency departments. 
Remarkably, management has changed little over the last century, and very little data are 
available to guide treatment.  Potential new therapies are often adopted into clinical care 
without robust evidence, however clinicians seeking to evaluate the same therapies in 
methodologically sound studies face high levels of scrutiny as well as regulatory and ethical 
obstacles.  This is partly because of the difficulty of conducting research in this setting, with 
informed consent issues in time-critical research being a major barrier.  This leads to the 
ethical paradox of using untested therapies in critically ill children without informed consent, 
but the regulatory and ethical barriers existing in researching these same therapies.  
 
Objectives 
The objectives of this thesis are to explore the paradox of informed consent issues in 
paediatric SE research. The specific objectives of the thesis are: to 1) Identify gaps and 
opportunities for research from a review of the existing literature on paediatric SE; 2) Inform 
the future research agenda in the management of paediatric SE by achieving consensus on 
research priorities among experts in managing this condition, consisting of paediatric 
neurologists and emergency physicians who treat children; 3) Determine if research 
priorities identified by experts align with priorities identified by consumers (parents of 
children with SE); 4) Determine what is known about the public’s perceptions and attitudes 
towards research in a paediatric emergency setting without prospective informed consent; 5) 
Explore attitudes of the general public to research in emergency settings without prior 
consent; 6) Explore parental attitudes to a deferred consent process in the emergency 
department (ED) setting, including the management of SE.   
 
Methods 
In this thesis multiple methodologies are used to achieve the stated objectives.  The thesis 
consists of two separate, but interconnected streams. Stream one explores the existing 
knowledge of paediatric SE, identifies research priorities and explores the feasibility of 
addressing these knowledge gaps.  Stream two explores the barriers to research in 
paediatric SE, namely issues of consent in time-critical research. At the confluence of these 
two streams is the discussion highlighting a roadmap for addressing the various knowledge 
gaps in paediatric SE, for the improved care of this condition.  Methodologies used in the 
thesis include literature reviews (narrative, systematic, perspective), Delphi consensus 
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technique, a cross-sectional population-based survey (with qualitative and quantitative 
components), and a qualitative study (semi-structured interviews resulting in thematic 
analysis).  
 
Results 
Chapters 2 and 3 of the thesis comprise reviews of the existing literature on the 
epidemiology, investigation, management of paediatric SE as well as specifically exploring 
pre-hospital aspects of paediatric SE care.  A historical lack of consistency with definitions 
and classification has been a limitation of existing comparative studies. Consistency in 
definitions moving forward is essential to future research efforts.  The review found an 
incomplete understanding of the epidemiology of paediatric SE, with a dearth of local data. 
The fundamental question of whether seizure duration is an independent predictor of poor 
outcome, when confounding factors such as age and aetiology are controlled for, remains 
unanswered. Optimal investigation and management of paediatric SE are based on low level 
evidence. Observational data suggest that treatment is often delayed, but beyond first line 
care, management guidelines are based on expert opinion only.  Definitive evidence on the 
pre-hospital management of paediatric SE is lacking, and the review highlighted substantial 
variation in local protocols around Australia and New Zealand.  
 
Chapter 4 reports the results of a Delphi study to achieve consensus on research priorities in 
paediatric SE among experts (neurologists and emergency physicians). Nine priority 
research questions are identified, consisting of second line management including 
levetiracetam (efficacy, dose and timing), use of third line agents, induction of anaesthesia 
(timing and best agent), management of focal SE, and indicators of “subtle SE”.  Some of 
these priorities are unlikely to be addressed in clinical trials with traditional concepts of 
informed consent, and other methods will be required such as alternative study designs and 
alternative approaches to consent.   
 
Chapter 5 outlines a protocol for a clinical trial of second line management of paediatric SE.  
This trial directly addresses two of the nine priorities identified by the Delphi process.  The 
trial epitomises the paradox of informed consent in paediatric SE research as the study 
intervention (levetiracetam) is being rapidly adopted into clinical care and protocols without 
any robust evidence of efficacy.  The study would not be possible with traditional models of 
informed consent applied and uses a controversial deferred consent process.  
 
Chapter 6 presents the historical context of informed consent in emergency research, 
highlighting important principles of the Declaration of Helsinki and the historically inconstant 
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approach taken in emergency medicine as exemplified in the cardiac mega trials.  Chapter 7 
presents the results of a systematic review of empirical evidence on informed consent issues 
specific to paediatric emergency medicine.  Thirteen studies included in the review found 
that the public are generally supportive of alternatives to prospective informed consent, with 
important considerations being the level of risk involved, and informing the parents about the 
research involvement as soon as possible.  Other major themes explored in the review are 
capacity of parents to provide informed consent, feasibility of informed consent and modified 
consent processes. There were no Australian studies identified in the review.   
 
Chapter 8 presents results of a national, cross-sectional, population-based survey on 
attitudes about research without prospective informed consent. This is the first study of its 
kind in an Australian population, and the results indicate that the public are generally 
supportive of the concept. Level of risk and the time-critical nature of the intervention are 
again identified as important considerations.  
 
Chapter 9 reports the results of a novel Australian study on the attitudes and experiences of 
parents attending the ED with their children on the concepts of deferred or retrospective 
consent.  The qualitative study of 39 parents finds universal support for emergency research 
and an acknowledgment of the limitations of traditional consent under these circumstances. 
Participants are generally supportive of deferred consent. Health and research literacy is 
identified as an important issue, potentially leading to some confusion with difficult concepts.   
 
Discussion 
In the modern era of evidence-based medicine, it is not satisfactory for the management of 
potentially life-threatening conditions such as paediatric SE to be based on inadequate 
evidence. It should not be acceptable to use untested or experimental therapies for clinical 
care without consent, when research and evaluation of the same therapies is burdened by 
regulations and administrative and ethical requirements.  The literature reviews and Delphi 
study presented in this thesis outline many knowledge gaps in the management of paediatric 
SE and opportunities for further research. Several of the research priorities identified are 
unlikely to be addressed in adequately powered, traditional randomised controlled trials.  
Alternative study designs and alternatives to traditional concepts of informed consent will be 
required. Recent innovations and advances in electronic health information systems and 
electronic medical records may represent an elegant solution, and present an opportunity to 
embed data collection on infrequent presentations and conditions into routine practice. The 
added possibility exists of embedding treatment allocation into such systems where true 
equipoise exists, resulting in the necessary robust evidence to drive practice change. 
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Importantly, this could be achieved without exposing patients to any additional risk which 
represents a recurrent theme of concern in this thesis surrounding research without explicit 
prospective consent. This research demonstrates that the public recognise the requirement 
for research without prospective informed consent, with the degree of risk being a key 
consideration.  Policy makers and guidelines need to explicitly address this type of research 
in regulatory documents, to ensure such research can continue, and the trust of the public 
and community in maintained.  In Australia, guideline documents do not explicitly define 
requirements for emergency and time-critical research and specific requirements vary by 
jurisdictions due to local legal requirements.  This needs to be addressed as a priority, to 
ensure that important research into time-critical and life-threatening conditions such as 
paediatric SE can continue.  The involvement of consumers in the process, such as the data 
presented in this thesis, is essential in maintain the trust of the community.  
 
Conclusion 
Paediatric SE is an important cause of morbidity and mortality in children.  Care often 
involves unproven therapies that are introduced into standard care and guidelines.  This 
generally occurs with community acceptance and legal protections for time-critical 
interventions. Paradoxically, quality research is often thwarted due in part to ethical 
complexities, including the inability to obtain prospective informed consent in time-critical 
situations.  In situations where there is clinical equipoise, and clear evidence does not exist, 
a compelling ethical argument can be made that similar standards should be applied to 
research, especially when considering the additional protections offered under the oversight 
of a high-quality randomised controlled trial. The data presented in this thesis indicates that 
the general public do not make a distinction between clinical care and research, providing 
that there is no exposure to additional risk. This research represents an important first step 
in the design of a program of research on paediatric SE to address these important clinical 
issues, in an ethical manner that will be acceptable to the community. A combination of real 
time registry, learning health systems, and innovative clinical trial designs is required, with 
consent requirements that are appropriate for the level of risk to participants, and congruent 
with community expectations.   
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Chapter 1. Introduction 
 
“Once a new drug or a new preparation is on the market a paradoxical situation 
arises. If I decide to treat my patients with the new drug, whether because a 
colleague thinks it is good, or because the advertisements are persuasive, or 
because I like to be regarded as avant-guard, I am perfectly free to do so. But if I 
decide that it would be more satisfactory to do a controlled study, either to compare 
the new drug with the old or to compare the new drug with no drug at all, it 
becomes research and I should seek the approval of my colleagues on the 
research ethics sub-committee.  I need permission to give a new drug to half my 
patients but not to give it to them all.” 
(R.W. Smithells, Dept of Paediatrics, University of Leeds, 1975) 
 
1.1 Overview 
The above quote from Smithells illustrates the paradox of informed consent in paediatric 
emergency research that was present in 1975.1  This paradox is no different today, and 
paediatric status epilepticus (SE) exemplifies the current situation, which is the basis of this 
thesis.  In this introduction, the history of research in and the understanding of SE will be 
briefly outlined, including contemporary definitions and classifications.  I will detail the 
barriers to research in the field, including the requirement for informed consent in time-
critical research.  This introduction will set the stage for the body of work that follows. Finally, 
I will outline the aims and objectives of the research, which is ultimately to improve the 
management of paediatric SE in Australia and New Zealand.  
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1.2 Case study 
 
  
The ambulance service notifies the Emergency Department (ED) of the imminent 
arrival of a previously well, three-year-old girl who is currently having a generalised 
seizure.  The seizure started 25 minutes previously and has been resistant to first 
line management by paramedics.  Prior to arrival in four minutes, the ED has time 
to make some preparations.  Team roles are allocated to staff, medical dosage 
calculations are made based on the estimated weight, and equipment is prepared 
for emergency treatment.  The paediatric intensive care unit (PICU) team is also in 
attendance, as they were in the department for another case.   
 
On arrival, the ambulance hands over that the child was home from childcare today 
due to a mild upper respiratory tract infection (URTI).  She has no past medical 
history and is not taking any regular medications. Throughout the day she was 
resting on the couch and slightly lethargic. Twenty-nine minutes prior her eyes were 
observed to roll back, she became stiff, unresponsive, with symmetrical tonic-clonic 
seizure activity in all limbs.  This seizure activity was still present when the 
ambulance arrived 11 minutes after it had started and has persisted (total time 29 
minutes) despite one dose of midazolam intramuscularly (IM) and one dose 
intravenously (IV) as per ambulance protocols.  A brief focused examination found 
airway, breathing and circulation to be intact, but confirms ongoing seizure activity 
with head and eyes deviated to the left, and fine tonic-clonic movements of both 
arms and legs.   
 
The girl’s mother is in attendance with the ambulance crew.  An oxygen mask 
covers the girls face.  You instruct the nurses to prepare an infusion of phenytoin, 
as a second line agent, as benzodiazepines have been ineffective.  The PICU 
consultant suggests perhaps levetiracetam to be more effective, and promptly 
explains to the mother that a new medication, “Keppra” can be given through a drip 
to help stop seizures such as this.  He continues, that even though the drug is not 
licenced for this role, he believes it is the best course of action.  The mother nods 
and agrees that whatever will make her daughter better is fine.   
 
The levetiracetam is administered, and preparations are made to intubate and 
ventilate the child. Ketamine is used as an induction agent, and seizures appear to 
finish as this agent is given.  The endotracheal tube is placed easily, and the child 
is transferred to the PICU.  Further evaluation of the child does not determine a 
specific cause for the seizure.  Her course in PICU is uneventful and she makes an 
excellent recovery.  
 
 24 
1.3 Status epilepticus 
SE has confounded clinicians for hundreds of years.  Paediatric convulsive SE remains the 
most common neurological emergency causing children to present to hospital EDs today.  
Early descriptions of SE decry the lack of data, lack of consensus definitions, incomplete 
understanding of pathophysiology, and lack of available effective therapies.2,3  These 
themes are arguably equally evident in the contemporary medical literature on SE.   
 
1.4 An historical perspective on status epilepticus and its management 
Descriptions of convulsive SE have appeared in the medical literature for over a century.2-4 
Consistency in definitions has proven problematic for researching SE.  In 1904 Clarke and 
Prout wrote “We must admit that it is with status as with many other phases of epilepsy; it 
has no exact definition”.2(p295) The evolutions of SE definitions will be described in more detail 
in section 1.5.  
 
While early observational reports provide some insights to the natural history of the 
condition, outcomes, pathological observations of fatal cases, and therapeutics of the time, 
the “great rarity of the condition”2 has always been and remains a barrier to quality data.  
The systemic complications of SE were aptly described based on the astute descriptions in 
early reports: “the state is almost always sooner or later accompanied by a marked rise of 
temperature, pulse and respiratory frequency, which is indicative of exhaustion”.2(p305)  Early 
authors also recognized the higher potential for “grand mal” epilepsy to result in more 
significant consequences, and interestingly a description of decreasing motor symptoms with 
ongoing seizure duration: “at last the convulsions lessen in frequency and the stuporous 
stage is ushered in with the coma or collapse” then “until death or convalescence, slight 
convulsive tremors may occasionally occur”.2(p304)  However, even with limited therapeutic 
options, the prognosis was not uniformly poor.  Survival in these early reported series was 
30-50%, and cases of survival were described after more than nine to 12 days of ongoing 
SE.2 Contemporary incidence, aetiology and outcome will be detailed in Chapter 2. 
 
While some aspects of management have changed significantly, others have remained 
remarkably constant.  In 1914 Shanahan wrote of the management of SE: “the most urgently 
indicated procedure has been, in my experience, a free irrigation of the lower bowel”.3(p287) 
The basis was seemingly to rid the entire gastrointestinal tract of “poisonous substances” 
thought to be causative.  However, Shanahan went on to recommend sedation: “choral 
hydrate or amylene hydrate should be given by enema in a dosage of sufficient size to 
quickly bring about sedation of the patient”.3(p288) While guidelines today emphasize 
management of airway, breathing and circulation in preference to urgent bowel irrigation, the 
 25 
importance of sedation is identified as important and continues to be a mainstay of therapy 
to this time.  
 
1.4.1 Early drug treatments  
Pharmacological agents have been used for treating SE for over 150 years.  Bromides were 
the first effective antiepileptic drugs described for convulsive SE, introduced in the 1860s.4  
Since the early 1900s the importance of sedation has also been recognized, when inhalation 
of chloroform or concoctions of chloral hydrate, morphine, bromide and opium were 
introduced as treatments.2,5 Barbiturates appeared on the scene in the 1920’s and 30’s, 
followed by phenytoin and paraldehyde in the 1950’s.4  Widespread administration of 
benzodiazepines diazepam and clonazepam was introduced after reports of successful 
treatment of convulsive SE in France in the 1960s,2,5-7 and their use remains first line in 
current recommendations.  Use of anaesthetic agents propofol and high-dose midazolam 
were first reported in 1977 and 1978.4  Many of these drug classes continue to be used 
today, although some, like paraldehyde, have lost favour.  
 
Since the 1960s there has been a continuous increase in drugs available for chronic 
epilepsy, however the number of drugs for SE has remained relatively unchanged.  This 
trend likely reflects the highly profitable nature of medications for chronic conditions to the 
pharmaceutical industry, compared with medications for acute conditions.  Some newer 
drugs have been reported in case series as effective, but none yet satisfy the levels of 
evidence to be incorporated into standard care.8-10  Other advances such as sophisticated 
critical care techniques have increased the available treatment options.9  Despite the 
progress over the last century it is likely that in another 100 years our current management 
strategies may appear as primitive as bowel irrigation. Current management of SE in 
children will be described in chapter 2. 
 
1.5 Definitions of status epilepticus 
Since 1970 SE has been included in the International League Against Epilepsy (ILAE) 
classification of seizures, where it was defined as a “seizure that persists for a sufficient 
length of time or is repeated frequently enough to produce a fixed and enduring condition”.11 
Since that time slight modifications to the definition have occurred, with the intent as with all 
medical classification systems, to facilitate communication among physicians, improve 
treatment, and facilitate the conduct of epidemiological and interventional research.  In 1981 
the definition was modified to describe a seizure that “persists for a sufficient length of time 
or is repeated frequently enough that recovery between attacks does not occur”.12   
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While early ILAE definitions did not specify a precise definition for the duration of a seizure 
to qualify as SE,11,12 definitions in standard texts, guidelines, major research papers and 
clinical trials have usually included such time frames.13-19  From a pragmatic perspective, SE 
has traditionally been defined as more than 30 minutes of continuous seizure activity, or two 
or more sequential seizures without full recovery of consciousness between seizures.20 
 
Seizures typically resolve spontaneously by 3-5 minutes.  Spontaneous cessation becomes 
less likely once a seizure has been in progress for more than 5 minutes, and response to 
anticonvulsants decreases with increasing seizure duration.  It is unusual for seizures to last 
30 minutes.  This led to a revised operational definition of convulsive SE in the late 1990s, 
based on when one would be expected to commence treatment, proposed as seizures of 
five minutes or more.20 This definition has been implemented in recent and contemporary 
prospective trials of convulsive SE.15,18,21  
 
Seizure duration has been a focus of SE research, since other factors that have been 
associated with poor outcome such as age and seizure aetiology are not modifiable.  Animal 
data support the contention that longer seizures are harmful and result in irreversible brain 
damage and poorer outcomes,22 although quality evidence in humans is lacking.   
 
Recently the ILAE task force on the classification of SE released a report outlining a 
proposed new definition and classification of SE.23  The new definition incorporates concepts 
outlined above, such as the importance of time points of clinical relevance to decision-
making, and consistency with previous epidemiological and clinical work. The proposed 
definition is: 
 
“SE is a condition resulting either from the failure of the mechanisms responsible for 
seizure termination or from the initiation of mechanisms which lead to abnormally 
prolonged seizures (after time point t1).  It is a condition that can have long-term 
consequences (after time point t2), including neuronal death, neuronal injury, and 
alteration of neuronal networks, depending on the type and duration of seizures”.23(p3) 
 
The proponents of this new definition concede that the definition is based on imperfect 
knowledge and should continue to evolve.  Time points of t1 and t2 were based on animal 
data and correspond with traditional and operational definitions outlined above of 5 and 30 
minutes for tonic-clonic SE (and 10 and > 60 minutes for focal SE with impaired 
consciousness).  These terms are explained further below.  
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1.6 Classification 
1.6.1 Overview  
Classification systems for SE have evolved with definitions of SE.11,24  In their report on the 
classification of SE in 2015, the ILAE task force proposed a system incorporating 4 axes:23 
 
1. Semiology 
2. Aetiology 
3. Electroencephalographic correlates 
4. Age 
 
This classification acknowledges that at least half of patients presenting in SE will not have 
epilepsy, and therefore previously used seizure classifications are probably not appropriate. 
The framework is intended to promote “clinical diagnosis, investigation, and therapeutic 
approaches for each patient”.23(p3) 
 
Although it is preferable to classify the patient according to each of the four axes, they are of 
variable importance in the acute care and emergency setting.  Where information about age 
and semiology would be immediately available, electroencephalographs (EEG) are 
sporadically available acutely outside of research settings in Australia and New Zealand, 
and aetiology may only become apparent with time and may not be available to assist with 
acute management decisions.   
 
1.6.2 Axis 1 – Semiology 
The semiology axis characterises the clinical presentation of SE and can be simplified as 
being composed of two main components; firstly, the presence or absence of prominent 
motor symptoms, and secondly the degree of impairment of consciousness.  While 
conceptually this is relatively straight forward, the classification system entails more than 20 
discrete categories (Table 1.1).23 Components of SE presentation considered of vital 
importance by neurologists and epileptologists may not be considered part of a standard 
focused history and examination performed by acute care physicians or routinely 
documented in medical records, even if elicited in the ED. Further, recognition of subtle 
convulsive SE and non-convulsive SE is problematic in the ED.  
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Table 1. 1 Axis 1 Classification of status epilepticus 
 
 
(A) With prominent motor symptoms 
A.1 Convulsive SE (synonym: tonic–clonic SE) 
A.1.a. Generalized convulsive 
A.1.b. Focal onset evolving into bilateral convulsive SE 
A.1.c. Unknown whether focal or generalized 
A.2 Myoclonic SE (prominent epileptic myoclonic jerks) 
A.2.a. With coma 
A.2.b. Without coma 
A.3 Focal motor 
A.3.a. Repeated focal motor seizures (Jacksonian) 
A.3.b. Epilepsia partialis continua 
A.3.c. Adversive status 
A.3.d. Oculoclonic status 
A.3.e. Ictal paresis (i.e., focal inhibitory SE) 
A.4 Tonic status 
A.5 Hyperkinetic SE 
(B) Without prominent motor symptoms (i.e., non-convulsive SE) 
B.1 Non-convulsive SE with coma (including so-called “subtle” SE) 
B.2 Non-convulsive SE without coma 
B.2.a. Generalized 
B.2.a.a Typical absence status 
B.2.a.b Atypical absence status 
B.2.a.c Myoclonic absence status 
B.2.b. Focal 
B.2.b.a Without impairment of consciousness (aura continua, with 
autonomic, sensory, visual, olfactory, gustatory, emotional/ 
psychic/experiential, or auditory symptoms) 
B.2.b.b Aphasic status 
B.2.b.c With impaired consciousness 
B.2.c Unknown whether focal or generalized 
B.2.c.a Autonomic SE 
 
 
 
1.6.3 Axis 2 – Aetiology  
The second axis, the classification of aetiology of SE, remains largely consistent with 
previous ILAE organisation of seizures and epilepsies.25 The term epilepsy encompasses 
numerous different conditions with variable manifestations and many patients with SE will 
not have epilepsy. The aetiology of SE is divided into known (i.e. symptomatic) and unknown 
(i.e. cryptogenic) groups.  The known group is further subdivided into acute, remote and 
progressive SE in defined electroclinical syndromes (Table 2).23 A more extensive but not 
definitive list of potential causes is found in Appendix 1.1.23 The aetiology of SE is different in 
adults and children, for example most published series report prolonged febrile seizures as a 
major cause in children, which would be an example of an electroclinical syndrome.25  Other 
practical criteria for the classification of aetiology in epidemiological studies have been 
suggested by the ILAE.26 
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Table 1.2 Aetiology of status epilepticus 
 
 
Known (i.e., symptomatic) 
Acute (e.g., stroke, intoxication, malaria, encephalitis, etc.) 
Remote (e.g., posttraumatic, postencephalitic, poststroke, etc.) 
Progressive (e.g., brain tumor, Lafora’s disease and other PMEs, 
dementias) 
SE in defined electroclinical syndromes 
Unknown (i.e., cryptogenic) 
 
1.6.4 Axis 3 – Electroencephalograph correlates 
EEG in the emergency setting is recommended where possible, particularly where non-
convulsive SE is a possibility.27,28 However, there are no evidence based EEG criteria for 
SE, with proposed terminology to describe EEG findings in SE including location, name of 
pattern, morphology, time related features, modulation, and effect of interventions on EEG.  
Currently this resource intensive investigation is not available in many EDs or acute care 
settings in Australia and New Zealand, and its utility remains unknown.  
 
1.6.5 Axis 4 – Age 
Electroclinical syndromes of SE differ according to age, therefore the taskforce has clarified 
this with axis 4. The discrete groups are: 
 
Neonatal (0-30 days) 
Infancy (1 month to 2 years) 
Childhood (>2 to 12 years) 
Adolescence and adulthood (>12 to 59 years) 
Elderly (>=60 years) 
 
1.7 Barriers to researching paediatric status epilepticus 
The paucity of high-level evidence regarding paediatric SE management is typical of many 
areas of emergency medicine.  Management strategies employed in EDs are frequently not 
evidence based or supported by high quality randomised controlled trials (RCT). The lack of 
high-quality evidence would perhaps surprise consumers of emergency services. Barriers to 
performing research in EDs include the chaotic environment and highly variable workload 
that is unpredictable and fluctuates, making the study of all but the most frequent conditions 
problematic. In addition, outcomes in modern EDs are generally excellent, therefore 
meaningful outcome differences are hard to prove, and regulatory requirements for research 
have become increasingly complex. The lack of high-quality evidence to guide management 
is perhaps even more evident in the pre-hospital setting.  Chapter 3 will explore this 
knowledge gap by reviewing the existing literature on pre-hospital care of paediatric SE.   
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The majority of available literature concerning SE has been produced by neurologists, 
paediatric neurologists and critical care physicians, and published almost exclusively in 
neurology journals rather than directed to the emergency medicine community.  This is 
despite the fact that the overwhelming majority of cases are managed by emergency 
physicians.  The research culture within emergency medicine is perhaps not as established 
as within other specialties, but this situation is slowly changing, including in paediatric 
emergency medicine, with the creation of several successful research networks.29,30  With 
many unanswered questions in paediatric SE, a widely consultative process to determine 
research priorities is required, involving ED physicians, neurologists and consumers.  
 
One further barrier to research in SE, and emergency and critical care research in general, 
is the difficulty obtaining prospective informed consent for research.  People seeking 
emergency care are considered a vulnerable population and involved in a dependent 
relationship with clinicians (who may also be researchers) leading to ethical dilemmas.  
These are exacerbated in paediatric emergency care research, where children themselves 
are often also considered vulnerable. For periods in recent history, ED research in 
developed countries such as the United States (US) and United Kingdom (UK) all but 
ceased because regulatory requirements were not conducive to research in critically unwell 
people.31,32 Recently, strategies using alternatives to prospective informed consent have 
improved this situation, however little is known about the public’s perception of research in 
these circumstances. It is imperative that researchers incorporate the attitudes and beliefs of 
the public into future research designs to ensure the maintenance of public trust, and that 
the research agenda can be continued to the benefit of society.   
 
In Australia, while provisions exist in the National Health and Medical Research Council 
(NHMRC) statement33 and the Declaration of Helsinki34 for research to occur without 
prospective informed consent, the practice remains controversial and has seldom been 
utilised in paediatric research. In Queensland, the validity and legality of research under 
these circumstances has been questioned in draft documents circulated by Queensland 
Health (supplementary appendix 1.2) threatening current and future research efforts.  
 
Research into paediatric SE is typical of the difficulty of conducting quality research in acute 
and emergency situations. Presentations are infrequent, but the consequences of 
inadequate management can be severe. Management beyond initial care is not evidence 
based, and issues of consent are applicable as management is time-critical, therapies have 
a narrow therapeutic window and the traditional valid prospective informed consent is 
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impossible to obtain prior to enrolling a particular patient in a study on SE in the emergency 
setting. Therefore, research efforts to improve outcomes of children with SE are inextricably 
linked to the concepts of informed consent in emergency research requiring both of these 
aspects to be addressed to improve the care of children with SE.   
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1.8 Aims and objectives  
The aim of this body of work is to explore the paradox of informed consent issues in 
paediatric SE research, ultimately to improve the management of paediatric SE in Australia 
and New Zealand.   
 
The specific objectives of the thesis are to: 
 
1. Identify gaps and opportunities for research from a review of the existing literature on 
paediatric SE. 
 
2. Inform the future research agenda in the management of paediatric SE by achieving 
consensus on research priorities among experts in managing this condition, consisting of 
paediatric neurologists and emergency physicians who treat children.   
 
3. Determine if research priorities identified by experts align with priorities identified by 
consumers (parents of children with SE).  
 
4. Determine what is known about the public’s perceptions and attitudes towards research in 
a paediatric emergency setting without prospective informed consent.  
 
5. Explore attitudes of the general public to research in emergency settings without prior 
consent. 
 
6. Explore parental attitudes to a deferred consent process in the ED setting, including the 
management of SE.   
 
1.9 Conceptual model of thesis 
This thesis consists of two separate, but interconnected streams.  These streams are 
displayed graphically in Figure 1.1. Stream one explores the existing knowledge of 
paediatric SE, identifies research priorities for SE including those of the community, and 
explores the feasibility of addressing these knowledge gaps. Stream two explores barriers to 
research in paediatric SE, namely issues of consent for time-critical ED research.  At the 
confluence of these two streams is the discussion, highlighting a roadmap for addressing the 
various knowledge gaps in paediatric SE, for the improved care of this condition.  
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Figure 1. 1 Conceptual model of thesis 
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1.10 Overview of the methods 
In this thesis, multiple methodologies are used to achieve the stated objectives.  The thesis 
structure and relevant methodology are summarised below. The thesis comprises two 
streams.  Stream 1: four chapters, three of which are published manuscripts; Stream 2: Four 
chapters, each of which is a published manuscript.  
 
Chapter 2 (objective 1) comprises a narrative review of existing literature on the 
epidemiology of paediatric SE, specifically the incidence, aetiology and outcome. The 
chapter goes on to explore investigation and management of paediatric SE.  This will 
provide the context and background for the thesis.  
 
Chapter 3 (objective 1) is a review of the prehospital care of paediatric SE, and focuses on 
the unique aspects of pre-hospital care as an opportunity to improve the management and 
outcomes of children with SE. This chapter is inserted as published [Furyk J, Watt K, Emeto 
TI, Dalziel S, Bodnar D, Riney K, Babl F. Review article: Paediatric status epilepticus in the 
pre-hospital setting: An update. Emerg Med Australas: 2017 Aug; 29(4):383-390. PubMed 
PMID: 28627014. DOI: 10.1111/1742-6723.12824]. 
 
Chapter 4 (objectives 2 and 3) reports on the findings of a Delphi study conducted to 
determine consensus priorities for research in paediatric SE with experts (emergency 
physicians and paediatric neurologists) and consumers. This chapter is inserted as 
published [Furyk J, Ray R, Watt K, Dalziel SR, Oakely E, Mackay M, Dabscheck G, Riney K, 
Babl FE. Consensus research priorities for paediatric status epilepticus: A Delphi study of 
health consumers, researchers and clinicians. Seizure. 2018 Feb 5;56:104-9. PubMed 
PMID: 29471256. DOI: 10.1016/j.seizure.2018.01.025].  
 
Chapter 5 (objective 2) is the final chapter of the first stream of the thesis. It addresses a 
well-recognised knowledge gap in the second line management of paediatric SE. This 
chapter details the protocol of an RCT evaluating the second line management of paediatric 
SE, and incorporates the controversial deferred consent process. This chapter is inserted as 
published [Dalziel SR, Furyk J, Bonissch M, Oakley E, Borland M, Neutze J, Donath S, 
Sharpe C, Harvey S, Davidson A, Craig S, Phillips N, George S, Rao A, Cheng N, Zhang M, 
Sinn K, Kochar A, Brabyn C Babl FE, PREDICT research network. A multicentre randomised 
controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children 
(protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study. 
BMC Pediatr 2017 Jun 22;17(1):152. PubMed PMID: 28641582. DOI: 10.1186/s12887-017-
0887-8]. 
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Chapter 6 (objective 4) is the first chapter in the second stream of this thesis. The issues of 
informed consent in emergency research such as SE clinical interventional trials are 
explored. This is a review and perspectives paper, and is inserted as published [Furyk JS, 
Lawton L, Ting JY, Taylor DM. Perspective: Informed Consent in emergency care research: 
An oxymoron. Emergency medicine Australasia: EMA. 2017;29(1):110-2. Epub 28 July 
2016]. This chapter sets the scene for the remainder of the thesis.  
 
Chapter 7 (objective 4) is a systematic review of alternatives to informed consent in 
paediatric emergency and acute care research.  It is inserted as published [Furyk J, McBain-
Rigg K, Renison B, Watt K, Franklin RC, Emeto T, Ray R, Babl F, Dalziel S. A 
comprehensive systematic review of stakeholder attitudes to alternatives to prospective 
informed consent in paediatric acute care research. BMC Medical Ethics (2018) 19:89 
https://doi.org/10.1186/s12910-018-0327-9]. 
 
Chapter 8 (objective 5) reports on the findings of a national, population-based phone survey 
on community attitudes to research in emergency settings without prospective consent. This 
chapter is inserted as published [Furyk J, Franklin RC, Watt K, Emeto TI, Dalziel SR, 
McBain-Rigg K, Nikola Stepanov N, Babl FE and PREDICT. Community attitudes to 
emergency research without prospective informed consent: A survey of the general 
population. Emerg Med Australas. (2018) 30, 547–555. PubMed PMID: 29718588.  DOI: 
10.1111/1742-6723.12958].   
 
Chapter 9 (objective 6) reports on the findings of a qualitative study of the attitudes of 
parents to research without prospective consent in the ED setting, including in the case of 
SE. This chapter is the final chapter in the second stream of the thesis. It is inserted as 
published [Furyk J, McBain-Rigg K, Watt K, Emeto T, Franklin RC, Franklin D, Schibler A, 
Dalziel SR, Babl FE, Wilson C, Phillips N, Ray R, on behalf of PREDICT. Qualitative 
evaluation of a deferred consent process in paediatric emergency research: a PREDICT 
study. BMJ Open 2017;7(11): e018562. PubMed PMID 29146655. doi:10.1136/bmjopen-
2017-018562]. 
 
Chapter 10 is the final chapter of the thesis. It comprises a synthesis of the overall findings 
in the context of the relevant literature, strengths and limitations and concludes with 
implications for practice, research and policy, with a roadmap for further research in 
paediatric SE. 
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Chapter 2.  Background – Epidemiology, investigation and 
management of paediatric status epilepticus 
 
2.1 Overview 
Paediatric SE represents a distinct clinical syndrome from adult SE. This chapter outlines 
the unique epidemiology of paediatric SE, focussing on incidence, aetiology and outcomes 
in a developed world setting. The chapter goes on and explores the investigation and 
management of SE in children, and highlights differences from adults. The objectives of this 
review and this chapter are to provide the context for the thesis, outline the magnitude and 
effect of paediatric SE on the community, outline current standard emergency management, 
and hence the potential impact of successful interventions for this condition (thesis objective 
1). The Medline search strategy used in this literature review was developed with assistance 
of a medical librarian (supplementary appendix 2.1). Figure 2.1 places this chapter in the 
conceptual framework of the broader work relative to other elements of the thesis. 
Figure 2. 1 Conceptual model of thesis 
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2.2 Incidence of paediatric status epilepticus  
The epidemiology of SE has not been well studied in the paediatric population.  There have 
been few population-based epidemiological studies of SE and convulsive SE on which to 
base estimates of incidence.  Significant differences exist between resource rich and 
resource poor settings, and this review will focus on the former. The variation in published 
rates seen in the paediatric populations studied to date can be explained by methodological 
issues, particularly regarding case ascertainment.16 Studies reporting incidence in mixed 
adult and paediatric populations generally report a bimodal age distribution, with peaks at < 
1 year and greater than 60 years. These studies have demonstrated ethnic variation with 
higher rates in non-white populations possibly due to a combination of biologic, 
socioeconomic and cultural factors, although fewer data are available for paediatric 
populations.35-38 
 
2.2.1 Population-based studies 
Several population-based studies have attempted to estimate the incidence of paediatric 
convulsive SE.35,38-43 The study with arguably the most robust methodology was a 
prospective population-based study of childhood convulsive SE in North London.16 The 
North London Convulsive Status Epilepticus in Childhood Surveillance Study defined 
convulsive SE as tonic, clonic, or tonic-clonic  (continuous convulsive SE), or two or more 
such seizures between which consciousness was not regained (intermittent convulsive SE), 
which lasted for at least 30 minutes.16 They included children aged 28 days to 15 years, in a 
geographic area of approximately 500 square kilometres in north London, enrolled via a 
clinical network of 18 hospitals, with 24 hour ED care. The study enrolled 226 children, of 
which 176 had a first ever seizure (23% of which started in hospital), over 24 months. The 
authors estimated the crude incidence of convulsive SE (adjusted for ascertainment) to be 
17 to 23 cases per 100,000 per year, a figure significantly higher than in adult studies. 
Incidence was highest in very young children, at 51 per 100,000 in children aged < 1 year 
and declined with increasing age to 2 per 100,000 in those aged 10 to 15 years. 
Extrapolation of these data to other regions is difficult, as key aetiological agents and 
triggers, such as congenital malformations and epidemiology of infectious diseases, may 
vary in different regions and countries. 
 
2.2.2 Mixed adult and paediatric studies 
Other studies reporting the incidence of SE have not been paediatric specific, have 
classified SE differently and have used varying methodology making comparisons difficult.  
These have included population studies in Finland, Switzerland, Reunion Island, Japan, 
Italy, and the US.35,38-44 SE in La Réunion Island in children aged 1 to 10 years was reported 
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as 6.6 per 100,000 but specifically excluded the prolonged febrile seizure subgroup which 
constitutes a large proportion in other series, and the estimates were based on very small 
numbers.40 In French-speaking Switzerland the incidence of convulsive SE decreased with 
increasing age from 38.7 per 100,000 in 0 to 4 year olds, to 10.9 per 100,000 in 5 to 14 year 
olds.41 In Virginia, United States, DeLorenzo described incidence in the paediatric population 
(0 to 15 years) of almost 40 cases per 100,000, again highest in those < 1 year,35 this was 
similar in other US studies.44 In Italy and Finland results from two retrospective cohort 
studies were roughly concordant with other studies with incidence of 52 and 47.5 per 
100,000 per year respectively.39,42 In the only study of an Asian population, in Japan, the 
reported incidence was 38.8 per 100,000.43 See Table 2.1. 
 
Table 2. 1 Aetiology of paediatric status epilepticus 
Author Study 
description 
Country / Setting Definition of 
SE 
Age range  Total number of 
children (n) 
Aetiology (as described in report)  Incidence (as 
described in 
paper) 
Bhalla 2014 Prospective, 
observational 
population study 
French Reunion Island > 30 minutes 0-19 years 13 excluded febrile seizures & not 
described for children separately 
 
0-9 years: 6.6 
per 100,000 
population per 
year 
10-19 years: 2.9 
per 100,000 
population per 
year 
Ericksson 
1997 
Retrospective, 
Population based  
Tampere, Finland >30 minutes 1 month to 
15 years 
65 I  15 (23%) 
FSE  24 (37%) 
AS  13 (22%) 
RS  10 (16%) 
PN  3 (5%) 
N/A 
Nishiyama 
2007 
Retrospective, 
Population 
based, 12 months 
2003 
Okayama city, Japan > 30 minutes 31 days to 
< 15 years 
46 (37 first episodes) AS  8 (22%) 
PFS 17 (46%) 
RS  5 (13%) 
C  7 (19%) 
38.8 per 100,000 
population, per 
year 
Hussain 2007 Retrospective PICU, UK >30 minutes 1 month to 
15 years 
137 PFC 47 (34%) 
RS  38 (28%) 
AS  24 (18%) 
I  15 (11%) 
PE  6 (4%) 
U   7 (5%) 
N/A 
Singh 2010 Prospective 
“database” 
Single centre US, 
tertiary paed 
>20 minutes < 18 years 144 (first episodes) FSE  46 (32%) 
AS  24 (17%) 
RS  26 (18%) 
C  42 (29%) 
I  6 (4%) 
N/A 
Kravljanac 
2015 
Retrospective Serbia, 1995-2011 >30 minutes 0.2 to 16 
years 
602 episodes SE (396 
children) 
I  113/602 (18.8%) 
RS  126 (20.9%) 
FSE  93 (15.4%) 
AS  101 (16.8%) 
PE  169 (28.1%) 
N/A 
Metsaranta 
2004 
Retrospective, 
population based 
Tampere University 
Hospital, Finland 
>5 minutes 1 month to 
16 years 
186 PFS  41.9% 
RS  28% 
AS 3.9% 
I  26.2% 
47.5 per 100,000 
per population 
per year 
Chin 2006 Prospective, 
observational 
trial (Registry) 
London, population 
based  
>30 minutes  176 PFS  56 (31.8%) 
AS  30  (17.0%) 
RS  29 (16.5%) 
AR  28 (15.9%) 
I  18 (10.2%) 
C  3 (1.7%) 
U  12 (6.8%) 
17-23 per 
100,000 per 
population per 
year 
Chamberlain 
2014 
Interventional, 
Randomized 
Controlled Trial 
(RCT) 
 1) ≥ 3 seizures 
in an hour 
2) ≥ seizures 
without 
recovery 
3) Current 
seizure > 5 min  
3 months 
to < 18 
years 
273 Febrile  89 (32.6%) 
Low AED levels  25 (9.2%) 
Acute symptomatic  38 (13.9%) 
Remote symptomatic  27 (9.9%) 
Idiopathic 81 (29.7%) 
Other 12 (4.4%) 
N/A 
Lewena 2009 Retrospective 
cohort 
Australia, 8 EDs > 10 minutes  18 d to 20 
years 
542 Febrile  115 (21%) 
Epilepsy  188 (35%) 
Other neuro  130 (24%) 
Idiopathic 76 (14%) 
Enceph/mening 16 (3%) 
Metabolic 5 (1%) 
N/A 
DeLorenzo 
1996 
Prospective, 
population based 
Richmond, Virginia 
(USA) 
> 30 minutes 0 to < 16 
(subgroup) 
100 Febrile*  52 (52%) 
RS  39 (39%) 
LAED  21 (21%) 
39 per 100,000 
per population 
per year 
Momen 2015 RCT Iran > 5 min > 1 month 100 Febrile 49 (49%) 
RS  25 (25%) 
Idiopathic 26 (26%) 
N/A 
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Coeytaux 
2000 
Prospective, 
population based 
Switzerland > 30 minutes 0-14 years 64 AS  42 (65.6%) 
RS 11 (17.2%) 
AR 5 (7.8%) 
Idiopathic  3 (4.7%) 
Cryptogenic (4.7%) 
0–4 years: 38.7 
per 100,000 
population per 
year 
5–14 years: 10.9 
per 100,000 
population per 
year 
Bergamo 
2015 
Retrospective, 
population based 
Italy > 5 min (SE) 0-15 years ϕAll seizures 214 
SE 51 
ϕFebrile  120 (56%) 
RS  41 (19%) 
I  19 (9%) 
ARS 11 (5%) 
CER 8 (4%) 
CwG 4 (2%) 
AS 5 (2%) 
U 7 (3%) 
52 per 100,000 
per population 
per year (SE > 5 
minutes) 
7 per 100,000 
(SE > 30 
minutes) 
Wu 2002 Retrospective, 
population based 
California, USA, 1991-
98 
> 30 minutes 0-19 years 2885 (Not reported for children separately) 0-4:         7.52 
per 100,000 
5-19:       2.57 
per 100,000 
 
Wlech 2015 RCT Multi-centre USA, 33 
EMS services, 79 
hospitals 
> 5 minutes < 18 years 
(children 
eligible 
with 
estimate wt 
> 13 kg)  
120 Known  n=105 
PFS  23/105 (21.9%) 
Idiopathic 47/105 (45%) 
Non compliance  12/105 (11.4%) 
non epileptic seizure 10/120 (8%) 
 
 
N/A 
Maytal 1989 Prospective and 
retrospective 
New York, USA > 30 minutes 1 month to 
18 years 
193 I 46 (24%) 
RS 45 (23%) 
PFS 46 (24%) 
AS 45 (23%) 
PE 11 (6%) 
 
 
Hesdorffer 
1998 
Population 
based, 
retrospective 
Rochester Minesotta, 
USA 
>  30 minutes All ages 
(reported 
0-19 
reported 
separately) 
76 PFS (21%) 
AS 36 (47%) 
I/C 11 (14%) 
RS 13 (17%) 
 
< 1 year : 135 
per 100,000 
1-4 years: 35.3 
per 100,000 
5-9 years: 12.2 
per 100,000 
10-14 years: 3.7 
per 100,000 
5-19 years: 6.5 
per 100,000 
Notes: Notes: PFS prolonged febrile seizure, AS acute symptomatic, RS remote symptomatic, AR acute on remote, I idiopathic, C cryptogenic, U unclassified, RCT 
randomized controlled trial, FSE febrile status epilepticus, PE progressive encephalopathy, PFC prolonged febrile convulsion, PN progressive neurological, CER 
cryptogenic epilepsy related, CwG convulsions with gastroenteritis, *includes all infective causes,  ϕAetiology includes seizures 0-5 minutes duration 
 
Approximately 10% of children with childhood onset epilepsy will have at least one episode 
of SE in their lifetime.45 Conversely, children who experience a first episode of SE only have 
a 30% chance of subsequent diagnosis of epilepsy.46  
 
In summary, the incidence of convulsive SE in the paediatric population is highest in children 
< 1 year old and decreases with age.  The reported incidence is probably in the order of 20 
per 100,000 population at risk if using the traditional definition of SE being a seizure lasting > 
30 minutes, the time point historically used in most studies. The incidence would certainly be 
higher if including children with seizures from 5 to 29 minutes.  Incidence is much higher in 
developing world settings, where the underlying aetiology is different. 
 
2.3 Aetiology of paediatric status epilepticus 
Approximately 10% of first seizures in children with epilepsy present as SE.16,43,47-49 It has 
been proposed that susceptibility to develop SE may result from a failure of endogenous 
anticonvulsant mechanisms in the brain.50 The aetiology of SE seems to be different in 
adults and children. Even amongst the paediatric population, there are significant differences 
between children of varying ages in terms of incidence, aetiology, frequency and prior 
neurological abnormalities.37  For example, in children less than two years, febrile SE and 
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acute symptomatic aetiologies predominate, whereas in older children the aetiology is more 
likely to be remote symptomatic or unknown.37  Causes of SE in adults commonly include 
cerebrovascular accidents, non-compliance with medication in known epileptics, metabolic 
disturbances, drug toxicity, infection and inflammation.51 Available data in children is limited 
by variability in methodology, the quality of studies to date and lack of uniformity regarding 
classification and reporting.  
 
Aetiology represents the second of four axes within the proposed new SE classification 
system23 and remains largely consistent with previous ILAE organisation of seizures and 
epilepsies.25 The underlying cause or aetiology is first classified as either known (i.e. 
symptomatic) or unknown (i.e. cryptogenic). The terms “idiopathic” and “genetic” which have 
been previously used to classify SE are no longer preferred, as the underlying aetiology of 
the SE episode may be known, for example inappropriate AED levels.  Known 
(symptomatic) causes are further subdivided to “acute”, “remote”, “progressive” and “SE in 
defined electroclinical syndromes”.23  
 
The “acute symptomatic” group is analogous to the previously used “provoked” term, and 
describes SE occurring during an acute illness or acute CNS insult e.g. stroke, intoxication, 
encephalopathy, meningitis, electrolyte disturbance, hypoxia, trauma or malaria.16,23,52,53 The 
recommended definition of an acute symptomatic seizure encompasses the following:  1) 
seizures occurring within a week of cerebrovascular accident, traumatic brain injury, anoxic 
encephalopathy or intracranial surgery, 2) a subdural haematoma or CNS infection at the 
time of diagnosis, 3) during the active phase of multiple sclerosis or other autoimmune 
disease or 4) a specific biochemical or haematological abnormality within 24 hours, or drug 
intoxication or withdrawal including; serum glucose < 36 mg/dl (2.0 mM) or >450 mg/dl 
(25mM) associated with ketosis, sodium < 115 mg/dl (<5 mM), calcium < 5.0 mg/dl (<1.2 
mM), magnesium < 0.8 mg/dl (<0.3 mM), urea nitrogen >100 mg/dl (>35.7 mM) and 
creatinine > 10.0 mg/dl (>884 lM).23 Seizures associated with a fever greater than 38.5 
degrees Celsius have at times been categorised as acute symptomatic,52 however the 
outcome for prolonged febrile seizures is generally better than for other acute symptomatic 
causes.54 Therefore, the usefulness of including prolonged febrile seizures within the acute 
symptomatic group is questionable, and some studies have reported prolonged febrile 
seizures as a separate category or as a subgroup of acute symptomatic (see Table 2.1).  
 
The term “remote symptomatic” describes SE occurring without an acute provocation in a 
patient with a history of a CNS abnormality, more than a week previously e.g. following 
trauma, encephalitis, stroke or CNS malformation.16,23,53 The “progressive” symptomatic 
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episodes of SE encompasses progressive CNS disorders such as tumours, other 
progressive epilepsies and dementias.  The last group is SE in defined electro-clinical 
syndromes, and the recent proposed ILAE SE classification includes prolonged febrile 
seizures in this group.23 
 
Numerous studies in various populations using various methodologies have described the 
aetiology of SE in the paediatric population in developed countries15,16,35,41-44,46,49,55-58 (See 
Table 2.1). Prolonged febrile seizures account for 21-52% of cases (overall accounting for 
about 30% of cases).15,16,35,41-44,46,49,55-58 Reported acute symptomatic SE cases ranged from 
4 to 65% but were generally about 20% in most series, and remote symptomatic SE was 
ranged from 10 to 23 but were generally about 17%.  Many studies used the term 
“idiopathic”, which as stated earlier is no longer preferred, with the proportion of SE 
attributed as idiopathic ranging from 4 to 30% (with wide variation). Differences may be 
explained by variable methods of data collection, definitions, case ascertainment, and 
methodological rigour.    
 
The most comprehensive data on the aetiology and natural history of convulsive SE comes 
from the North London convulsive SE in Childhood Surveillance Study.16 In this study a third 
of episodes of convulsive SE were due to prolonged febrile seizures, 17% had acute 
symptomatic causes including electrolyte imbalance, hypoglycaemia, hypocalcaemia or 
hypomagnesaemia, or an acute CNS infection, and remote symptomatic and acute on 
remote symptomatic accounted for 16% each. Less than a quarter of the children had a past 
history of convulsive SE and over half were previously neurologically normal.16   
 
The rate of meningitis in children presenting with febrile SE has shown wide variation in the 
literature to date, from close to 1%49 up to 40%59 of febrile SE presentations. This variation is 
again likely to be due to methodological differences in the studies. The authors of the North 
London SE in childhood surveillance study found that SE presentations with a fever of > 
38°C had a rate of bacterial meningitis of 12%. A further 8% showed evidence of a viral CNS 
infection. The authors concluded that clinicians should have a high index of suspicion of an 
infective aetiology in such presentations.16,60  
 
The only available Australasian data on paediatric SE comes from a retrospective study 
conducted by the PREDICT network.61 The five-year study period (2000 to 2004) identified 
542 episodes of SE in eight paediatric EDs in Australia and New Zealand.  While the 
“practical” definition of SE was applied with duration of 10 minutes used, 94% had seizure 
duration of greater than 30 minutes. In this cohort a history of seizures was present in 67% 
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of cases, prolonged febrile convulsions accounted for 21% of cases (considerably less than 
in other studies), and encephalitis or meningitis was present in 3%.61 The major 
methodological difference between the Australasian study and the North London study was 
that the Australasian study was retrospective and restricted to patients presenting to the ED, 
whereas the North London study was prospective and population-based.61,62 
 
The following section will briefly review some of the important acute causes of SE, which 
may have implications for management e.g. prolonged febrile seizures, inflammatory, 
trauma etc.  
 
2.3.1 Prolonged febrile seizure 
All studies highlight the importance of prolonged febrile convulsions in causing SE in the 
paediatric population.16,39,43 A prospective study specifically of febrile SE from five sites in the 
United States enrolled 199 patients, aged 4 months to 6 years from 2003 to 2010.63,64 SE 
was again defined as lasting ³ 30 minutes or a series of seizures without full recovery in 
between that lasted ³ 30 minutes; the median seizure duration was 70 minutes.64 The cohort 
specifically excluded children with meningitis and other acute symptomatic causes.  Children 
underwent a standardised assessment, including imaging and testing for human herpesvirus 
(HHV) -6 and HHV-7, and interestingly found evidence of viraemia in a third of patients.64 
 
2.3.2 Inflammatory status epilepticus  
Inflammatory and immune mediated encephalopathies are being increasingly recognised as 
rare but important causes of seizures and SE. Infective causes of inflammation have long 
been considered an important subgroup of patients presenting with SE, including viral, 
bacterial and parasitic causes, but autoimmune causes are increasingly recognised. 
Autoantibodies to both neuronal surface and intracellular elements are important.  Much of 
the current knowledge of this comes from adults, and although they are responsible for only 
a small proportion of cases of SE, outcomes may benefit from specific therapeutic 
approaches, therefore SE of unknown origin may benefit from screening for anti-neuronal 
antibodies.65,66 
 
It is likely that further antibodies will be identified for encephalidities currently classified as 
unknown cause. These encephalidities can be divided into paraneoplastic and 
autoimmune.65 The most commonly described include antibodies to glutamic acid 
decarboxylase (GAD) and N-methyl-d–aspartate (NMDA) receptors, thyroid and voltage 
gated potassium channel (VGKC) complex.  With GAD and VGKC complex causing SE 
more frequently in paediatric populations, more commonly in older children.67 Most patients 
 43 
with an inflammatory cause will have a prodromal phase or preceding illness to suggest the 
diagnosis. 
 
Two clinical syndromes have also been described, which although induced by fever, have 
not been found to be associated with microbiological or autoimmune causes.  These are 
known as fever induced refractory epileptic encephalopathy in school age children (FIRES) 
and idiopathic hemiconvulsive hemiplegia syndrome (IHHS).68 Both syndromes have a poor 
prognosis.  FIRES can evolve into SE, refractory epilepsy, focal seizures and progressive 
cognitive decline.  IHHS begins in infancy with unilateral clonic SE and is followed by 
hemiplegia and a treatment resistant epilepsy syndrome.  Occurring in previously healthy 
children, the aetiology of FIRES and IHHS is unknown but is thought likely to have an 
inflammatory origin.67,68 
 
2.3.3 Drug associated status epilepticus  
Although drugs are well known to cause seizures and SE, they represent an infrequent 
cause of SE in children.  Estimates in adults are that drugs, both in therapeutic doses and 
overdose, account for approximately 5% of SE,69 but epidemiological studies are limited and 
of variable quality with causality difficult to establish. However, drug associated SE is an 
important aetiology for clinicians to consider, as ingested substances may have implications 
for management.  Anti-epileptic drugs (AED) may themselves cause SE, although 
establishing this is itself very difficult.  Most classes of AED have been implicated in causing 
SE in both toxic and therapeutic doses.69 
 
Antidepressants, anxiolytics and illicit drugs are an important cause of SE in adults, but 
exposure to these agents in children is less common.  Effects can involve multiple CNS 
neurotransmitters to lower the seizure threshold.  Unintentional intoxication with these 
medications does occur in children, and can result in SE with tricyclic antidepressants an 
important class.62 Intentional intoxication and suicidal intent becomes increasingly more 
prevalent in adolescents.62 
 
A potentially important group is antibiotic associated seizures,69,70 although again 
establishing causation is problematic.  Biological plausibility exists, as neurotoxicity exists 
with certain antibiotics including cephalosporins, other beta-lactams and quinolones.69-71 The 
mechanism is likely to be related to a decrease in gamma-aminobutyric acid (GABA) 
release, and subsequent increase in excitatory neurotransmitters.   The relative importance 
in SE in children is unknown. 
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Another infrequent cause of SE is that of isoniazid toxicity, usually unintentional intoxication 
when children take medications of family members.72,73 Such seizures are related to 
pyridoxine depletion, necessary for GABA production, and respond to pyridoxine 
replacement.73 There are also several reports of theophylline causing SE, both at 
therapeutic and toxic levels.69,74 Antihistamines, which may be available over the counter 
have also been associated with SE.  Easy access to these medications may lead to toxicity 
in children. 
 
In summary, drugs are rarely considered by front line practitioners, and potentially implicated 
drugs may be overlooked as a potential cause of SE if not specifically asked about.  A 
medication history should always be sought in all SE presentations, and potential access to 
epileptogenic agents explored. Close contact with tuberculosis should lead to the 
consideration of possible isoniazid toxicity. 
 
2.3.4 Genetic factors associated with status epilepticus  
The genetics of SE are complex, and our knowledge and technology examining the genetic 
contribution to disease is constantly evolving.  The importance of genetic factors in the 
development of SE has been verified by twin studies.75 Many genetic mutations are known 
to be strongly associated with SE, relating to multiple different systems and pathways, 
however this knowledge has not yet led to any advances in management or improved 
outcomes.76 Knowledge of genetic factors is currently not of practical utility for clinicians, and 
remains an area for further research. 
 
2.3.5 Traumatic status epilepticus 
Trauma with head injury is a well-documented cause of seizures and SE in children. 
Although the aetiology may be obvious from the history and examination, history may not be 
forthcoming in the case of non-accidental injury, thus the diagnosis should always be 
considered.77,78 A further important cause of SE in children, is hypoxia or anoxia such as 
from drowning episodes. This is particularly relevant in Australia where rates of drowning 
remain high. As with infective, inflammatory and drug associated aetiologies identification of 
trauma or hypoxia as a cause of SE will lead to additional management focused on the 
causal mechanism.  
 
2.3.6 Psychogenic status epilepticus 
Although not included in most SE classifications of aetiology, psychogenic seizure 
presentations are an important differential diagnosis of paediatric SE.  Under-recognised by 
emergency clinical staff in the paediatric population their incidence increases with age, 
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although they have been reported in children as young as eight.79 Psychogenic seizures can 
present as non-epileptic SE, and result in unnecessary and potentially harmful interventions 
including medications, intubation, iatrogenic complications and can delay appropriate 
psychological therapies.80  Commonly precipitated by acutely stressful events, most patients 
have a family or personal history of epilepsy and co-existent psychiatric diagnosis.81 Pelvic 
thrusting is said to be a useful clinical clue, although such movements can occur in other 
epilepsy syndromes as well.82  Repeated video EEG assessment provides the correct 
diagnosis.  In a recent high-quality pre-hospital RCT of seizure management, 8% of 
paediatric patients (<17 years) with SE were adjudicated to have had non-epileptic 
seizures.18,83  
 
2.4 Paediatric status epilepticus outcomes and consequences 
SE is without doubt associated with significant morbidity and mortality.  Outcomes are 
considerably better in the paediatric group compared with adults.9 The prognosis of SE is 
highly dependent on the age of the patient, the aetiology and the duration of seizure 
activity.9,84 Of these factors, only the duration of seizure activity is potentially modifiable, but 
it is not clear whether interventions to reduce the duration of seizure result in improved 
outcomes.  From the available evidence, the confounding effect of aetiology is inextricably 
linked to seizure duration and prognosis.84  
 
Apart from lack of data due to the relative infrequency of the condition, another difficulty in 
describing the outcome of paediatric SE is the lack of standardized definitions, including 
outcomes, over time.54 Reviews of outcomes for SE have generally used a 30 minute cut-off, 
which may conflict with contemporary definitions and clinical practice.23 In addition to 
mortality, studies of paediatric SE have reported morbidity including the subsequent 
development of epilepsy or recurrent seizures, neurological deficits, cognitive impairments, 
behavioural problems and hippocampal injury (particularly with febrile SE). The relative 
frequencies of outcomes have been associated with the quality of the primary studies, with 
higher quality studies generally reporting better outcomes, both in terms of morbidity and 
mortality.54 
 
Although seeking treatable causes is a vital component of ED assessment as it may have 
implications for management, accurate prognostication in this acute phase is not possible.  
For example, while autoimmune SE may require a lengthy hospitalisation and prognosis 
may initially appear poor, many patients recover completely.67  
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2.4.1 Mortality 
The reported mortality of SE in paediatric patients differs markedly from adult series9,22 and 
has probably been decreasing over time; although this might be partly explained by 
variations in definitions, methodologies and variable quality of studies and limited follow up.  
A systematic review of 63 studies suggested that studies of higher quality tended to 
demonstrate lower morbidity and mortality than lesser quality studies.54 In the highest quality 
studies, short-term mortality of convulsive SE was 2.7 to 5.2%, and this increased to 5-8% if 
admitted to PICU.54  More recent studies report similar mortality.  The North London 
convulsive SE childhood surveillance study reported that the case fatality rate for first ever 
episode of SE was 3%,16 and a large study in Serbia reported a case fatality rate of 5.1%.57  
These rates are much lower than adult mortality from SE of up to 30%9 or 38% in the 
elderly.22  Refractory SE in children mortality is higher, at about 15-21% and neurological 
disability is also very high in survivors in this group.57,85  
 
The main determinant of mortality is the causative factor, with most deaths occurring in 
acute or remote symptomatic patients.22,54  For example, mortality of 0-2% was reported for 
“unprovoked” or febrile SE compare to 12-16% for acute symptomatic.54 Children with 
meningitis and encephalitis appear to have a poor prognosis, as do children with brain injury 
or anoxia.22,86  Young age of onset was also associated with high mortality, but this result 
was confounded by the same age group also having a high rate of acute symptomatic 
causes.54 Studies have not consistently observed an association between longer duration of 
seizure activity and higher mortality.22,35,44 
 
2.4.2 Recurrent status epilepticus and development of epilepsy 
The association of SE with the development of epilepsy has also been addressed by a 
number of studies, although again hindered by similar problems with lack of consistent 
definitions. Where the aetiology is “unknown”, previously called the idiopathic group, it is 
difficult to ascertain whether development of epilepsy resulted from the episode of SE or 
whether the SE was simply the first seizure in the presentation of epilepsy.  Risk of seizure 
after first unprovoked episode of SE is similar to the rate of seizure after first non-SE 
seizures, although reported rates have varied remarkably from 13 to 74%.54 Chin et al in 
North London reported 13% recurrence of SE during 12-month follow up,16 whilst others 
have estimated rates of 25-40% up to 24 months.46,55 Risk of development of epilepsy also 
seems to depend on the aetiology with rates highest for acute or remote symptomatic 
causes, or those with previous neurological abnormalities with rates up to 50%.22   
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Overall SE may recur in up to 20% of individuals within four years.54 Similar to the 
development of epilepsy, there are low rates of recurrence in “idiopathic” and prolonged 
febrile seizures and higher rates in acute, remote and progressive symptomatic groups.  
 
2.4.3 Duration of seizure  
While it seems unusual to suggest that the effect of seizure duration on outcome is 
unknown, the often-quoted time frames of seizure duration per se resulting in harmful effects 
e.g. after 30 minutes of continuous seizure activity, are based on limited and inadequate 
evidence consisting mostly of extrapolation from animal models.  These models of SE have 
found longer seizure duration to be associated with neuronal damage, poor outcome and the 
development of epilepsy.23 In humans, studies have not been able to adequately control for 
the important effect of aetiology on outcomes of SE in clinical situations and clearly RCTs 
are impossible.  An adult study found an association with epilepsy and duration only with 
acute symptomatic seizures.87 It seems aetiology, resistance to treatment and poor outcome 
are all inextricably linked and it is difficult to separate the degree of neuronal damage 
secondary to prolonged convulsion and neuronal damage result from the underlying cause.37  
 
2.4.4 Neurological, cognitive and behavioural impairments. 
Long term sequelae such as focal neurological deficits, neurocognitive deficits and 
behavioural problems have been suspected to result from episodes of SE in children.  The 
incidence appears to be less than 15%.22  Again, the effect of aetiology is difficult to 
completely assess, and it is likely that this is the most important factor in determining the 
outcomes.22,54 The effect of SE on intelligence quotient (IQ) has been studied, without any 
consistent findings, and further research is required.22   
 
2.4.5 Outcome after febrile status epilepticus  
Prolonged febrile seizures are an important cause of SE in children, and although mortality 
after febrile SE is low, other possible longer-term consequences of this condition have been 
explored.63,88 There is concern about morbidity, including cognitive problems and 
development of epilepsy.88 Data on epilepsy following a prolonged febrile seizure is 
controversial. Incidence of epilepsy after a febrile SE is about 5-10%, therefore significantly 
higher than the lifetime population risk of 1.6 to 3%, which is thought to double with brief 
febrile seizures.22,54,89  Febrile SE has also been implicated in affecting memory and the 
development quotient.90 It has been suggested that febrile SE may cause hippocampal injury 
and mesial temporal sclerosis leading to the development of temporal lobe epilepsy.22,91  
The alternative view is that such lesions merely indicate a predisposition to febrile seizures.  
Studies have not found an association between febrile SE characteristics (e.g. duration and 
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treatment) and outcomes.  More widespread, subtle brain injury not confined to the 
hippocampal area has also been suggested but is not universally accepted.88  
 
Understanding the pathogenesis of prolonged febrile seizures is the focus of ongoing 
research efforts with the intention of identifying novel treatments to reduce complications.64 
Whether the magnitude of the problem is sufficient to justify pursuing potentially expensive 
trials and therapies needs to be carefully considered and involve clinicians, researchers and 
the community to ensure that scarce research resources are allocated appropriately.   
 
2.4.6 Non-convulsive status epilepticus  
Whether non-convulsive SE causes neuronal injury is the subject of debate.87 In animal 
models SE induces anatomical changes and reorganization of neural networks that may 
result in injury and epilepsy.  It has been suggested that the “electronic seizure burden” may 
contribute to unfavourable outcomes in children,92 however studies have not found this 
consistently. Mortality rate for non-convulsive SE seems to be higher than for SE per se in 
paediatric patients but again problems arise with various definitions, variety of settings and 
populations studied as well as variations in care.92 It is likely that as with SE, the underlying 
aetiology remains the most important prognostic factor for outcome in non-convulsive SE.   
 
2.4.7 Consequences of status epilepticus 
Seizure activity can be considered detrimental both directly from neuronal damage to the 
brain, and secondary to systemic complications.  Prolonged seizure activity can result in 
complications such as hypoxia and hypercarbia, hypotension, acidosis, rhabdomyolysis and 
hypoglycaemia.93 Hypotension and respiratory compromise may be exacerbated by 
anticonvulsant administration. Rarely, cardiopulmonary complications can occur. Whether 
addressing these systemic complications has an effect on outcomes has not been 
adequately explored in the literature.  They are usually not mentioned in existing guidelines 
but remain important considerations when managing an episode of SE. 
 
2.5 Investigation of paediatric status epilepticus 
A comprehensive diagnostic evaluation of children who present with SE is necessary to 
identify potential causes that may require specific therapy. A specific underlying cause is 
more likely to be detected in younger patients.94 Investigations will be guided by patient 
history and examination findings with a detailed history most likely to be of highest yield. 
Investigations may include various combinations of laboratory testing, including AED levels if 
relevant, toxicology screening, neuroimaging with computed tomography (CT) or magnetic 
resonance imaging (MRI), video electroencephalogram (EEG), lumbar puncture (LP), and 
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genetic testing, depending on the circumstances. Patients with a first seizure presenting as 
SE warrant a more extensive evaluation than patients with known seizure disorder. Some of 
the workup may be performed after stabilisation, in the ED, ward or ICU.94 
 
2.5.1 Laboratory Investigations  
As with other life-threatening emergencies, evaluation and treatment of SE are performed 
simultaneously. Point of care blood glucose testing is important in the ED or pre-hospital 
setting, as although hypoglycaemia is a relatively uncommon cause of SE, it is a readily 
reversible cause.53 Serum electrolytes are also routinely recommended in the ED, however 
abnormalities of electrolytes such as sodium, calcium or glucose are only found in about 6% 
of children with convulsive SE,  and causality is not clear.53 Low AED levels are infrequently 
thought to cause SE in children, but low AED levels have been reported in as many as a 
third of patients, hence checking of relevant serum levels is usually recommended in 
children known to have epilepsy without another predisposing cause.53 
 
Blood cultures and full blood examinations should be obtained if there is any suspicion of 
sepsis on clinical grounds, although results are rarely useful in the acute setting.  Central 
nervous system (CNS) infection is variably reported, however constitutes up to 10% in some 
series.37,53,60 Prolonged febrile seizure (without CNS infection) is the most common cause of 
convulsive SE in children, but difficult to differentiate clinically from CNS infection.  It is 
therefore prudent to evaluate any child with fever and SE for the possibility of CNS infection, 
with LP performed unless contraindicated especially in children less than two years old.  
Cerebrospinal fluid (CSF) interpretation can be problematic as it has been suggested that 
CSF pleocytosis can be present from seizures in the absence of CNS infection.53 Recent 
retrospective and prospective studies found varying rates, however if detected it should be 
assumed to be due to infection.95-97 
 
While conclusive data are lacking, CSF analysis is not routinely necessary in the absence of 
fever.53 LP and CSF analysis can be considered if there is ongoing concern for infection or 
immune mediated encephalopathy, the latter being rare but increasingly recognised.98 This 
diagnosis is especially important in adolescence and should be considered if there is a 
history of prolonged encephalopathy or suggestive findings on imaging.  
 
2.5.2 Neuroimaging 
Neuroimaging is indicated in all patients presenting with a first episode of SE and has a high 
diagnostic yield.49,53,99 CT or MRI identify an aetiology in more than 30% of cases; mostly 
lesions associated with a remote cause, and often leading to a change in acute 
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management.49,99 CT is routinely available in the ED setting, and is more sensitive at 
detecting acute intracranial blood, although with the disadvantage of exposure to potentially 
harmful ionizing radiation for the patient.  MRI is generally less available in the acute setting, 
more commonly requires sedation, but has superior sensitivity for lesions other than acute 
intracranial blood.49,99 In a prospective study of children with new onset seizures presenting 
as SE, MRI demonstrated abnormalities in 14/30 (47%) of children with a normal CT head.49 
These findings were supported by a more recent study where 27% of emergent findings 
were discovered on MRI in similar patients after a normal non-contrast CT scan.99 While it 
may not be possible, or desirable, for the patient to undertake an MRI examination during 
the early phase of their hospital course, this examination should be undertaken once 
seizures are controlled and the patient stabilised. 
 
In patients known to have epilepsy, clinical judgment permits omitting most of the above 
investigations, however these investigations should be considered if seizures are not typical 
for the patient, are prolonged or are refractory to treatment.   
 
2.5.3 Special tests 
Identification of genetic mutations related to syndromes associated with SE, such as SCN1A 
gene mutations of Dravet syndrome is possible,100 however there is limited evidence for the 
utility of routine genetic testing in SE either acutely or as an outpatient.53 Similarly, 
recommendations on immunological and metabolic testing are based on very little evidence, 
but may be warranted selectively in the ICU if no cause is apparent.53 Circumstances that 
may suggest the requirement for genetic and metabolic testing include recurrent or periodic 
episodes of SE, which is not relevant on the first presentation or in the ED. Other clinical 
features may suggest the need for a more extensive work up, such as failure to thrive, 
developmental delay or ataxia.  Toxicology testing may be indicated if a clinical suspicion 
exists based on history, examination or characteristic laboratory results, and may be 
performed on either urine or blood samples.53 
 
2.5.4 Electroencephalogram in the emergency department 
The EEG is an investigation that has been used for over 50 years to examine cortical 
electrical activity.27 Guidelines and expert opinion recommend performing an EEG on all 
children presenting with SE as soon as possible, but these recommendations are based on 
low quality evidence.28,101,102 The reported benefits of EEG include the identification of non-
convulsive SE or subclinical seizures in comatose children, where non-convulsive SE maybe 
responsible for up to a third of cases and is associated with poor outcomes.28,103-105 
Conversely, EEG, and particularly video EEG, may also suggest non-epileptic seizures in 
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some circumstances, and avoid potentially harmful escalation of therapy. Other benefits of 
EEG include assisting with seizure characterisation and location and assessing the efficacy 
of interventions and guiding therapy.28,106 
 
While EEG in the management of SE is referred to as “standard practice” in publications 
from the US and elsewhere,27,107 the costly and resource intensive exercise is not routinely 
available in other settings, including Australia.  A UK study of SE found it was infrequently 
available in adults,108 with little reason to believe this would be different in children.  
 
Future developments may include the use of a limited array of electrodes, or an electrode 
cap and the development of high-speed algorithms using quantitative analysis of EEG to 
assist with diagnosis.102,107,109,110 An area of ongoing work is examining whether 
interpretation of EEG in ED by untrained individuals relying on “trend data” rather than the 
original trace recording might be possible111 but this is not ready for clinical application 
currently.  
 
In summary, while routine use of EEG in ED is difficult to justify without robust evidence of 
patient outcome benefit, or cost effectiveness data, it may be prudent instead to advocate for 
judicious use in circumstances where timely access to acute EEG is likely to have the most 
impact on SE management in children.  These could include suspected psychogenic 
seizures, where escalation of therapy could be associated with harm without benefit, and 
when children fail to return to baseline after an episode of SE, as non-convulsive SE may be 
present and remain undiagnosed.49,94 
 
2.6 Management of paediatric status epilepticus 
2.6.1 General principles 
SE is an infrequent presentation, consequently conducting high quality clinical trials has 
been difficult, and requires considerable resources and infrastructure.  The duration of 
seizure activity is associated with poor outcomes and is potentially modifiable therefore this 
is often the focus of research efforts.   Systematic reviews of management of SE in children 
include only trials of “first line” agents, with little data supporting management decisions 
beyond this stage.112 Management beyond first line drugs is based on expert and consensus 
opinion only.  As with any true emergency, assessment and management occur 
simultaneously.  The immediate priorities include attending to basic resuscitation 
requirements (supporting airway, breathing and circulation), the administration of anti-
convulsant medication to stop seizures, identifying and treating the likely cause, and the 
prevention of the secondary consequences of SE.113  
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Guidelines generally take a stepwise approach to treatment.  Typically, two doses of 
benzodiazepines are given as first line anticonvulsants. If they fail, various second line 
anticonvulsants are administered followed by rapid sequence induction (RSI) of anaesthesia 
and intubation.9,13 The use of benzodiazepines is supported by good quality evidence, and 
most patients achieve seizure control with these agents.19,112 Recent guidelines have 
advocated replacing the terms “first line” and “second line”, with a preference for 
“emergency”, “urgent” and “refractory” management to stress the time-critical nature of the 
interventions102 or “initial therapy phase” (5-20 min), “second therapy phase” (20-40 min), 
and “third therapy phase” (40-60 min).9 Without disputing the time-critical element, there 
does not seem to be sufficient justification to change widely used nomenclature. 
Consequently, the new terms have not yet been widely adopted, therefore in the sections 
that follow, the traditional terms first and second line treatment will be used. 
 
2.6.2 First line drugs 
Multiple anticonvulsants have been studied as first line therapy and current evidence and 
expert opinion support the use of benzodiazepines in this situation.102 The “Veteran Affairs” 
study of SE in adults was pivotal in establishing the efficacy of benzodiazepines as first line 
agents.114 These agents are usually effective in terminating seizures, especially if used early 
and in an adequate dose.115 The benzodiazepines most frequently studied and used for this 
purpose are lorazepam, diazepam and midazolam. Evidence based recommendations and 
guidelines have advocated either IV lorazepam (0.1mg/kg/dose) repeat if needed, IV 
diazepam (0.15-0.2mg/kg/dose) repeated if needed or IM midazolam 10mg for >40kg and 
5mg for 13-40kg, single dose, all supported by high level evidence of efficacy.9,116 The IM 
midazolam dosing above is based on a large RCT18, although intuitively one would assume 
that a weight-based dosing regimen would be preferable, avoiding wide dose ranges. The 
recommended dosing of IM midazolam is 0.1-0.2 mg/kg/dose, repeated in 10 minutes.13 
 
Attention to detail of benzodiazepine dosing is important in management of SE. 
Benzodiazepine dosing has been reported to be outside of recommended dose ranges 
nearly a quarter of the time,117 with both under- and over-treatment potentially problematic. 
Under-dosing of benzodiazepine is potentially associated with reduced efficacy while 
excessive dosing of benzodiazepine can lead to respiratory depression and the need for ICU 
admission.51,117 
 
In terms of choice of benzodiazepine, there is no strong evidence to favour any particular 
agent. Other considerations such as availability of agent, and availability of delivery route 
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influence decision-making.  In the hospital setting, as in the home and pre-hospital setting, 
there has been much work on the preferred route of administration.  While IV administration 
is likely to be preferable if available, administration of anticonvulsant medications should 
certainly not be delayed in cases where immediate IV access is not available or difficult.  
Other routes include sublingual (SL), per rectum (PR), buccal (BC), intranasal (IN), IM and 
intraosseous (IO).118 Traditionally, rectal diazepam was administered, but recently other 
options are generally preferred.  Although the rectal mucosa provides excellent absorption, 
there are a number of disadvantages to this route that limits its utility.119  Potential barriers to 
use of the rectal route of administration include reluctance of parents or other caregivers 
(teachers, carers etc.) to use this route, the requirement to remove clothes which might lead 
to delays or may not be appropriate in public places, physical difficulties of administration 
while a patient is actively seizing, which may require multiple individuals in order to 
administer the medication, and the fact that this route may not be culturally acceptable in 
some societies.119 Alternative routes of administration are gaining popularity due to efficacy 
and ease of use of which the best efficacy data supports IN or IM midazolam in situations 
where the IV route is not readily available.118   
 
Internationally, a number of clinicians and guidelines recommend IV lorazepam as the 
preferred benzodiazepine for management of SE if IV access is available.102 However, 
lorazepam is not available in some countries, including in Australia. Additionally, a recent 
high quality RCT in 2014 conducted in 273 children, demonstrated that 0.1 mg/kg of IV 
lorazepam was found to have similar seizure termination as 0.2mg/kg of IV diazepam, with 
the latter agent having less respiratory depression.15 Further, lorazepam is relatively heat 
labile requiring refrigeration for storage, compared to diazepam and midazolam which have 
long shelf life at room temperature.110  A high quality comparison of IV lorazepam with IV 
midazolam has not been conducted.  
 
Midazolam is a highly water-soluble benzodiazepine, has a fast onset of action and excellent 
CNS penetration, a wide margin of safety and broad therapeutic index.59 It is effective via 
multiple routes of administration, including IM and is a safe and effective alternative to IV 
lorazepam in the pre-hospital setting.18 A further benefit is that midazolam can be used in 
higher doses as an infusion as a second or third line agent.59  A meta-analysis comparing 
midazolam with diazepam found midazolam to be as effective as diazepam when the IV 
routes of administration of both drugs were compared, and superior to diazepam when 
routes other than IV were assessed, due to more rapid administration.120 A recent network 
meta-analysis comparing the efficacy of midazolam, lorazepam and diazepam in treating 
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paediatric status epilepticus (including 16 RCTs from 1,821 patients) determined that 
midazolam had the highest probability of achieving seizure termination.121 
 
The most recent Australian data regarding management of paediatric SE is over a decade 
old.  At that time diazepam was the most frequently used first line agent.61 It is not clear 
whether physicians have since adopted other agents, particularly midazolam. 
 
2.6.3 Second line drugs 
Studies have suggested that time to administration of second line agents may be slower 
than is desirable.  A retrospective Australian study reported that in the EDs of seven 
children’s hospitals the median time to administration of a second line drug was 24 minutes 
in SE.61 In a prospective study in the US, this time point was a median of 69 minutes, 
suggesting delays in escalating care.122 
 
Professional societies have stated that there is insufficient evidence to recommend any of 
the second line agents.116 Although none of the second line therapies have been evaluated 
in children in high quality RCTs, surveys and observational data indicate that the preferred 
second line agent by emergency physicians and neurologists remains phenytoin or 
fosphenytoin.123,124 Retrospective data suggest that phenytoin is only effective in about 60% 
of cases61 and it has other potential problems that make the prospect of other agents 
desirable.   Phenytoin has a well-documented adverse effect profile including hepatotoxicity, 
pancytopenia, phlebitis, Stevens-Johnson syndrome, hypotension, cardiotoxicity, 
extravasations causing tissue necrosis and purple glove syndrome.125 The potential for 
cardiotoxicity necessitates slow infusion and cardiac monitoring.125 The cardiac toxicity of 
phenytoin has resulted in a number of documented deaths from inappropriate dosing or 
infusion rates when phenytoin has been given as a loading dose, as is the case in SE 
management. Fosphenytoin is used internationally due to concerns about safety of 
phenytoin, mainly cardiac arrhythmias and tissue necrosis.  Fosphenytoin can be 
administered more rapidly than phenytoin, but as a pro-drug, effective blood and tissue 
concentrations of the drug are probably not available any faster.9,113 Further, idiosyncratic 
adverse events associated with phenytoin, such as Stevens-Johnson syndrome are still 
reported with fosphenytoin. Fosphenytoin is not available in Australia or New Zealand.   
 
Newer agents such as levetiracetam, valproate and lacosamide have been proposed, and 
reported as effective second line SE agents, however evidence is limited to case reports and 
small case series.9 Several observational studies have suggested levetiracetam may be safe 
and effective in SE, with doses ranging from 20-60mg/kg.126,127 Advantages include that it 
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can be given rapidly, and has a favourable safety profile compared to phenytoin.  In a 
retrospective study comparing two of these newer agents in adults with SE with phenytoin, 
efficacy of phenytoin did not differ from levetiracetam or valproate.128 A recent RCT in India, 
also in adults, similarly did not demonstrate superiority of the “newer agents”.129 Lacosamide 
is another agent that has generated interest, but also without robust evidence.127 In 
summary, despite the well-known problems with phenytoin, and no strong evidence to 
support its use, it would be premature to adopt these new agents at this point.  Ongoing 
trials in Australia and New Zealand, United Kingdom and the U.S. will clarify the role of three 
of these agents in paediatric and adult SE.21,130  
 
2.6.4 Management of refractory status epilepticus (third line therapy) 
As with other aspects of SE, definitions of prolonged SE, refractory SE and super-refractory 
SE have changed over the years.  Refractory SE usually now refers to when first and 
second line drugs fail to control the seizure, rather than indicating a specific time period for 
the length of seizure.28,98,131  Super-refractory SE denotes seizures that persist or recur 
despite administration of continuous infusion anticonvulsants or general anaesthesia.28,98,132 
 
Traditionally, if second line agents fail, guidelines – based on expert opinion - have 
advocated anaesthetic doses of thiopental, midazolam, pentobarbital or propofol.127 Use of 
these medications is generally associated with the requirement for endotracheal intubation, 
because of the effect of the medications on respiratory drive and airway reflexes. There is no 
evidence that any of these agents is superior to another for refractory SE. 
 
There is some evidence that high dose midazolam infusion is effective and is probably an 
appropriate initial choice for refractory SE.131,133 A recent systematic review found 521 cases 
of midazolam infusion use in refractory SE, with seizure control achieved in 76% of cases.132  
The recommendation is to start therapy with a bolus of 0.1mg/kg and an infusion at 
0.2mg/kg/hr, with a repeat bolus and doubling of the infusion at 10 minutes if seizure activity 
is ongoing.133 The infusion can continue to be titrated up, ideally guided by continuous EEG 
monitoring but specialist advice sought, as complications can occur at high infusion rates, 
such as hyperchloraemic, non-anion gap metabolic acidosis. Rarely hemodynamic support 
is required. 
 
Infusions of general anaesthetics are another option for refractory SE.  Propofol infusions 
used in adults are considered to have an unacceptable risk of propofol infusion syndrome in 
children.133 Barbiturates, in particular thiopentone, pentobarbital and phenobarbital are often 
recommended for this purpose.  These agents have excellent CNS penetration, and have 
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actions on GABA receptors, NMDA receptors as well as effects on chloride, potassium and 
calcium channels.133 These medications can reduce the cerebral metabolic rate, which is 
thought to be advantageous in management of refractory SE.  High lipid solubility leads to 
prolonged drug effects, long elimination half-life, and consequently may lead to slow 
recovery.133,134 The main problems with this class of drugs are respiratory depression and 
hypotension.133,134  
 
An RCT in adults with refractory SE comparing propofol with barbiturates was terminated 
early for slow recruitment, with only 23 patients of a required 150 enrolled.135 While no 
difference in outcome was shown, it was clearly underpowered to provide any useful 
information, except confirming the difficulty in conducting trials in this cohort of patients.135 
The best practices for airway management in SE are unclear.136  
 
Another strategy that has been advocated is the use of third line agents without the 
requirement for intubation e.g. using agents without respiratory depressant effects 
(valproate, phenytoin, levetiracetam, lacosomide) when they have not been used as second 
line agents.101,113,137,138 Put another way this could be considered repeating “second-line 
therapy”. A recent adult trial in India demonstrated additional benefit when these agents 
were used third and fourth line, although this was not the primary objective of the study, but 
rather a pragmatic reflection of their practice environment and resources.129 However, this 
may be instructive in patients for whom intubation is not desirable such as chronic patients 
with recurrent SE, and worthy of further study.  
 
Ketamine has received recent attention as a method of terminating refractory SE,8,10,139 and 
is an attractive option to emergency physicians, who are likely to be familiar with its use in 
other situations. It has favourable hemodynamic effects, and less effect on respiratory 
reflexes and ventilation than other agents.  Ketamine is an NMDA-receptor antagonist that 
produces dissociative anaesthesia without cardiorespiratory depression.  To date, reported 
series have used ketamine well down the treatment algorithm, after many other treatments 
have failed.140 The effect of earlier use of ketamine, as a second or third line agent, is not 
known but is the subject of a current clinical trial in Italy.139 If ketamine is found to be 
effective in seizure termination, it might be again most useful in circumstances when 
intubation is undesirable, e.g. in patients with frequent or recurrent SE with comorbidities.   
 
Inhalational anaesthetics such as isoflurane have been used for refractory SE for many 
years. Although the precise mechanism of action is not known, it is likely to involve a number 
of receptors.  These medications usually induce immediate cessation of seizure activity 
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regardless of duration, type or aetiology.138,141 They are not generally available to ED 
providers, are usually tried only as a last resort, and there is very little supporting evidence in 
children.  Titration is usually assisted with continuous EEG monitoring.133 
 
2.6.5 Novel strategies 
Therapeutic hypothermia for the management of refractory SE and super-refractory SE has 
also been described. A small case series describes cooling to 30-35 degrees Celsius, 
however treatment effect independent of other factors has not been established.  There are 
adult trials underway.142 
 
A ketogenic diet, consisting of high fat, low carbohydrate and adequate protein, has also 
been advocated for refractory epilepsy syndromes. The basis for this approach is the 
efficacy of a ketogenic diet in patients with poorly controlled drug resistant epilepsy with 
frequent seizures. In refractory SE and super-refractory SE the therapy is given through a 
feeding tube.133 The use of this intervention is probably last line in patients with refractory SE 
and super-refractory SE and thus is likely to be of less relevance to emergency physicians, 
although there are trials underway in adults. 
 
2.6.6 Management of non-convulsive status epilepticus 
Historically, various definitions of non-convulsive SE have been used, making interpretation 
of the available literature problematic.  Conventionally definitions have included both 
absence status epilepticus and complex partial status epilepticus, with known differences in 
outcomes.92 These have been classified separately in a report on definition and classification 
from the ILAE task force, and are associated with differing time frames to tonic-clonic SE.23 
Studies have invariably been performed in the ICU setting rather than ED, and have 
incorporated EEG criteria for identification, making them of little relevance to ED physicians, 
who are unlikely to have this information available.92 Whether treatment can improve 
outcome is unknown, and as with convulsive SE, the underlying cause is probably the most 
important prognostic factor.92 Optimal management strategies are unknown, but until further 
data is available, if diagnosed or suspected in the ED, management should progress along 
similar lines as for convulsive SE. 
 
2.6.7 Specific aetiology 
Identification of a presumed cause of SE may necessitate specific directed treatment in 
addition to supportive and anticonvulsant treatment.  For suspected infective aetiology, 
obviously antibiotics are indicated as per local and national guidelines for meningitis, as well 
as an antiviral such as acyclovir for possible Herpes simplex infection depending on the 
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clinical circumstances.143 If suspected, treatment should not be delayed for confirmation by 
laboratory tests.   
 
Other inflammatory conditions such as immunological or autoimmune encephalitis can 
cause refractory SE. If suspected clinically or by the presence of autoantibodies, oligoclonal 
bands in the CSF or typical MRI findings, immunomodulating treatments such as steroids or 
IV immunoglobulin can be used, but specialist advice from a neurologist or infectious 
disease specialist is warranted.143 Other drugs with anti-inflammatory properties may also be 
useful, and some have advocated ketamine as having such properties.67  
 
SE suspected to be due to a toxicological cause or overdose may result in changes to 
standard management algorithms. While phenytoin is most often recommended in SE 
protocols where benzodiazepines have failed, this agent may cause cardiac toxicity, and is 
not advised in this situation - barbiturates may be preferable.144 The roles of valproate and 
levetiracetam are still unknown for this purpose.69 
 
2.7 Summary 
This chapter has outlined the epidemiology, investigation and management of paediatric SE, 
with a focus on the developed world.  Within the limitations of the data and problems related 
to various definitions, the incidence appears to be in the order of 20 per 100,000 per year.  
Aetiology is varied and seems to be the most important contributor to outcomes.  Prolonged 
febrile seizures are the most common cause of paediatric SE, and are generally associated 
with good outcomes, but can be difficult to differentiate from more sinister causes in the 
initial stages of evaluation. Investigation and management of paediatric SE usually occur 
simultaneously due to the urgency and time-critical nature of the condition.  The quality of 
the evidence to inform decisions is generally poor, and management algorithms are based 
largely on theoretical considerations, tradition and expert opinion. Identification of likely 
aetiology may influence treatment decisions, therefore is of value, particularly for infective, 
inflammatory or toxicological causes.  The duration of seizure activity is the only factor 
associated with outcome that is potentially modifiable, therefore research efforts have 
usually concentrated on this aspect of care. In advanced medical systems, emergency 
interventions are frequently delivered by highly trained paramedical staff in the field, before 
arriving at a hospital.  As time to treatment is thought to be of key importance, this may 
prove to have a substantial impact on early intervention for paediatric SE.  Chapter 3 
presents a review of pre-hospital care of paediatric SE.  
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Chapter 3 – Paediatric status epilepticus in the pre-hospital setting: A 
review  
 
3.1 Overview 
Early intervention is important in achieving seizure control in SE, and a potentially modifiable 
factor affecting outcomes. Management in the pre-hospital environment represents an 
opportunity to affect outcomes but presents unique challenges.  This chapter addresses 
objective 1 of this thesis, and specifically the topic of pre-hospital care of paediatric SE. As 
with the ED setting described in the preceding chapters, research in the pre-hospital setting 
is challenging, and most guidelines and protocols are not evidence based.  Limited 
resources, time, and difficulties with informed consent are important barriers.  Despite this, a 
number of important advances in the management of SE have occurred in the pre-hospital 
environment. The objectives of this review are to present an overview of the available 
evidence on pre-hospital aspects of paediatric SE, to describe current practice in Australia 
and New Zealand, assess for variation in care, make recommendations about care of these 
patients, and outline future research priorities.  Figure 3.1 places this chapter in the 
conceptual framework of the broader thesis relative to other elements 
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Figure 3. 1 Conceptual model of thesis 
 
 
This chapter comprises a published manuscript. It is inserted as published. The citation is: 
 
Furyk J, Watt K, Emeto TI, Dalziel S, Bodnar D, Riney K, Babl F. Review article: Paediatric 
status epilepticus in the pre-hospital setting: An update. Emergency medicine Australasia: 
EMA. 2017 Jun 18. PubMed PMID: 28627014. DOI: 10.1111/1742-6723.12824 
 
3.2 Publication in Emergency Medicine Australasia
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3.3 Supplementary file 
See Appendix 3.1 – Medline search strategy  
 
3.4 Summary 
This chapter comprised a review article of paediatric SE.  The objectives of the review were 
to present an overview of available evidence in pre-hospital care of paediatric SE and to 
assess current pre-hospital guidelines in Australia and New Zealand. A literature search was 
conducted on databases Embase, Medline and Web of Science. Title and abstracts were 
screened, and full articles retrieved for inclusion if relevant to the objectives. State and 
territory ambulance services were contacted for protocols, and additional searches were 
performed for grey literature and on Google scholar.  
 
The main findings from this chapter are summarised below: 
 
• Paediatric SE is a common critical condition encountered by pre-hospital providers, 
and management can be challenging in this environment. 
• Epidemiology and the general principles of management of paediatric SE are 
described, including home treatment, choice of benzodiazepines, preferred routes of 
administration and blood glucose testing. 
• Pre-hospital paediatric SE management protocols were evaluated, revealing 
significant variation in doses and routes of administration, which may influence 
treatment decisions in the ED. 
• The optimal timing and dosing remain unknown. 
 
It is evident that variations exist in the pre-hospital management of paediatric SE, without 
robust evidence of the optimal pharmacological agent, timing and route of administration. 
While such variation in practice represents an opportunity to evaluate this “natural 
experiment” with quality, prospectively collected observational data, this alone is unlikely to 
change practice, and further high-quality clinical trials are required.  In the emergency and 
pre-hospital setting, high-quality randomised controlled trials have traditionally been 
infrequent due to the many unique challenges of conducting research in this setting. One 
such challenge is the complex ethical issues surrounding obtaining prospective informed 
consent for research, in a time-critical situation.  Given the difficulty involved in conducting 
such research, it is essential that valuable research resources are allocated appropriately, 
and that important stakeholders are engaged in the process of setting the research agenda.  
One strategy is to seek consensus on research priorities from experts.  Chapter 4 outlines a 
Delphi consensus process of research priorities in paediatric SE.   
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Chapter 4 – Consensus research priorities for paediatric status 
epilepticus: A Delphi study of health consumers, researchers and 
clinicians. 
 
4.1 Overview 
Conducting high quality research in the pre-hospital and emergency settings is challenging.  
Presentations of individual conditions are infrequent and there are often competing priorities 
in an austere, stressful environment where the main focus is on managing time-critical and 
life-threatening conditions. The challenge is increased by the difficulty in obtaining informed 
consent.   Given the substantial effort required to conduct research in this setting, it is crucial 
that a collaborative, widely consulted, systematic approach to identifying and clarifying the 
immediate research priorities in SE is utilised to ensure limited research resources are 
directed appropriately.   One approach to identify research priorities among relevant 
stakeholders is a Delphi process.  Chapter 4 addresses objectives 2 and 3 of the thesis. In 
this chapter a Delphi process for achieving consensus research priorities in paediatric SE 
among experts and consumers is presented. Figure 4.1 places this chapter in the context of 
the broader thesis. 
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Figure 4. 1 Conceptual model of thesis 
 
 
 
The first part of the chapter comprises a brief overview of the Delphi process. The remainder 
of the chapter consists of a published article. It is inserted as published. The citation is: 
 
Furyk J, Ray R, Watt K, Dalziel SR, Oakely E, Mackay M, et al. Consensus research 
priorities for paediatric status epilepticus: A Delphi study of health consumers, researchers 
and clinicians. Seizure. 2018 Feb 5;56:104-9. PubMed PMID: 29471256. 
10.1016/j.seizure.2018.01.025 
 
 
4.2 The Delphi technique 
The Delphi technique was initially developed by the Research and Development Corporation 
in California in the 1950s for achieving consensus of opinion within a certain topic area from 
experts in the field.145,146  It is named after the oracle on the island of Delphi in Greece, who 
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was believed to accurately predict the future.  Originally designed for military planning 
purposes, the technique has been applied successfully in various fields and plays an important 
role in health sciences research, in the development of ideas and priorities.  Briefly the 
technique involves the solicitation and collation of opinions and judgements from experts in a 
particular field through a set of carefully designed sequential questionnaires, with information 
from previous responses summarised and fed back to participants.147 
 
The initial round is used to generate and verify issues and ideas. This first step usually consists 
of open-ended questions soliciting specific information about the content of subsequent 
questionnaires.  Responses to the open-ended questions are then converted to a structured 
questionnaire to be used as the survey instrument in the second round. Subsequent rounds 
attempt to achieve consensus on the issues and ideas raised in round one, with researchers 
collating and returning responses to participants presenting the position of the whole group 
and the participants own position on the research issue. Every participant reassesses their 
initial judgement about the information provided. Generally, three to six iterations are 
employed, although three rounds is usually sufficient to reach consensus on a topic, as 
additional rounds produce minimal change in opinion.147  
 
The major benefits of the technique are to avoid the limitations of using less formal techniques 
to achieve consensus such as through committees and panels, which can be prone to 
domination by powerful individuals and influenced by personalities.  The benefits of anonymity 
and confidentiality contribute to the development of true expert consensus.  The process also 
allows participants to generate additional insights and more thoroughly clarify information.  As 
there is no requirement to meet face-to-face, clinicians from disparate geographical areas can 
be included. Modern technology such as electronic surveys have further simplified the 
execution of the process and facilitated the development and implementation. 
 
In health sciences research the technique is most useful to address clinical issues that may 
not be amenable to evaluation in randomized clinical trials or quantitative data analysis where 
incomplete data exist.  Delphi technique is useful to determine informed judgements on topics 
spanning a range of disciplines such as neurology and emergency medicine.  Within 
paediatrics the technique has been successfully used to identify research priorities in the field 
of neurology with respect to cerebral palsy, and to identify general emergency medicine 
research priorities in the United Kingdom and Australia.148-150  
4.3 Publication in Seizure: European Journal of Epilepsy. 
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4.4 Supplementary file. 
See appendix 4.1. Table S5.1.1 Complete Delphi question rankings and scores. Table 
S5.1.2 Expert text comments on consensus High Priority questions in round 2 and 3.  
 
4.5 Summary 
Chapter 4 address objectives 2 and 3 of this thesis and comprises a Delphi study designed 
to achieve consensus on research priorities in paediatric SE among experts and consumers. 
A three round Delphi process was conducted. Questions generated by round one were 
collated into themes, and developed into mutually exclusive research questions in structured 
questionnaires in rounds two and three.  Participants rated the perceived priority of 
questions using a seven-point Likert-type, ordinal scale.  Main findings from this chapter are 
summarised below: 
 
• The perspective of emergency physicians is underrepresented in SE literature and 
guideline development.  
 
• Consensus was achieved on research priorities in the management of paediatric SE 
among paediatric neurologists and emergency physicians and aligned with priorities 
identified by health consumers. 
 
• The process identified nine priority research questions, consisting of second line 
management including levetiracetam (efficacy, dose and timing), use of third line 
agents, induction of anaesthesia (timing and best agent), management of focal SE, and 
indicators of “subtle SE”.  
 
• Consumers identified important research themes including drug therapies and treatment 
efficacy, causes and “triggers”, and outcomes and prognostication 
 
• Incorporating stakeholders’ perspectives into the development of research priorities may 
lead to highly engaged researchers and increased likelihood of translating research into 
clinical practice. 
 
Important priority areas in the management of paediatric SE were identified in the research 
presented in this chapter.  Many of the research questions may not be possible to address 
with traditional concepts of informed consent for research, and alternative approaches need 
further exploration.  Some of the components raised in the process include therapies and 
interventions that have in some ways already been incorporated into clinical care and 
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protocols for the management of paediatric SE, despite a striking lack of quality evidence.  
This highlights the paradox of informed consent in research and management of paediatric 
SE.  Research has traditionally been difficult in these circumstances, however clinicians can 
opt to incorporate un-validated practices into clinical care without the need for informed 
consent. Comparative effectiveness research, where there is true equipoise (like comparing 
two “standard therapies”), and observational research in this context also requires informed 
consent in most circumstances in Australia and New Zealand.  Involvement of stakeholders 
in determining research priorities justifies research in challenging circumstances, such as 
where prospective informed consent is not possible, and will ensure results are rapidly 
translated into practice. One of the main priority areas identified by the Delphi consensus 
process was that of second line management, and specifically levetiracetam.  Chapter 5 
outlines a protocol for a randomised controlled trial of levetiracetam and phenytoin in the 
second line management of paediatric SE.  This trial represents one of the first paediatric 
trials conducted in Australia and New Zealand, using a “deferred” consent process.   
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Chapter 5 - A multicentre randomised controlled trial of levetiracetam 
versus phenytoin for convulsive status epilepticus in children 
(protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) 
 
5.1 Overview 
As outlined in Chapters 2 and 3 of this thesis, various benzodiazepines are most frequently 
used as first line in the management of paediatric SE, however there is a dearth of evidence 
to inform second line management. While no high-quality evidence supports the use of any 
of the interventions in common use, newer agents have found their way into clinical practice 
and guidelines.  Second line agents, and in particular levetiracetam were identified in three 
of the nine research priority questions by the Delphi process of Chapter 4.  This Chapter 
addresses objective 2 of this thesis and outlines the protocol for a randomized controlled trial 
of levetiracetam compared to phenytoin, in the second line management of paediatric SE. 
The trial protocol directly addresses the question identified by the Delphi process; “In 
children with convulsive SE, is levetiracetam superior to phenytoin for efficacy (seizure 
termination) and safety (adverse effects)? “.  Figure 5.1 places this chapter in the context of 
the broader thesis.   
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Figure 5. 1 Conceptual model of thesis 
 
The Chapter consists of a published article.  It is inserted as published: 
 
Dalziel SR, Furyk J, Bonisch M, Oakley E, Borland M, Neutze J, et al. A multicentre 
randomised controlled trial of levetiracetam versus phenytoin for convulsive status 
epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - 
a PREDICT study. BMC Pediatr. 2017 Jun 22;17(1):152. doi: 10.1186/s12887-017-0887-8. 
 
5.2 Publication in BMC Paediatrics.  
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5.3 Summary 
Chapter 5 describes the protocol for a randomized controlled trial of second line 
management of paediatric SE, addressing a priority identified by the Delphi study, and 
utilizing a deferred consent process. The study aims to determine whether levetiracetam is a 
better second line agent than the current standard practice of phenytoin.  
 
• 200 Children from three months to 16 years will be recruited in participating sites. 
 
• The primary outcome will be cessation of seizure activity at five minutes following 
completion of infusion.   
 
• As valid informed consent would be impossible to obtain in these circumstances the 
study uses a deferred consent process.  
 
The results of this study will provide the first high quality evidence of second line 
management of paediatric SE.  The results of this landmark study are likely to generate 
significant interest internationally and influence treatment guidelines globally.  A 
controversial aspect of the trial design is the enrolment of participants without prior informed 
consent from parents.  The trial protocol states that investigators will seek delayed 
retrospective consent for participation, with written informed consent to remain in the study 
sought as soon as possible after stabilization of the child. Four ethics committees in this 
multicenter trial approved this process, which has not been utilized in large multicenter 
paediatric trials in Australia or New Zealand previously.  Recruitment prior to prospective 
informed consent was considered an important aspect of the study design, and integral to 
the validity of results and the success of the trial.  While enrolment prior to informed consent 
is addressed in various ethical guidance documents, the unfamiliarity with the process 
provoked debate regarding the ethical acceptability of the trial by certain groups including 
clinicians, ethics committees and policy makers.  In Australia, the NHMRC are currently 
reviewing their national statement guidance documents addressing precisely this issue and 
calling for input from stakeholders. In Chapter 6, issues regarding the conduct of emergency 
medicine research without prospective informed consent from a historical and international 
perspective are discussed, with a particular focus on those relevant to our local setting.  How 
informed consent in time-critical research is addressed in future ethical guidance documents 
will have a profound influence on emergency medicine research in this country.  This will in 
turn impact upon the quality of care in emergency departments in general and the availability 
of evidence-based therapies for the most vulnerable patients in particular. 
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Chapter 6. Informed Consent in Emergency Care Research  
 
“The physician who is convinced a certain treatment works will 
almost never find an ethicist in his path whereas his colleague 
who wonders and doubts and wants to learn will stumble over 
piles of them”  
Attributed to T.C. Chalmers (1917-1996, Physician, EBM pioneer, Harvard)  
 
6.1 Overview 
As previously stated much of the practice of emergency medicine, including paediatric SE is 
not based on high-level evidence. Performing randomised trials in paediatric SE such as the 
ConSEPT trial outlined in Chapter 6, and other types of research in the ED setting presents 
difficulties when prospective informed consent is not possible.  This chapter provides a 
perspective on informed consent in emergency care research. Figure 6.1 places the chapter 
in the context of the broader thesis. 
 
Figure 6. 1 Conceptual model of thesis 
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6.2 Introduction 
Every day thousands of patients in Australia and New Zealand present to ED for emergent 
and critical care. Emergency physicians have an obligation to ensure their practice is 
underpinned by the highest quality evidence available, yet interventions that are utilized 
every day are often are not evidence based, remain controversial and are potentially 
harmful.151 The role of adrenaline in out-of-hospital cardiac arrest is a prime example.  
Administration of adrenaline to patients in cardiac arrest is included in all international 
cardiac arrest algorithms and is frequently depicted as lifesaving in television and movies.  
However, this belies the reality that the utility of the adrenaline has been debated for 
decades, with no evidence of benefit, and some suggestion of harm.152 Difficulties in 
conducting the necessary conclusive clinical trial means that adrenaline remains in 
management algorithms based on expert opinion and tradition, the lowest levels of medical 
evidence to inform practice.153,154 The use of oxygen for patients suffering myocardial 
infarction is another example, which was routine for many years before researchers recently 
questioned the practice, with limited evidence suggesting potential harm.155 Subsequently in 
a large RCT of over 6,000 patients the practice was not found to be beneficial.156 In 
paediatric emergency medicine, the management of SE is another example, where practice 
beyond first line care is based solely on expert opinion and tradition.9 Clinical trials are 
urgently needed in many areas of emergency medicine to clarify important clinical questions. 
Historically, many well-intentioned medical therapies, whose use was recommended based 
on expert opinion or tradition, have been found to be harmful after proper scientific study and 
subsequently discontinued, a phenomenon termed medical reversal.151,157 
 
The requirement to obtain informed consent in emergency and critical care research has 
commonly been cited as a barrier to ED research.32,158-161 While the role of informed consent 
is well established in conventional medical research and clearly delineated in the NHMRC 
guidelines,33 aspects of the informed consent process in clinical research in the emergency 
setting deserve additional consideration.  There are complex ethical, logistical and regulatory 
issues centred on informed consent that need careful deliberation in the unique context of 
research in critically ill patients. These issues are perhaps more problematic in paediatric 
emergency research as children are considered a vulnerable group, and generally do not 
consent to research themselves, with proxy consent from guardians usually sought.  
 
A paradox exists where emergency medicine providers readily prescribe medications for 
clinical care that have not been rigorously evaluated, often without the explicit consent of the 
patient or ethical approval, yet barriers around issues of informed consent for research make 
evaluating such therapies problematic, even if they are in common use.  Consequently, 
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many therapies in routine use remain unproven. This contravenes community expectations 
that the care patients receive from their treating clinician is evidence-based.  
 
Confusion around the requirement for informed consent and the ethical and legal 
implications of research where informed consent is not possible are critical factors limiting 
research in emergent and life-threatening conditions.158,160,162 Strategies to optimize the 
ethical and governance review process and ensure emergency research aligns with 
community expectations are necessary to ensure emergency interventions can be 
thoroughly evaluated.  
 
6.2.1 Ethical conduct and ethical principles 
Conducting research on humans is guided by the principles and values of respect for human 
beings, research merit, integrity, justice, and beneficence.33 Respect for human beings 
includes acknowledging the importance of autonomy, and the importance of determining 
one’s own life and making one’s own decisions, and also providing protection for people with 
reduced autonomy. Research merit and integrity necessitates that the proposed research is 
appropriately designed to achieve its aims, based on rigorous science, and the researchers 
are capable of conducting such research, otherwise human participation cannot be ethically 
justified.  Justice in the research context refers to the equitable distribution of the benefits 
and burdens of research.  Finally, beneficence takes into account the relative risks, harms, 
and potential benefits of the research to participants and to the broader community.  Ethics 
committees are given the responsibility of making judgments about research considering 
these elements and balancing the potential benefits and risks to the participant, and the 
requirement for informed consent from participants.33 
 
6.3 Historical Perspective 
6.3.1 Nuremberg Code 
The public’s trust in the credibility of medical research has had several setbacks during the 
evolution to what we now term as the era of evidence-based medicine.  In the first half of the 
20th century, in the name of “medical research”, doctors in Nazi Germany performed heinous 
crimes on vulnerable populations including psychiatric patients, inmates of concentration 
camps, children with disabilities and others.  Twenty-three individuals were subsequently 
tried for war crimes and crimes against humanity in Nuremberg in 1947; many received 
convictions and seven received the death penalty.163 At the conclusion of the trials, the 
judges produced the “Nuremberg Code”, a human rights document outlining the procedures 
necessary for acceptable medical research.  The code included 10 points to protect the 
rights and welfare of research subjects.  The code strongly emphasised informed consent, 
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starting with the statement “the voluntary consent of the human subject is absolutely 
essential”.163 Critics considered this overly simplistic for clinician researchers, and 
questioned the relevance of consent to the atrocities committed in the name of research, 
which were experiments with little scientific merit, questionable importance or simply torture 
and mass murder.163 
 
Although the Nuremberg code was a significant advance, it was not widely adopted.  The 
emphasis on informed consent did not appear to recognise that situations may exist where 
informed consent may not be feasible, or indeed that the time taken to obtain informed 
consent may be detrimental. The document was written by lawyers and consequently 
criticized as “overly legal” and described by some as a “code for barbarians” and not 
required for civilised clinicians.163 What cannot be disputed though was that the credibility of 
the medical research community was significantly shaken by revelations of the extent of 
atrocities committed.  
 
6.3.2 Declaration of Helsinki 
In 1964 the World Medical Association published a policy for research ethics referred to as 
the Declaration of Helsinki.  A key element of the document was the clear distinction 
between therapeutic and non-therapeutic research, the former requiring consent “if at all 
possible”.34 The declaration was updated and expanded in 1975, again with some latitude 
for clinician researchers to consider the feasibility of consent in all circumstances.  This was 
further refined in 1983 and 1996, with specific reference to minors included for the first time.   
The Declaration of Helsinki remains the ethical framework to guide investigators in clinical 
medical research.   
 
The current version of the Declaration of Helsinki acknowledges that circumstances exist 
when prospective informed consent is not possible, proposing alternative strategies by 
stating;  
 
“If the research cannot be delayed, the study may proceed without informed 
consent provided that the specific reasons for involving subjects with a 
condition that renders them unable to give informed consent have been 
stated in the research protocol and the study has been approved by a 
research ethics committee. Consent to remain in the research should be 
obtained as soon as possible from the subject or a legally authorized 
representative” 34 
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6.3.3 The Tuskegee syphilis experiment 
Another episode that had a profound and possibly ongoing effect on the public’s perception 
of medical research, particularly research involving minorities and other vulnerable groups, 
was the Tuskegee syphilis experiment in the US. Again, the actions of those involved are 
difficult to fathom, and the episode has been described as a “national tragedy”.163 From 1932 
to as recently as 1972 the US Public Health Service conducted a “natural experiment” or 
non-therapeutic study of the effects of untreated advanced, tertiary syphilis in more than 400 
mostly poorly educated and illiterate black males in Alabama.  The study observed the 
clinical effects, and participants were actively denied treatment, despite penicillin becoming 
available in the 1940s as a known treatment for the condition. Consent was not obtained, 
and participants were deceived about the purpose of the study, with information withheld 
about their diagnosis.  Many may have believed that they were receiving treatment.164 The 
study was finally exposed in 1972 when a past employee of the Public Health Service 
provided information to the press about the experiment.  The story generated widespread 
public outrage, leaving a legacy of resentment of government agencies, particularly in black 
American communities.  The experiment has been described as “a symbol of research 
malfeasance in which virtually every principle underlying the ethical treatment of human 
subjects of research was violated”.163 
 
6.3.4 Belmont report 
Prompted by the public outrage in the aftermath of the Tuskegee syphilis experiment the US 
government commissioned the Belmont report in 1978. The report offers a framework for 
analysing the ethical issues that arise from medical research, with the objective of improving 
research oversight systems to provide greater protection for research participants. The 
report outlined the three basic moral principles underlying the conduct of research as: 
respect for persons (informed consent), beneficence (risk versus benefit assessment), and 
justice (selection of research participants).  Although not without critics, it has had a 
profound influence on medical ethics and government policy and even the practice of clinical 
medicine.163   
 
6.4 What is informed consent? 
6.4.1 Definitions 
Informed consent for general medical care has not been a central tenant of the profession 
for as long as one might expect, with the term “informed consent” thought to have only first 
been used in a court ruling in the UK in 1981.165 Prior generations of clinicians routinely 
sheltered patients from information that they considered might be harmful.  Such paternalism 
is now generally discouraged, and informed consent for medical interventions is now 
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ethically and legally required, with the level of detail expected commensurate with level of 
risk.  That is, the higher the risk, the more detailed explanation required.  Key elements of 
informed consent include disclosure, comprehension, voluntariness, competence and 
consent.166 In emergency situations doctors regularly provide clinical care without obtaining 
informed consent.  The community has trust in the medical profession and individual doctors 
to behave in a responsible way, and provide care that is in the patient’s best interests.165 
 
Research standards for the Australian context are published by the NHMRC.33 These 
standards specify that informed consent is an important component of conducting ethical 
research, and patients should be adequately apprised of the risks and benefits of 
participation.33,167 Informed consent for research is an exercise of a voluntary choice to 
participate in research, based on the provision and subsequent comprehension of 
information about the purpose, methods, demands, risks, inconveniences, discomforts and 
possible outcomes of research.33 However, a signature on a consent form does not equate 
with informed consent, and obtaining informed consent does not necessarily equate with 
ethical research.168,169 Commonly accepted guiding principles are that a person’s decision to 
participate in research needs to be voluntary. This includes having adequate time to 
consider the details of the research being proposed and the opportunity to ask questions 
about the requirements and risks of participation in the research.33,167 In Australia valid 
consent requires three elements to be present: the capacity to make voluntary decisions; 
that the consent is free and voluntary; and that the consent covers the act performed. As 
noted by White et al, if any one of these elements is absent, consent is undermined and can 
“transform the treatment into a potential assault”.170 In the conventional model of medical 
research, often involving repeated visits to a clinician and an extended period of both 
consideration and prospective study, these  requirements can be easily satisfied. Similarly, 
there are obviously situations where it is possible to obtain informed consent prior to 
enrolment in emergency medical research.  In these circumstances, there is a requirement 
that ED staff are trained in the principles of Good Clinical Practice, provide comprehensive 
information, and allow sufficient time to consider participation without coercion.33 Refusal 
should not prejudice clinical care. 
 
6.4.2 Clinical care versus research 
Consent for emergent clinical care is often not sought in life-threatening situations.  The 
community generally accepts that medical staff in these circumstances are acting in patients’ 
best interests.  It remains controversial if such an approach is acceptable in research. In 
comparative effectiveness trials, where true equipoise exists between clinicians and 
allocation to treatment is determined by the trial process, it can be argued that from a 
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patient’s perspective there is negligible additional risk in not seeking consent for participation 
in a trial in a life-threatening situation compared to treatment outside of a trial protocol in a 
similar situation.171-173 However, there is insufficient data on what is acceptable to the 
community or general public in these situations.  Further, some evidence from other 
research settings suggests that patients’ understanding of research may be suboptimal, with 
concepts of clinical care and research often confused, while participation in research is often 
linked to personal gain for the participant.  
 
6.4.3 Is informed consent possible in time-critical research?  
For many important clinical questions in emergency medicine research, obtaining informed 
consent using the ideal or optimal principles described may not be feasible. The paradigm of 
informed consent is underpinned by the patient’s competence. Unfortunately, in the context 
of emergency research, critically ill or injured patients will often lack capacity because of the 
illness or injury itself; patients with severe head injuries or unconscious cardiac arrest 
patients are obvious examples.  Difficulty arises in other acute situations where patients may 
be alert or their proxies may be available, but it is unlikely they maintain sufficient decision-
making capacity to consent to research.  Examples include patients having an acute 
myocardial infarction (AMI) being approached for enrolment in an interventional trial, or 
parents of a child in SE being approached for consent in a clinical trial.  The phrase 
“situational incapacity” has been used to described circumstances where decision-making 
abilities seem to be compromised because of highly emotional or stressful 
circumstances.174,175 The possibility of coercion is also a factor even when patients are 
thought to retain capacity.  All ED patients could be described as potentially vulnerable as 
they present at a time of crisis and may be anxious, sick, in pain, and/or disoriented as well 
as highly dependent on the acute care they are receiving.174 Care must be taken to ensure 
that any consent process does not equate to exploitation.   
 
Insufficient time is also a critical factor.   If the participant retains capacity, there is often 
insufficient time available to adequately consider the pros and cons of participation.  If the 
participant lacks capacity, there may be difficulties associated with locating an appropriate 
substitute or surrogate decision maker (SDM). Many interventions are time-critical and have 
a short therapeutic window.  Contacting a SDM to consent for a cardiac arrest trial is 
logistically impossible. It has been postulated that delays involved in seeking consent in 
certain circumstances where the therapeutic window is short, may result in worse outcomes 
for patients, be less likely to show benefit in trials, and hence be unethical.176,177 For example 
it has been estimated that in the second international study of infarct survival (ISIS-2) trial, a 
study of streptokinase and aspirin in over 17,000 adults with AMI, that a delay of 20 minutes 
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for consent procedures would have been associated with 10 more deaths in the active 
treatment arm.178 
 
Other logistic issues also make the process of informed consent difficult in the emergency 
setting. Potential participants may present sporadically or after hours, and to achieve 
meaningful results enrolment may involve clinical staff rather than study investigators to 
screen, identify and consent eligible patients in busy environments. This delegates the duty 
of consent to non-investigator staff, with possible implications over the adequacy of the 
process and a conflict of responsibilities. In critical situations a recruiting clinician may feel 
that fully informed consent procedures interfere with adequate management of the patient 
and impede the ability to treat a patient expeditiously thus risking delays to lifesaving care.	 
In multisite research, it is common for the same trial to be subject to differing consent 
requirements in different jurisdictions according to the requirements of local human research 
ethics committees (HREC).179   
 
6.4.4 The Cardiac trials 
An area of emergency medicine that has perhaps been the subject of more rigorous 
research than any other is the management of AMI.  This is despite the significant ethical 
issues involved in conducting research in patients with AMI.  Adequate informed consent is 
dubious given the extreme stress and anxiety of the situation and the potential effects of 
medications on cognition.  Interventions for AMI are known to be time-critical, and obtaining 
informed consent, intended to protect participants from harm, conversely may cause harm if 
delays to treatment result.  In clinical circumstances obtaining informed consent has been 
described as “uninformed trust” with patients often preferring to leave treatment decisions to 
the physician.180 Various large cardiac trials have approached this issue from different 
perspectives.  
 
The majority of trials have used a conventional approach to informed consent; the provision 
of oral and written information, followed by signing a consent form and allocation to a 
treatment arm.178 Published reports of the trials provide very little information of how consent 
was approached, and little acknowledgement of the limitations of the procedure.178,181 The 
first Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO) trial in 1993, a study of thrombolytic agents in over 40,000 
patients, from 1,000 hospitals in multiple countries including the US, Europe and Australia, 
reported only that “patients gave consent for participation”.182 In contrast, the “Gruppo 
Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico” (GISSI) thrombolytic trials 
between 1986 and 1994 enrolled patients without consent, but subsequently informed the 
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patients about participation.178,181 This approach was apparently to “protect the right of the 
patient not to be exposed to an emotionally burdensome request for informed consent”, and 
that ethics committees associated with the trials did not believe meaningful consent would 
be possible under the circumstances.183 Contemporaneously, in the ISIS-2 trial in 16 
countries, at 417 hospitals, informed consent requirements varied between sites from not 
being required to requiring formal prospective written consent.184 US sites in ISIS-2 required 
a 4-page consent form, which was associated with lower recruitment rate than in other 
countries, and criticised as designed to protect physicians from litigation rather than be in the 
interests of participants.178  
 
Research into the consent processes of these trials suggests that many participants 
considered themselves not to be competent at the time of consent.  Many (11-43%) had no 
or almost no recollection of the consent process, and in one study almost a quarter were not 
aware that they had participated in a study.178,185,186 Oral information was recalled better than 
written information.178,185,186  
 
6.4.5 Issues specific to paediatrics 
Historically children have been subject to exploitation by medical researchers, and as such 
are considered a potentially vulnerable group.163 Clinical research in paediatric emergencies 
is necessary to ensure management of children is evidence-based and effective.    The 
concept that participation in medical research involves accepting a certain level of personal 
risk for societal benefit may be too complex for children to grasp.163 
 
The ability of children under the age of 16 to consent for medical treatment is often 
described in terms of “Gillick competence”.  This is based on a ruling in the UK House of 
Lords in 1985 and acknowledged under Australian law.187 It is usually based on the 
individual doctor’s assessment to determine if the minor in question can fully understand the 
treatment proposed.187 The application of Gillick competence to medical research is 
controversial, as it has been argued that often the assessor stands to gain personally from 
the involvement in research, therefore similar standards are not appropriate.187 Almost 
invariably, consent for participation in research is sought from parents.  As children develop 
and mature, they can be more involved in discussions regarding participation in medical 
research, and many jurisdictions have a requirement for assent, which is said to be possible 
from as early as seven years of age.188 
 
There are a number of limitations to seeking consent from parents in emergency situations, 
similar to seeking consent from other SDM of incapacitated adults. Briefly, these include that 
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parents may not be immediately available, which could be critical in interventions with a 
short therapeutic window.  Parents are also affected by situational incapacity at a vulnerable 
moment, in a highly stressful setting and upsetting circumstances such as a sick child.  
Furthermore, there is evidence that decisions by proxies may not reflect those of the 
participants.32 These issues are expanded on in the following sections.   
 
Given that the child themselves usually does not get the opportunity to consent to or decline 
participation, the responsibility for protecting the participant, and the potentially complex risk 
benefit assessment lies with ethics committees, and generally requires the possibility of 
direct benefit to participants, and that the research is low risk.  
 
6.4.6 What is informed consent in Australia 
The principles of informed consent for research in Australia are outlined in the NHMRC 
National Statement on Ethical Conduct in Human Research.33 The document outlines that 
consent needs to be a voluntary choice and based on sufficient information and adequate 
understanding of the research and the implications of participation.  The document also 
outlines conditions under which the requirement can be qualified or waived. Importantly 
participants or proxies should not be subjected to any coercion and any inducements are 
ethically unacceptable. Involvement of children and young people in decisions should 
increase as maturity and capacity increases.33 
 
6.5 Alternatives to informed consent 
In Australia, over the last decade or so, administrative, ethical and legislative changes have 
had a significant impact on the implementation and conduct of emergency and critical care 
research.  This is because the mechanisms of decision-making about persons who lack the 
capacity to make decisions for themselves, either temporarily or permanently, is facilitated 
by state and territory jurisdictional legislation about guardianship.170 Each jurisdiction has 
enacted its own legislation with common law playing only a limited role.170 Confusion among 
emergency physicians, ethicists, legal advisors and HRECs around differences between the 
guardianship requirements of each jurisdiction and terminology in documents suggests that 
the special circumstance of emergency, pre-hospital and critical care research was not 
adequately considered when legislation and other relevant documents were drafted. In 
Australia alternatives to prospective informed consent include proxy consent, a waiver from 
individual participant consent, and retrospective or deferred consent, although the 
implementation has been variably interpreted with repercussions for the research being 
conducted. Although the NHRMC specifies conditions for patients who cannot consent for 
themselves (table 6.1), these stipulations are subject to higher regulatory authority in all 
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jurisdictions of Australia.33,179 Accordingly large multi-national clinical trials have frequently 
been conducted with varying consent procedures employed in differing jurisdictions.  This 
may itself be unethical and has the potential to lead to bias.  
 
6.5.1 Proxy consent 
Seeking a surrogate decision maker, or proxy consent, is most commonly utilised when the 
individual participant is incapable of providing informed consent due to the effects of the 
medical condition of interest. This is the usual practice for invasive medical therapy or 
procedures when a patient otherwise lacks capacity. However evidence exists that relatives 
and friends often demonstrate poor agreement with the wishes of the participant.32 Proxy 
consent also may not be available in an appropriate timely manner necessary for some 
interventions with a narrow therapeutic window, as is the case for many emergency 
conditions and treatments. In the Corticosteroid Randomisation After Significant Head Injury 
(CRASH) trial, seeking proxy consent was associated with a delay to treatment of 1.2 hours 
compared to when requirement for consent was waived.177 Time spent seeking such consent 
may distract staff from appropriate clinical care in these circumstances, and treatment 
delays may harm patients.  Even if available in a timely manner, close friends and relatives 
may also be too distressed to adequately comprehend information being provided to them to 
enable for them to provide truly informed consent. 
 
6.5.2 Waiver of informed consent 
A waiver of informed consent is allowable in Australia in certain circumstances unless 
prohibited by law (see Table 6.1).33 While conducting research on individuals raises 
concerns about unethical practice and contravenes individual autonomy, conversely denying 
patients the opportunity of participating in such research, with associated potential benefit, 
contravenes the ethical principle of justice.169 When emergency medicine research requires 
a waiver of informed consent, the responsibility to protect participants rests with a rigorous 
HREC approval process. The requirements that need to be satisfied to qualify for waived 
consent are open to interpretation by HRECs. Ethics committees are charged with weighing 
the balance of potentially waiving a patient’s right to consent, the societal benefit and 
importance of undertaking the research, and the potential lost opportunity for the patient to 
participate in a study. For ethics committees used to considering the conventional model of 
medical research consent, the specific issues and needs of emergency researchers may not 
be apparent. Not infrequently, the same trial is conducted with differing consent 
requirements among study sites, even if operating under the same ethical guiding principles 
and legal framework in the same country.189 This can affect patient recruitment, and 
potentially result in selection bias.   
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Table 6. 1 Requirements to qualify to waive consent 
National Health and Medical Research Council – National Statement (section 2.3.6) 
a) involvement in the research carries no more than low risk to participants.   
b) the benefits from the research justify any risks of harm associated with not 
seeking consent.   
c) it is impracticable to obtain consent. 
d) there is no known or likely reason for thinking that participants would not have 
consented if they had been asked. 
e) there is sufficient protection of their privacy. 
f) there is an adequate plan to protect the confidentiality of data. 
g) in case the results have significance for the participants’ welfare there is, where 
practicable, a plan for making information arising from the research available to 
them. 
h) the possibility of commercial exploitation of derivatives of the data or tissue will 
not deprive the participants of any financial benefits to which they would be 
entitled. 
i) the waiver is not prohibited by State, federal, or international law. 
 
To qualify to waive consent the NHMRC national statement in section 2.3.6 a, has a 
requirement that the research “carries no more than low risk” (See Table 6.1) which it goes 
on to define as where the “only foreseeable risk is one of discomfort”.33  The relevance to 
patients who are critically unwell is unclear. Such a statement is clearly unsuited to the 
unique nature of emergency research, which often by its nature is high risk. This terminology 
is confusing for researchers and is variably interpreted by committees. A related concept of 
“incremental risk” has been advocated by some authors.31,190 
 
In the US the ability of the ethics committee to waive consent is supplemented by the 
requirement for consultation with community representatives and advocates.  Experience 
from large international multicentre emergency trials suggests that conditions in Australia are 
more stringent and prohibitive than in other countries such as the UK and US,191 which may 
have a negative impact on the attractiveness of Australia as a research destination, limiting 
opportunities to participate in large multicentre studies and stifling the development of 
research infrastructure in Australia. 
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6.5.3 Deferred consent 
A further option is that of deferred, delayed or retrospective consent. Similar to a waiver of 
informed consent, deferred consent is used when it is not possible to obtain prospective 
informed consent from the participant before randomisation.  Consent is obtained from 
participants (or proxy) as soon as practical, after the intervention has been given.  Consent 
is obtained to remain in the trial, to use data and to allow follow up.192-195 Critics argue that 
use of the term consent is a misnomer, as the intervention has already been given, and 
consent is being sought to continue in the trial and for the inclusion of data already 
collected.196 
 
Waivers and deferred consent aim to avoid selection bias and maximise recruitment by 
including sicker patients who would otherwise not be offered the opportunity to take part in a 
trial. It allows study treatment to be delivered rapidly in an emergency, with potential benefits 
for the individual patient. Deferred consent reduces staff anxiety with regard to implementing 
a trial protocol and requires less deviation from routine clinical care.197 
 
Barren et al suggest the informed consent process needs to be adapted to the emergency 
setting by “eliminating some of the less essential elements” where time pressures and 
certain amount of vulnerability existed but patients still may have capacity to consent and 
refuse.174 Whether this is acceptable, and which elements can be excluded requires further 
research.  
 
6.5.4 Alternative trial designs 
The controversial Zelen trial design is another technique that has been suggested to 
overcome difficulties in obtaining informed consent for ED research.198 Zelen originally 
described a design where randomisation occurs before consent is obtained, and consent is 
only sought in the intervention arm.  The approach aims to reduce unnecessary anxiety and 
distress of those allocated to standard treatments, and Zelen argued that it may improve 
recruitment rates.  However, ethical concerns that the design contravenes individual 
autonomy means that the approach has seldom been used, and it is not generally accepted 
in medical research culture.199-201 
 
6.5.5 Clinical care versus research  
The ease and acceptability of clinicians using unproven therapies clinically without the 
ethical and legislative obstacles involved in collecting data in the same patients remains a 
frustrating paradox to researchers. It is interesting to consider the patient’s perspective in 
cases where there is no clear standard of care derived from evidence. In such cases the 
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person attending ED may or may not receive certain treatments depending on factors such 
as which clinician happens to be scheduled at work, individual clinician whims, experience or 
opinion, or local institutional protocol. Thus, for the patient with the condition under 
consideration, the treatment they receive is effectively “random”. Therefore, from the 
patient’s perspective, the distinction between therapy and research is somewhat artificial. 
Legislation designed to protect participants may be inadvertently leading to harm, by 
obstructing research efforts to identify which treatments are effective.  A perplexing situation 
exists where patients often report a willingness to accept an unproven intervention, on the 
recommendation of their doctor for clinical care, but are more wary if told data will be 
collected as part of a study, and more concerned if they are to be randomised.190,202 This 
does not seem to be related to trust, but it is difficult for medical researchers to understand 
given the rigorous protections in place as part of a clinical trial.  This may be related to a 
poor understanding of the importance of rigorous scientific methods by patients.  
Participants’ perceptions about the process of randomisation is a common theme of 
concern, with perhaps little understanding of the scientific importance of randomisation and 
perceptions of being a “guinea pig”.203 Regardless, the majority of patients are generally still 
willing to participate in an RCT.202 
 
6.6 Publication in Emergency Medicine Australasia 
A synopsis of this chapter was published in Emergency Medicine Australasia as a 
perspective piece, on behalf of the Australasian College of Emergency Medicine, Clinical 
Trials Group (ACEM-CTG).  It is inserted as published. 
 
Furyk J, Lawton LD, Ting JYS, McD Taylor, D. Informed consent in emergency care 
research: An oxymoron? Emerg Med Australas. 2017 Feb;29(1):110-112. PubMed PMID: 
27469986. DOI: 10.1111/1742-6723.12642. 
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6.7 Summary  
Chapter 6 outlines the historical background and current issues regarding informed consent 
in paediatric emergency medicine research, and emergency research in general.  The 
paradox of using unproven treatments for clinical care, and obstacles involved in 
researching potentially lifesaving interventions were explored.  The main findings of the 
chapter are: 
• Many treatments commonly used in emergency medicine are not based on high 
quality evidence.   
• In paediatric SE, and many other areas of emergency medicine, clinical questions 
remain unanswered because the research involves situations where informed 
consent would be problematic or impossible. 
• Research studies and clinical trials are urgently needed in paediatric SE and other 
areas of emergency medicine to ensure that treatments being used are effective.   
• International research ethical statements consider the requirement for research 
without informed consent, but Australian guidelines lack clarity, significant confusion 
exists and implementation is variable. 
• Research about consent issues in emergency settings is inadequate; this is 
particularly true for children, rightly regarded as a particularly vulnerable group.   
A synopsis of this chapter was published in Emergency Medicine Australasia, as a 
perspective piece, with input from members of the ACEM CTG.  The intent of publishing the 
article was to stimulate debate and shine a light on the issues facing clinician researchers on 
a daily basis, that were impacting research in clinically important areas and affecting clinical 
care.  An aspect of the debate that is under-represented in the Australian context is that of 
consumers.  There are no available data on the views of the general public with regard to 
research in emergency situations when prospective informed consent is not possible.  
Chapter 7 begins to address this knowledge gap, using a comprehensive systematic review 
the chapter explores the available empirical evidence on research without informed consent 
specific to paediatric emergency medicine. This is particularly relevant to research in 
paediatric SE.   
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Chapter 7. A comprehensive systematic review of stakeholder 
attitudes to alternatives to prospective informed consent in paediatric 
acute care research. 
 
7.1 Overview 
Robust evidence is often lacking in paediatric SE and other areas of paediatric emergency 
and critical care.  The approach taken to dealing with informed consent, one of the 
underlying principles of ethical research, is an important aspect of the design of research in 
this field. Due to the infrequency of utilising approaches other than prospective informed 
consent in these settings, researchers, clinicians and even ethics committees may be 
unfamiliar with the complex ethical issues involved.  A comprehensive systematic review of 
the available empiric evidence on alternatives to prospective informed consent, including the 
attitudes and opinions of participants, parents, researchers and others is crucial to inform the 
planning and design of studies addressing important knowledge gaps in paediatric SE and 
other acute and life-threatening paediatric conditions.  This chapter addresses objective 4 of 
the thesis and presents the results of a systematic review of the evidence relating to the 
process, experiences and acceptability of alternatives to prospective informed consent, in 
the paediatric emergency and acute care setting. Figure 7.1 places this chapter in the 
context of the broader thesis. 
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Figure 7. 1 Conceptual model of thesis 
 
 
The chapter consists of a published article. It is inserted as published:   
 
Furyk J, McBain-Rigg K, Renison B, Watt KA, Franklin R, Emeto T, Ray R, Babl F, Dalziel S. 
A comprehensive systematic review of stakeholder attitudes to alternatives to prospective 
informed consent in paediatric acute care research. BMC Medical Ethics (2018) 19:89 
https://doi.org/10.1186/s12910-018-0327-9 
 
7.2 Publication in BMC Medical Ethics 
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7.3 Supplementary file 
See supplementary appendix 7.1 – Medline (Ovid) Search.  
 
7.4 Summary 
Chapter 7 addresses objective 4 of the thesis and describes a comprehensive systematic 
review conducted according to preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines on alternatives to prospective informed consent in paediatric 
acute care research. Thirteen studies (none of which were Australian) were included in the 
review.  The main findings were: 
 
• Researchers, health practitioners and the community are generally supportive of 
enrolling children in studies where prospective informed consent is not possible with 
the provisions of limiting risk and informing parents as soon as possible.  
• Other major themes explored in published literature were the capacity of parents to 
provide informed consent, feasibility of informed consent, process issues, modified 
consent processes, child death, and community consultation. 
 
The review outlined the limited experience from international settings on alternatives to 
prospective informed consent in paediatric emergency medicine and critical care research.  
The results are highly relevant to the design of paediatric SE research locally, although data 
from the Australian and New Zealand setting are urgently needed. Chapter 8 describes a 
survey of the Australian public on attitudes to research without informed consent in both 
adults and children. To ensure that research in emergency situations such as paediatric 
status epilepticus can continue, researchers and policy makers need to ensure strategies for 
enrolling participants into research studies and clinical trials align with community 
expectations, and that the voices of consumers are involved in the development of guiding 
frameworks for undertaking such research. 
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Chapter 8: Community attitudes to emergency research without 
prospective informed consent: A survey of the general population 
 
8.1 Overview 
Medical research in Australia is performed under guidelines issued by the NHMRC, local 
governance requirements, and legal requirements. As outlined in Chapter 6, requirements 
can vary for the same research in different jurisdictions.  Prospective, voluntary informed 
consent is a key aspect considered when approving conventional medical research. 
However, in certain emergency conditions, such as paediatric SE, when every minute 
counts, research must occur prior to obtaining informed consent, in order to evaluate new 
and existing therapies, and ensure patients are receiving the best possible care.  While 
provisions for this exist in research guidelines, the ethical basis for this is complex, and it is 
not known what the general public thinks about this type of research. This chapter 
addresses objective 5 of the thesis. Results are presented from a survey of the general 
public on the views and perspectives of clinical research in time-critical situations, when 
prospective informed consent is not possible.  Involving consumers in planning research and 
developing research guidelines is fundamental to maintaining the trust of the community.  
Figure 8.1 places this chapter in the context of the broader thesis. 
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Figure 8. 1 Conceptual model of thesis 
 
 
The chapter consists of a published article.  It is inserted as published: 
 
Furyk J, Franklin RC, Watt K, Emeto TI, Dalziel SR, McBain-Rigg K, Nikola Stepanov N, 
Babl FE and PREDICT. Community attitudes to emergency research without prospective 
informed consent: A survey of the general population. Emerg Med Australas. (2018) 30, 
547–555.  doi: 10.1111/1742-6723.12958 PMID: 29718588 
  
 
8.2 Publication in Emergency Medicine Australasia 
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8.3 Supplementary file  
See supplementary appendix 8.1. Manuscript appendices. Complete survey transcript. Table 
S1. Description of themes in qualitative analysis. 
 
8.4 Summary 
Chapter 8 addressed the significant knowledge gap around the Australian public’s 
perspectives on research in time-critical situations, without prospective informed consent.  
This study makes an important contribution to knowledge, as it is the first published study in 
Australia on this topic. The main findings of the population-based survey of 1200 participants 
were: 
 
• The public was generally supportive of the concept of research without prospective 
informed consent. 
• This was true for both adult and paediatric research. 
• The degree of risk, and the time-critical nature of the intervention were important 
considerations 
 
This was the first survey of this type in an Australian setting. The methodology used was 
limited in its ability to probe the reasoning behind individual responses.  However, this 
research implied that research guidelines are consistent with community expectations, and 
that the public is supportive of emergency research. The next chapter (Chapter 9) will 
explore the attitudes and opinions of parents presenting to Australian EDs on research 
without prospective informed consent in the context of two clinical trials in children, including 
an interventional trial in paediatric SE. 
 
  
 140 
Chapter 9: Qualitative evaluation of a deferred consent process in 
paediatric emergency research.  
 
9.1 Overview 
Alternative strategies to prospective informed consent have rarely been used in Australia 
and New Zealand to enrol participants into randomised controlled trials in paediatric 
emergency medicine. Emergency treatments are often instituted without informed consent 
for clinical care, even if treatments are unproven.  When a child is enrolled in a clinical trial 
and receives an intervention, and consent is sought from parents at a later stage to use the 
data and continue in the trial, the process is termed deferred, delayed or retrospective 
consent.  The acceptability of the process in paediatric emergency and critical care research 
is not known, as demonstrated by a systematic review (Chapter 7) during which no 
published Australian data were identified. Chapter 8 provided the first Australian population 
data on attitudes to alternatives to prospective informed consent in emergency research, but 
the methodology had limited ability to explore reasoning behind attitudes.  This chapter 
addresses objective 6 of this thesis and explores the experiences and attitudes of parents of 
children attending ED for acute conditions in relation to participation in research, when 
prospective informed consent is not possible.  Scenarios discussed in the interviews were 
based on authentic descriptions of cases of paediatric SE and bronchiolitis, and related to 
the parents’ recent experience in the ED. The qualitative methodology was well suited to 
address the aims of the study, enabling parents to provide greater insights into the 
reasoning behind opinions, and explore key issues in further detail.  Parents of children 
attending the emergency department were recruited and interviewed for the study.  The 
recent experience in attending the ED with a sick child enabled parents to contextualize the 
feelings of anxiety and vulnerability associated with such visits.  Figure 9.1 places this 
chapter in the context of the broader thesis. 
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Figure 9. 1 Conceptual model of thesis 
 
This chapter comprises a published manuscript.  It is inserted as published.  The citation is: 
 
Furyk J, McBain-Rigg K, Watt, K, Emeto T, Franklin RC, Franklin D, Schibler A, Dalziel S, 
Babl FE, Wilson C, Phillips N, Ray R, on behalf of PREDICT Qualitative evaluation of a 
deferred consent process in paediatric emergency research: a PREDICT study. BMJ Open 
2017;7:e018562. doi:10.1136/bmjopen-2017-018562 
 
9.2 Publication in BMJ Open
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9.3 Summary  
Chapter 9 addressed objective 6 and described a qualitative study of deferred consent in an 
interventional trial of paediatric SE in the ED setting.  Interviews were conducted with 39 
parents of children who presented to the ED with uncomplicated febrile seizures or 
bronchiolitis. The main findings of the study were as follows: 
 
• Parents were cognisant of the limitations of prospective informed consent in time 
limited situations. 
 
• Parents were generally, but not universally supportive of alternatives to prospective 
informed consent. 
 
• There was a strong theme of trust in the medical profession. 
 
• Research literacy was suboptimal, with confusion of some important concepts. 
 
 
This study gives voice to consumers in the design of paediatric emergency medicine clinical 
trials.  This research, performed in the context of two current clinical trials (1: second line 
management of paediatric SE; 2: high flow nasal cannula therapy in bronchiolitis), included 
participants from various geographic locations and varying ED types, making the results 
highly transferable. The qualitative methodology allowed a greater exploration of important 
questions and to clarify understanding of certain concepts.  The results build on and are 
broadly consistent with international literature identified in the systematic review (chapter 7) 
and our population survey (chapter 8) and support current research guidelines as aligning 
with community expectations. Chapter 10 is the discussion and conclusions based on the 
work included in the thesis.  The paradox of informed consent in the management and 
research of paediatric SE is discussed, with implications for future research and policy 
examined.   
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Chapter 10: Discussion and Conclusion 
 
10.1 Overview 
This thesis has explored the paradox of informed consent in paediatric status epilepticus 
(SE) research, with the aim of improving management of the condition in Australia and New 
Zealand.  As in many areas of emergency medicine, new therapies have been adopted 
without high quality evidence, partly because of the difficulty of research in emergency and 
time-critical situations. Astute clinicians have for decades observed the paradox that it 
seems acceptable for clinicians to adopt new therapies for the clinical care of patients 
without robust evidence, whereas physicians who would rather evaluate these same 
therapies with methodologically sound studies, face high levels of scrutiny as well as 
regulatory and ethical obstacles. Inadequate medical and research literacy may be at the 
core of this apparent contradiction.  Clinicians and the public often overestimate the 
effectiveness of the therapies used and fail to appreciate the additional protections that are 
afforded to research participants as part of a research protocol, compared to treatment 
decisions at the discretion of individual medical practitioners.   The exposure to risk of harm 
is a key concern of patients.  Ethical considerations should include any degree of additional 
risk to patients if exposed to an intervention as part of a research protocol, and the potential 
benefit to patients and the community of valuable medical knowledge about the efficacy of 
treatments.  These considerations must include informed consent requirements.   
 
A fundamental issue in a research programme to improve outcomes in paediatric SE is 
informed consent.  The requirement for prospective informed consent remains a significant 
barrier to the conduct of research in paediatric SE and time-critical situations, impairing the 
progress of medical knowledge.  Instead interventions of unknown or dubious benefit are 
used routinely.  This is contrary to patients’ expectations and is not acceptable in the era of 
evidence-based medicine.  In my thesis I have used multiple methodologies to explore these 
issues, including literature reviews (narrative, systematic, perspective), Delphi consensus 
technique, cross-sectional population-based survey (with qualitative and quantitative 
components), and qualitative study (semi-structured interviews resulting in thematic 
analyses).  The body of work has resulted in seven peer-reviewed publications.  Journals 
were actively chosen to disseminate the research findings to the most appropriate audience, 
to stimulate discussion and debate among stakeholders, with the primary objective of 
facilitating research in paediatric SE. Despite the research being situated primarily in 
paediatric SE, results are also more broadly applicable to other areas of emergency 
medicine.  
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This thesis comprised two parallel, yet complimentary streams.  The first stream (chapters 2 
to 5) explored existing knowledge of paediatric SE, and identified stakeholder research 
priorities for SE, as well as the feasibility of addressing these knowledge gaps.  In stream 
two, barriers to research in paediatric SE, namely issues of consent for time-critical ED 
research, were explored (chapters 6 to 9).  This final chapter of the thesis is at the 
confluence of these two streams.  In this discussion the six objectives of the thesis are 
reviewed, chapters and results are summarised, integrated and discussed in the context of 
previous research. Figure 10.1 provides an outline for the thesis as a whole and places this 
chapter in the context of the broader thesis.  This chapter concludes with the implications for 
policy, practice and further research.   
 
Figure 10. 1 Conceptual model of thesis 
 
Initial chapters of the thesis set the scene by outlining the background of paediatric SE.  In 
chapters 1 and 2, the background of paediatric SE was discussed, specifically in the 
Australasian emergency setting, and chapter 3 highlighted issues pertinent to the pre-
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hospital setting. Collectively, these chapters addressed objectives 1 of the thesis. Chapter 4 
was a study designed to achieve consensus on research priorities in paediatric SE using a 
Delphi technique, in clinical experts (emergency physicians and paediatric neurologists), as 
well as consumers.  This chapter addressed objectives 2 and 3 of the thesis. Chapter 5 
outlined the protocol for a randomised controlled trial addressing a key question in the 
management of SE in children.  As valid, prospective informed consent is not possible in this 
trial, the protocol includes a controversial deferred or retrospective consent process.  This 
chapter addresses objective 2 of the thesis. Chapters 6 to 9 comprised stream 2 of this 
programme of research and explored various aspects of alternatives to informed consent in 
emergency and paediatric emergency research.  This consisted of a literature review in the 
broader emergency medicine context, as well as the historical background (chapter 6), a 
systematic review of paediatric specific issues with alternatives to informed consent (chapter 
7 – objective 4); a national cross-sectional population-based survey of community attitudes 
to research in emergency settings without prospective informed consent (chapter 8 – 
objective 5) and a qualitative study of parents’ views in the context of paediatric SE research 
without prior consent (chapter 9 – objective 6).  
 
10.2 Knowledge gaps and research priorities in paediatric status epilepticus 
Treatment of SE has confounded physicians for over a century. “Sedation” proposed as an 
effective modality by Shanahan in 1914, remains the mainstay of therapy and the only 
evidence-based approach to this day.3  Chapters 1 and 2 provide a synopsis of the existing 
evidence and highlight important knowledge gaps in terms of epidemiology and aspects of 
diagnosis and management.  
 
Chapter 1 reviewed the definitions, history and classifications of paediatric SE. A lack of 
consistency in definitions of SE over time has been problematic in SE research. Accurate 
and consistent medical definitions are vital for communication among physicians, to improve 
treatment and facilitate research.  The traditional SE definition of a seizure of at least 30 
minutes has recently been replaced by an “operational” definition that has been utilised in 
clinical trials and addressed by the ILAE in a proposed consensus statement.15,20,23 This 
clinically relevant time frame of 5 minutes of continuous seizure activity emphasizing the 
time-critical nature of the condition, which would however prohibit obtaining prospective 
informed consent for research, and alternative strategies are required. 
 
A re-worked classification system has also been developed, and accompanied the new 
definition.23  This change was designed to facilitate future research efforts, and addressing 
issues with the previous classification used which was designed for epilepsy syndromes, 
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and not designed for a large proportion of patients with SE that do not have epilepsy. While 
significant steps forward, the reworked definitions and classification systems make 
interpretation of previous comparative studies difficult due to inconsistencies, and new data 
are urgently required.  
 
Chapter 2 highlighted the incomplete understanding of the incidence and epidemiology of 
paediatric SE, signifying opportunities for further research. What many consider to be the 
highest quality estimate for the incidence of paediatric convulsive SE comes from London, 
where the crude incidence was estimated at 17-23 per 100,000 per year.16  However, the 
definition used in this study included only seizures of greater than 30 minutes duration, 
therefore this likely represents a significant underestimate of incidence based on 
contemporary definitions. No quality observational studies to date have used such 
definitions; consequently, the true burden of disease remains unknown.  A further limitation 
of the existing epidemiological research is that these estimates are based solely on episodes 
of convulsive SE.  The impact of other types of SE is unknown.   
 
As identified in chapter 2, aetiology of SE is different in children compared to adults, and 
changes with different ages among children. Again, childhood data is limited by varying 
quality and methodologies of existing data. Along with changing definitions, classification 
systems have also undergone revisions.23  While the usefulness of the new system is 
evident, the changes again preclude comparisons with historical data.  Febrile SE remains 
an important cause in known SE, but estimates vary greatly in available studies. The clinical 
utility of febrile SE as a diagnosis is also questionable, as differentiation from potentially 
important infective syndromes including meningitis and encephalitis is difficult.  Estimates of 
the incidence of meningitis vary greatly, from one in five to one in ten60,61 and robust local 
data is urgently needed.  Other associations with potential causative factors such as 
antibiotics or other drugs, or inflammatory SE need to be explored. Even fundamental 
questions remain unanswered, such as whether seizure duration is an independent risk 
factor for poor prognosis, when controlled for the confounding effect of age and aetiology.  
Existing research does not provide conclusive evidence.  With improvements in technology 
and infrastructure (e.g. electronic health records, learning health systems and embedded 
clinical registries), that can improve routinely collected data, has the potential to improve the 
evidence base.  
 
Chapter 2 goes on to review the literature on the emergency investigation and management 
of paediatric SE. In emergency settings, assessment and management occur 
simultaneously.   The adequacy of the patient’s airway, breathing and circulation are 
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evaluated as a priority, and time-critical interventions are not delayed. Identification and 
accurate diagnosis of potential aetiology that may influence management decisions take 
precedence in this early phase of care.  Workup may vary according to the specifics of the 
clinical situation.  LP and CSF analysis are required if infection or immune mediated 
encephalopathy is suspected.53 Neuroimaging is indicated in first episodes of paediatric SE, 
but may be avoided in patients with known seizure disorders.53 Other investigations such as 
genetic testing are unlikely to affect management, but are an increasing area of research.  
Acute EEG although recommended, is infrequently available in the ED setting, even in well-
resourced paediatric specialist facilities in Australia and New Zealand. Use of simplified EEG 
tests and algorithms that may be more broadly applicable is a current area of research 
interest not yet proven to modify outcomes, but perhaps could be used judiciously in cases 
likely to affect outcome or management decisions such as suspected psychogenic or non-
convulsive SE. 
 
As mentioned, age, aetiology and duration of seizure activity are all associated with poor 
outcomes, but only seizure duration is potentially modifiable. Therefore, this is often the 
focus of attempts to improve outcomes. With regard to treatment, high-level evidence is 
available only for first line agents (benzodiazepines). Observational research suggests that 
treatment is often delayed or inappropriate doses are administered, and that timeliness is 
probably more important than routes of administration.63,122 Beyond first line treatment, data 
are inadequate and newer agents are increasingly used without evidence or based on low 
quality evidence. Levetiracetam, valproate, and lacosamide have all been variously 
proposed as second line agents in favour of the traditional phenytoin, which itself lacks high-
level evidence.127 None of these have been evaluated in high-quality trials.  Once suspected, 
treatment should be directed at specific causes, including antibiotics and/or antivirals if an 
infective cause is suspected. Similarly, toxicological causes or inflammatory conditions may 
benefit from directed treatments. This represents an important knowledge gap, and a 
potential area to improve outcomes. 
 
If timeliness of achieving seizure control is the most important modifiable factor, then 
addressing care in the pre-hospital setting represents an opportunity to improve outcomes.  
Pre-hospital care has evolved from merely patient transportation, to the early delivery of 
quality care by highly trained healthcare providers.  Chapter 3 summarises the available 
evidence on pre-hospital management of paediatric SE.  This literature review identified that 
definitive evidence is lacking, and that there is substantial variation in guidelines and 
protocols around Australia and New Zealand. Like in the ED, one of the barriers to pre-
hospital research is consent. Overseas adult studies in this setting have made significant 
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contributions to new knowledge over the last few decades in spite of the difficulty of 
performing clinical trials in this setting.18  Clear and consistent guidance on the requirements 
for emergency research utilising a waiver of informed consent in the US may have enabled 
this.  Clarification of the requirements in the Australian setting is urgently required, to 
encourage clinical trials in this space in Australia. Guideline and policy makers need to 
consider this unique environment when developing standards. The population distribution in 
Australia requires the coordination of various states and territories, and alignment of 
requirements to allow adequate power to answer important clinical questions.  The present 
situation in Australia with variation in care among disparate agencies represents a unique 
opportunity for quality observational research, and a natural experiment to examine 
effectiveness of protocols in routinely collected data or clinical registries, as well as 
opportunities to standardise care.  
 
10.3 Engaging relevant stakeholders in planning paediatric status epilepticus research 
Conducting research in the emergency setting is difficult and requires considerable 
infrastructure and costs.  To ensure limited research funds are directed appropriately, it is 
vital that a collaborative, widely consultative, systematic approach is used to identify and 
clarify the immediate research priorities in paediatric SE.   The engagement of key 
stakeholders such as experts in acute management, consumers and the general public is 
vital to provide input on both research priorities, and consent methods that are within 
acceptable community standards. 
 
The Delphi process outlined in Chapter 4 to develop consensus represents an important first 
step in developing research priorities for paediatric SE. Involvement of consumers ensured 
that their voice was represented in the process, which is increasingly required by funding 
agencies, and research ethics committees as a requirement for approval. The chapter 
described the multistage process of solicitation and refinement of research priorities in the 
management of paediatric SE among paediatric neurologists and emergency physicians 
using an electronic online survey. The study also involved determining if these priorities 
aligned with priorities identified by health consumers. Nine priority research questions were 
identified, consisting of second line management including levetiracetam (efficacy, dose and 
timing), use of third line agents, induction of anaesthesia (timing and best agent), 
management of focal SE, and indicators of “subtle SE”.  Consumers priorities included 
themes of drug therapies and treatment efficacy, causes and “triggers”, and outcomes and 
prognostication.  Some of these priority areas are unlikely to be addressed in clinical trials 
with traditional concepts of informed consent, and other methods may be more appropriate 
including alternative study designs and alternative approaches to consent.   
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Highlighting the paradox of informed consent in emergency management of paediatric SE, 
some of the priorities identified have already been incorporated into clinical care.  For 
example, intravenous levetiracetam has been increasingly recommended and used “off 
label” in EDs or incorporated into guidelines despite no high-level evidence in adults or 
children.204 Similarly, no studies are available to guide clinicians on anaesthetic induction 
agents, and well-meaning clinicians facing this clinical situation choose agents on nothing 
more than speculation, and loose theoretical considerations.  Given the infrequency of this 
scenario, study designs other than traditional RCTs may be more appropriate.  These may 
include cluster RCTs, quality observational studies or studies that access data from 
registries or electronic medical records, so called “learning health systems” or potentially 
registry randomised controlled trials (RRCT).  
 
It could be argued that the ethical and consent requirements for comparative effectiveness 
research, where two “standard therapies” exist should not be as stringent as for truly 
experimental research.  Recently, in adult emergency medicine, elegant research designs 
incorporated into clinical care where genuine equipoise has existed for decades, and large 
adequately powered clinical trials, have addressed important clinical questions without 
individual patient consent.  These include investigating the most appropriate crystalloids in 
sepsis,205 and oxygen administration in high-risk acute coronary syndromes.156 For example 
a recent large single centre trial in the US was conducted without individual patient consent, 
instead allocating patients intravenous fluid (balanced solutions versus normal saline) 
alternating between interventions according to the calendar month.205  This important trial 
demonstrated significant differences between the two commonly used and previously 
interchangeable fluids in terms of serious morbidity and mortality.205  Such a definitive trial 
has not previously been possible with conventional trial design and consent approaches.  
These designs have incorporated a randomisation process into a registry, so called RRCT.  
Although this design has methodological drawbacks compared to individual patient 
allocation, the benefits probably outweigh the downsides in acute care and emergency 
medicine where there are considerable competing priorities. These designs enrol patients to 
a specific intervention, without prospective informed consent.  Ethically and from the 
patient’s perspective, there is little difference to enrolling participants into an individually 
allocated RCT without prospective informed consent if this is logistically feasible in a given 
circumstance. In developing a programme of research to improve outcomes in paediatric 
SE, including research without prospective informed consent, it is imperative to assess the 
acceptability of these designs to the public to maintain the trust of the community.    
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A protocol for a clinical trial of second line management of paediatric SE was outlined in 
Chapter 5, the ConSEPT trial.  The study directly addressed two of the nine priorities 
identified in the Delphi process, being efficacy and dose of levetiracetam.  The trial seeks to 
determine if levetiracetam is a better second line agent than the current standard care of 
phenytoin.  The trial is urgently needed.  The situation with levetiracetam epitomises the 
paradox of informed consent in paediatric SE research. The drug is being rapidly adopted 
into practice by well-meaning clinicians without evidence (or informed consent), because of 
presumed advantages over the current standard care.204  For many clinicians, the 
compulsion to use the new drug levetiracetam has proved too strong to resist.  Although not 
the intention of the study design, the trial may also inform whether administration of a drug 
as a “third line” agent is a safe and effective strategy, rather than escalating to anaesthetic 
agents and intubation, as the protocol allows for cross over between agents as a treatment 
option at the clinician’s discretion.  Use of third line agents was also a priority identified by 
the Delphi process and as with anaesthetic or induction agents is unlikely to be addressed in 
clinical trials due to the infrequency of reaching this stage in the algorithm.  Results of this 
pivotal trial are keenly anticipated worldwide and are likely to have a profound and 
immediate influence on protocols for the management of this condition.   
 
A controversial aspect of the design of the ConSEPT trial was the “deferred consent” 
process.  Such a consent procedure has not previously been used in a major multicentre 
clinical paediatric trial in Australia and New Zealand.  Evaluation of this strategy and 
ensuring this was acceptable and within community standards was an important 
consideration when planning the trial. Chapters 6 to 9 of this thesis present the results of 
work conducted to determine acceptability of this approach. The protocol outlines the ethical 
justification for this consent process, which while allowable under current guidelines, and 
approved by several ethics committees, is being variably implemented at different sites. The 
NHMRC are aware of the limitations of the current guidance provided in the national 
statement, and the resultant confusion and inconsistency with implementation, and are 
currently reviewing the document with a stakeholder consultation process.  Empirical 
research into alternatives to informed consent is lacking in the Australian setting. Chapters 7 
to 9 address this knowledge gap and contribute valuable evidence to inform this issue.  
Ensuring a robust and consistent approach to consent requirements for clinical research is 
vital in ensuring that children with acute and life-threatening conditions receive evidence-
based care.  
 
Chapter 6 presents the background of the paradox of informed consent in emergency 
medicine research and presents some of the historical context including the Nuremburg 
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code and the Declaration of Helsinki.34  The historically inconsistent approach to consent in 
emergency research is illustrated by the cardiac “mega-trials” in one of the most researched 
areas of emergency medicine.178  A synopsis of this chapter was published as a perspective 
piece in Emergency Medicine Australasia, the journal of the Australasian College of 
Emergency Medicine.  The article was designed to stimulate debate and discussion among 
clinicians and researchers on the unique challenges of emergency medicine research, and 
the specific need to address research where informed consent is not possible when 
developing guidelines for research ethics committees.  
 
To gain a global perspective on issues of informed consent in paediatric emergency 
research, Chapter 7 detailed a systematic review of empirical evidence in this setting. The 
thirteen studies included in the review were generally supportive of the process with limiting 
risk and informing parents as soon as possible important considerations.  The lack of 
Australian studies was notable and clearly local data are urgently required.  
 
The requirement for informed consent in research was designed to protect participants from 
harm.34 However, internationally, and particularly in the US, consent processes are instead 
focused on protecting researchers from litigation.184 Seeking prospective informed consent in 
many circumstances may paradoxically lead to increased harm, associated with delays in 
treatment.176,177 Waivers of consent, delayed or retrospective consent have been utilised 
infrequently in paediatric emergency care research in Australia. The ethical issues when 
children are involved are more complex than when contemplating similar research in adults, 
as children are generally not viewed as able to understand the altruistic importance and 
societal benefits associated with involvement in medical research.  Consequently, chapter 8 
presented the results of a national, cross sectional, population-based survey of community 
attitudes on views about research without prospective informed consent, with quantitative 
and qualitative components.  This novel research demonstrated, for the first time in an 
Australian setting that the public are generally supportive of emergency research without 
prospective consent, although the degree of risk and time-critical nature of the intervention 
were identified as important considerations.  Importantly, attitudes of participants were 
similar when considering both adult and paediatric research, implying similar standards 
should apply, and providing important empirical evidence relevant to policy makers and 
revision of guidance documents.  
 
In chapter 9, the results of novel Australian research on attitudes and experiences of parents 
attending the ED with their children on the concepts of deferred or retrospective consent 
were presented.  The qualitative study included interviews with 39 parents and found 
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universal support for research in this setting.  As with consent for management in 
emergency situations, parents acknowledged the limitations of consent for research in time-
critical conditions such as paediatric SE and recognised the requirement for strategies such 
as deferred or retrospective consent.  Strong themes of trust in the medical profession 
emerged from the interviews.  Health and research literacy was identified as an important 
issue, possibly leading to confusion with difficult concepts. The methodology allowed greater 
exploration of ideas and clarification of relevant issues.  The data provided valuable insights 
for the design of future randomised controlled trials in this setting.  
 
10.4 Implications for practice, policy and research 
In the current era of evidence-based medicine, it is not satisfactory for the management of 
children with SE or other acute and time-critical conditions to be based on inadequate 
evidence, tradition or extrapolated from other settings. Alternatives to traditional concepts of 
informed consent and a consistent approach from ethics committees and guidance 
documents to encourage research in these important areas are required.  In comparative 
effectiveness research, where two truly comparable and acceptable treatment strategies 
exist, signifying true equipoise, the paradox of informed consent for research and clinical 
care must be addressed.  It should not be acceptable to use untested or experimental 
therapies for clinical care without consent, when research and evaluation of the same 
therapies is burdened by regulations and administrative and ethical requirements.   
 
Advances in technology including integrated health information systems and electronic 
medical records may present an elegant solution to this paradox.  These systems are now 
commonplace, and these innovations provide an excellent opportunity to embed data 
collection on infrequent presentations into routine data capture for clinical care, thereby 
enabling critical questions to be addressed more easily than has been possible previously.  
The level of evidence yielded would however fall short of what many consider to be the gold 
standard in evidence-based medicine, the RCT. Consequently, the evidence may not be 
sufficient to change the practice of some clinicians, although clearly representing a 
significant advance on the current situation.   
 
An extension of such routine data capture or registries is the embedding of treatment 
allocation into registries, so called RRCT.  The contention is that if true equipoise exists 
between two treatments for a given clinical situation, allocation can be embedded into these 
systems, producing the highest level of evidence, without exposing participants to any 
additional risk than what they would receive with “standard clinical care”, and in a very 
efficient manner.  This is crucial. A recurrent theme in the research presented in this thesis is 
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that the “level of risk” is the main concern for potential participants regarding the 
acceptability of research without prior consent.  This needs to be recognised as a priority, 
and ethical and legislative obstacles should be removed to facilitate this advance, and the 
potential to improve patient outcomes, whilst always protecting patient privacy and 
confidentiality.  
 
A Delphi process involving experts including emergency physicians and paediatric 
neurologists identified research priorities in paediatric SE. The robust methodology will 
provide support for future research funding applications, and involvement of a representative 
group of stakeholders should not only facilitate the research conduct, but also ensure results 
are rapidly translated into practice.  Funding bodies and human research ethics committees 
increasingly require methodologically sound community consultation about the acceptability 
of research to ensure it is consistent with societal standards and expectations.  Involvement 
of consumers in the Delphi process strengthens the findings of the study.  In this way, this 
research has paved the way for a comprehensive approach to improving the management 
and outcomes of children with SE utilising multiple methodologies.   
 
Several of the research priorities identified are unlikely to be addressed in adequately 
powered, traditional RCTs.  These include third line agents, and anaesthetic agents, which 
are used further down the algorithm when other treatments are ineffective.  Observational 
designs using routine data capture and so called “learning health systems” provide an 
excellent opportunity to standardise care and affect outcomes in this group.  Governments in 
advanced public health systems should fund such activities, which should become standard 
practice in health systems such as ours.  The possibility of RRCT, integrating clinical trials 
into these platforms, exists in the future.  The integration of research into clinical care may 
lead to increased awareness of the importance of acute and critical care research, with the 
flow on effects of increased research literacy in the community. 
 
This research demonstrates that the public recognises the requirement for emergency 
research where prior informed consent is not possible, and generally support this type of 
research with the degree of risk and being informed as soon as is practical. In Australia, a 
national approach to conducting emergency research is challenging because informed 
consent requirements vary according to jurisdiction, and current guidelines are unclear and 
variably interpreted.  Such a situation is itself unethical as it may affect the scientific validity 
of the research, with selection bias or delays to receiving interventions affecting efficacy, 
resulting in studies less likely to show benefit.  This must be addressed as a priority in the 
form of clear and transparent guidance by the NHMRC, in explicitly outlining the 
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requirements for research without prospective informed consent, and by aligning various 
state guardianship laws, ensuring that legal barriers to such research are removed. The 
NHMRC has recognised the need for greater clarity in this domain, and requested feedback 
on a document on research without consent. This thesis can ensure that the views of the 
public will contribute to this discussion and result in greater participation of emergency 
patients in research, improving the quality of care in time-critical illness.   
 
10.5 Strengths of the research 
The research presented in this thesis has many strengths, which have been highlighted in 
individual chapters and publications throughout the thesis.  Firstly, the research addresses 
an important clinical issue.  Paediatric SE is the most common emergency neurological 
condition in children.  Although presentations to individual emergency departments remain 
relatively infrequent, nationally it represents a considerable burden of disease, and is 
associated with morbidity and occasional mortality. It is a source of considerable anxiety and 
stress for clinicians and families, which has resource implications for health services.  While 
the research focussed on paediatric SE, the themes and issues of informed consent are 
directly transferable to other paediatric emergencies and time-critical research.  Multiple 
methodologies, including both qualitative and quantitative techniques, were actively chosen 
to explore greater depth and breadth of insights in relevant consumers (clinicians and 
parents) concerning research without prospective informed consent. This was novel 
research that has not been reported in an Australian population previously.  
 
Prior research in paediatric SE has been dominated by neurologists and intensive care 
physicians. A further strength of this thesis, is that this work was designed and conducted by 
an emergency physician, facilitating a unique perspective of front-line clinicians involved in 
acute care decisions. This aspect and involvement of emergency physicians in identifying 
research priorities is a unique and compelling aspect of the research.   
 
10.6 Limitations of the research 
The limitations of the individual studies that comprised this programme of work have been 
discussed in detail in the individual chapters throughout the thesis. Salient limitations are 
briefly summarised here.  
 
Chapter 2 (the literature review on the epidemiology, investigation and management of 
paediatric SE) was not a comprehensive systematic review.  Although recognised and 
methodologically sound techniques were used to identify relevant literature, the additional 
requirements of a comprehensive systematic review were not undertaken. This was 
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intentional – the subject has previously been extensively reviewed, and there was a well-
documented lack of original data on this topic. Hence a further systematic review was not 
expected to add anything meaningful to the evidence base but was important to include in 
this thesis to provide context. Hence, a traditional narrative approach was used. The 
additional (published) literature review on pre-hospital aspects was conducted to highlight 
the potential for advances in that space. For all published literature reviews, an 
acknowledged potential limitation, is publication bias, and inclusion of articles published in 
the English language.  
 
In chapter 4, the Delphi study, without a recognised gold standard of consensus, and various 
definitions used previously in health research, pragmatic decisions were made.  Further, 
only the single round was conducted for consumers. While the input of this group was 
considered highly important, this group were not considered “experts”, with variable health 
literacy. Achieving consensus among this group was not thought to be achievable or of 
additional value.  
 
In both chapter 8 (the national population-based survey) and chapter 9 (the qualitative study 
of deferred consent), hypothetical patients and scenarios were used, rather than parents of 
children who had actually been involved with interventional research.  The inclusion of these 
hypothetical cases allowed the data to be available sooner, to assist with planning of future 
and subsequent trials. Participants in the qualitative study (chapter 9) were parents of sick 
children who had recently presented at an ED, to enable contextualisation of the feelings of 
anxiety and vulnerability associated with such visits. However, it is acknowledged that 
exploration of the perspectives of parents of children exposed to such research may provide 
additional useful insights.  
 
Other biases already mentioned in the relevant section of the thesis include selection bias 
(chapter 4, chapter 8), and measurement bias (chapter 8, chapter 9). It is acknowledged that 
the findings presented here should be interpreted in the context of these limitations.  
 
11.7 Conclusion 
Paediatric SE remains an important clinical issue, resulting in significant morbidity and rarely 
mortality.  Care is often not evidence based, and unproven therapies are introduced into 
standard care and guidelines.  Paradoxically, quality research is often thwarted due in part to 
ethical complexities, including the inability to obtain prospective informed consent in time-
critical situations.  The solution to this issue is itself not straightforward but is achievable.   
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This thesis has utilised multiple methodologies to identify knowledge gaps and achieve 
consensus among key stakeholders on research priorities for paediatric SE and provided 
important novel insights into the community’s expectations around the requirement for 
prospective informed consent in such situations.  Future research in paediatric SE must 
utilise this information. It is crucial that clinical questions are addressed with quality study 
designs.  A combination of strategies is necessary which could involve observational data 
based on routinely collected registry data or as part of learning health systems for infrequent 
situations such as third line agents and anaesthetic agents, and for preliminary data for 
planning of RCTs.  The continued evolution and refinement of the concept of RRCTs has 
been an important recent innovation, and poses exciting prospects for addressing less 
frequent presentations, where clinical equipoise between two comparable treatment 
alternatives exists.  Alternatives to prospective consent are required to perform high quality 
RCTs, to provide high level, definitive evidence for important clinical questions such as 
second line drugs for managing paediatric SE.  Consent requirements for comparative 
effectiveness research, when true equipoise exists, should be reviewed, with data capture 
integrated into electronic health records and data collection systems.  To enable this vision 
to move forward, policy and ethical and legal guidance must recognise the value of this data 
to society.  Community debate about this issue would encourage higher research literacy 
among the general public.  Maintaining the trust of the public is vital in ensuring the research 
is within community expectations and is the key to achieving this objective.   
 
An important insight from the work presented was the trust in the medical profession.  While 
this was both pleasing and reassuring, the premise underlying this trust seems to include 
that the physician “will do what is in the best interests of the patient”.  This however, belies 
the fact that often we simply do not have high quality evidence for many of the interventions 
that are commonly employed in acute care and emergency medicine, and the optimal 
therapeutic approach is often speculative and left to the whims and preferences of individual 
clinicians.  The medical profession traditionally does not publicise uncertainty, presumably 
for fear of undermining the public’s trust.  Yet, greater transparency with the public about the 
paucity of high-quality evidence in emergency medicine may lead to increased support for 
emergency care research, with improvements in health and research literacy of the 
community.  This may facilitate and encourage research in this important area.   
 
The acceptance of emergency care without consent is well documented, and legal 
protections are in place for clinicians.  In situations where there is clinical equipoise, and 
clear evidence does not exist, a compelling ethical argument can be made that similar 
standards should be applied to research.  The paradox of the apparent community 
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acceptance of unproved interventions for clinical care, compared with the relative protections 
offered under the oversight of a quality randomised controlled trial are difficult to defend, and 
the data presented in this thesis does not seem to indicate that the general public make a 
distinction, providing that there is no exposure to additional risk. 
 
Research in the field of paediatric status epilepticus is inextricably linked to issues of 
informed consent in emergency and time-critical research.  This research represents an 
important first step in the design of a program of research on paediatric SE to address these 
important clinical issues, in an ethical manner that will be acceptable to the community. A 
combination of real time registry, learning health systems, and innovative clinical trial 
designs is required, with consent requirements that are appropriate for the level of risk to 
participants, and congruent with community expectations.   
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Appendices 
 
1.1 Supplementary Appendix – List of aetiologies that may cause status epilepticus 
 
 
 
1 Cerebrovascular diseases 
a Ischemic stroke 
b Intracerebral bleeding 
c Subarachnoid bleeding 
d Subdural hematoma 
e Epidural hematoma 
f Sinus venous thrombosis and cortical venous thrombosis 
g Posterior reversible leukoencephalopathy syndrome 
h Vascular dementia 
2 CNS infections 
a Acute bacterial meningitis 
b Chronic bacterial meningitis 
c Acute viral encephalitis (including Japanese B 
encephalitis, herpes simplex encephalitis, human 
herpesvirus 6) 
d Progressive multifocal leukoencephalopathy (PML) 
e Cerebral toxoplasmosis 
f Tuberculosis 
g Neurocysticercosis 
h Cerebral malaria 
i Atypical bacterial infections 
j HIV-related diseases 
k Prion diseases (Creutzfeldt-Jakob disease, CJD) 
l Protozoal infections 
m Fungal diseases 
n Subacute sclerosing panencephalitis 
o Progressive Rubella encephalitis 
3 Neurodegenerative diseases 
a Alzheimer’s disease 
b Corticobasal degeneration 
c Frontotemporal dementia 
4 Intracranial tumors 
a Glial tumors 
b Meningioma 
c Metastases 
d Lymphoma 
e Meningeosis neoplastica 
f Ependymoma 
g Primitive neuroectodermal tumor (PNET) 
5 Cortical dysplasias 
a Focal cortical dysplasia (FCD) II, tuberous sclerosis 
complex (TSC), hemimegalencephaly, hemihemimegalencephaly 
b Ganglioglioma, gangliocytoma, dysembryoplastic 
neuroepithelial tumor (DNET) 
c Periventricular nodular heterotopia (PNH) and other 
nodular heterotopias 
d Subcortical band heterotopia spectrum 
e Lissencephaly 
f Familial and sporadic polymicrogyria 
g Familial and sporadic schizencephaly 
h Infratentorial malformations (e.g., dentate dysplasia, 
mamillary dysplasia, etc.) 
 6 Head trauma 
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a Closed head injury 
b Open head injury 
c Penetrating head injury 
 7 Alcohol related 
a Intoxication 
b Alcohol withdrawal 
c Late alcohol encephalopathy with seizures 
d Wernicke encephalopathy 
 8 Intoxication 
a Drugs 
b Neurotoxins 
c Heavy metals 
 9 Withdrawal of or low levels of antiepileptic drugs 
 10 Cerebral hypoxia or anoxia 
 11 Metabolic disturbances (e.g., electrolyte imbalances, 
glucose imbalance, organ failure, acidosis, renal failure, 
hepatic encephalopathy, radiation encephalopathy, etc.) 
 12 Autoimmune disorders causing SE 
a Multiple sclerosis 
b Paraneoplastic encephalitis 
c Hashimoto’s encephalopathy 
d Anti-NMDA (N-methyl-D-aspartate) receptor encephalitis 
e Anti–voltage–gated potassium channel receptor 
encephalitis (including anti–leucine–rich glioma 
inactivated 1 encephalitis) 
f Anti-glutamic acid decarboxylase antibody associated 
encephalitis 
g Anti–alpha–amino–3–hydroxy–5–methylisoxazole– 
4–propionic acid receptor encephalitis 
h Seronegative autoimmune encephalitis 
i Rasmussen encephalitis 
j Cerebral lupus (systemic lupus erythematosus) 
k CREST (calcinosis, Raynaud phenomenon, esophageal 
dysmotility, sclerodactyly, telangiectasia) syndrome 
l Adult-onset Still’s disease 
m Goodpasture syndrome 
n Thrombotic thrombocytopenic purpura (Moschcowitz 
syndrome, Henoch Sch€onlein purpura) 
 13 Mitochondrial diseases causing SE 
a Alpers disease 
b Mitochondrial encephalopathy, lactic acidosis, and 
stroke-like episodes (MELAS) 
c Leigh syndrome 
d Myoclonic encephalopathy with ragged red fibers 
(MERRF) 
e Neuropathy, ataxia, and retinitis pigmentosa (NARP) 
14  Chromosomal aberrations and genetic anomalies 
a Ring chromosome 20 
b Angelman syndrome 
c Wolf-Hirshhorn syndrome 
d Fragile X syndrome 
e X-linked mental retardation syndrome 
f Ring chromosome 17 
g Rett syndrome 
h Down syndrome (trisomy 21) 
15  Neurocutaneous syndromes 
a Sturge-Weber syndrome 
16  Metabolic disorders 
a Porphyria 
b Menkes disease 
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c Wilson disease 
d Adrenoleukodystrophy 
e Alexander disease 
f Cobalamin C/D deficiency 
g Ornithine transcarbamylase deficiency 
h Hyperprolinemia 
i Maple syrup urine disease 
j 3-Methylcrotonyl Coenzyme A carboxylase deficiency 
k Lysinuric protein intolerance 
l Hydroxyglutaric aciduria 
m Metachromatic leukodystrophy 
n Neuronal ceroid lipofuscinosis (types I, II, III, 
including Kufs disease) 
o Lafora disease 
p Unverricht-Lundborg disease 
q Sialidosis (type I and II) 
r Morbus Gaucher 
s Beta ureidopropionase deficiency 
t 3-Hydroxyacyl CoenzymeAdehydrogenase deficiency 
u Carnitine palmitoyltransferase deficiency 
v Succinic semialdehyde dehydrogenase deficiency 
17  Others 
a Familial hemiplegic migraine 
b Infantile onset spinocerebellar ataxia (SCA) 
c Wrinkly skin syndrome 
d Neurocutaneous melanomatosis 
e Neuroserpin mutation 
f Wolfram syndrome 
g Autosomal recessive hyperekplexia 
h Cockayne syndrome 
i Cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) 
j Robinow syndrome 
k Malignant hyperpyrexia 
l Juvenile Huntington’ s disease (Westphal variant) 
 
1  
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1.2 Supplementary Appendix: Communiqué - Research involving patients who are 
unable to give consent 2017 
 
Human medical research is a complex area which involves consideration of both legal and 
ethical principles.  Any person undertaking human medical research is expected to comply 
with relevant policies and guidelines when conducting their studies, including the following: 
 
National Statement on Ethical Conduct in Human Research (National Statement) 
Queensland Health Research Ethics and Governance Health Service Directive and Research 
Management Policy 
Queensland Health’s Guide to Informed Decision-making in Healthcare 
 
It is essential that anyone conducting research involving humans obtains informed consent 
from the patient (or authorised substitute decision-maker) before enrolling that patient in a 
research study.  However, in specific circumstances, Human Research Ethics Committees 
(HREC) can grant a waiver of the requirement for patient consent to use the patient’s personal 
information, including personal health information, in research, including medical research.  
The conditions associated with granting a waiver are strict and advice should always be sought 
from the HREC.  
 
In some studies where a waiver has been granted, researchers may inform study participants 
or their substitute decision-makers about the study after the patient has been enrolled in the 
study.  Some researchers have incorrectly referred to this practice as obtaining ‘deferred’ or 
‘delayed’ consent for participation in the research study. 
 
The concepts of ‘deferred’ or ‘delayed’ consent are not supported by the National 
Statement or by Queensland Health 
 
The terms deferred or delayed consent are confusing.  They do not exist in the National 
Statement and do not constitute any form of consent. This is because it is not possible to 
obtain a person's consent to something after that thing has already happened. Accordingly, 
the concepts of deferred or delayed consent are not recognised or supported by Queensland 
Health, and Queensland Health requires that the terms must not be used by researchers or 
HRECs operating in Queensland Health. 
 
Waiver of consent for research using personal information in medical research or 
personal health information 
 
When an HREC grants a waiver of the requirement for patient consent to participate in a 
research study, research participants will characteristically not know that they, or perhaps their 
tissue or data, are involved in the research.  Once enrolled, researchers may inform the patient 
or substitute decision-maker about the inclusion of the patient in the research, but they would 
not be required to obtain consent at any stage.  
 
Where an HREC has waived the requirement for researchers to obtain a patient’s consent to 
be enrolled in a study, this does not mean that legal requirements regarding obtaining a 
patient’s informed consent to treatment have been waived. Regardless of whether a waiver 
has been granted from a research perspective, treating health practitioners must always 
discharge their legal duties to the patient, which include: 
 
to provide treatment only when a patient (or a substitute decision-maker) consents to that 
treatment, or where consent is not required (such as in an emergency situation); 
to warn patients of the material risks attaching to the treatment; and 
to exercise reasonable skill and care in the provision of services, including examination, 
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diagnosis and treatment. 
 
Patients who require medical care who may be unable to give consent 
 
When neither the potential research participant nor an authorised substitute decision-maker 
can consider the research proposal and give consent, such as in an emergency setting, an 
HREC may, having taken account of relevant jurisdictional laws, approve a research project 
without consent if the requirements of clause 4.4.13 of the National Statement are satisfied.  
If these requirements are satisfied, it may be open for health practitioners to decide (using 
reasonable professional judgement in the circumstances) to enrol a patient into a clinical 
research study, including research conducted in an emergency setting, without the patient’s 
(or a substitute decision-maker’s) consent to participate.  However, it is Queensland Health 
policy that this may only occur where: 
 
experimental treatments are not being tested as part of the research study; and 
the health practitioner has satisfied their legal duties to the patient, which includes having 
exercised reasonable skill and care in the provision of the treatments being studied. 
 
If the study involves researching, for example, the effectiveness of specific, randomly assigned 
clinical interventions, the study must involve an intervention where there is genuine uncertainty 
in the expert medical community over whether a treatment will be beneficial. If it is not known 
whether an intervention is effective, then it is Queensland Health policy that consent of the 
patient (or authorised substitute decision-maker) must be obtained. 
 
More information 
For more information, please contact the Health Innovation, Investment and Research 
Office, Department of Health on 3199 2973. 
 
National Health and Medical Research Council, National Statement on Ethical Conduct in 
Human Research 2007 (May 2015) < HYPERLINK 
"https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72_national_statement_
may_2015_150514_a.pdf" 
https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72_national_statement_
may_2015_150514_a.pdf>.  
 QHEPS, Research Ethics and Governance Health Service Directive # QH-HSD-035:2016  
HYPERLINK "https://www.health.qld.gov.au/__data/assets/pdf_file/0025/494008/qh-hsd-
035.pdf" https://www.health.qld.gov.au/__data/assets/pdf_file/0025/494008/qh-hsd-035.pdf 
 QHEPS, Research Management Policy QH-POL-013:2015 (23 June 2015)  HYPERLINK 
"https://www.health.qld.gov.au/system-governance/policies-standards/doh-policy/policy/qh-
pol-013.pdf" https://www.health.qld.gov.au/system-governance/policies-standards/doh-
policy/policy/qh-pol-013.pdf.  
 QHEPS, Queensland Health Guide to Informed Decision-making in Healthcare (February 
2012) < HYPERLINK "https://www.health.qld.gov.au/consent/documents/ic-guide.pdf" 
https://www.health.qld.gov.au/consent/documents/ic-guide.pdf>.  
 For information regarding who can legally provide consent on behalf of patients who lack 
capacity to make decisions about a person’s healthcare, consult the Queensland Health 
Guide to Informed Decision-making in Healthcare, available on QHEPS here:  HYPERLINK 
"https://www.health.qld.gov.au/consent/documents/ic-guide.pdf" 
https://www.health.qld.gov.au/consent/documents/ic-guide.pdf.  
 For information regarding when it may be appropriate for an HREC to waive the 
requirement for informed consent to participate in a research study, consult clause 2.3.9 of 
the National Statement on Ethical Conduct in Human Research.  
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Just a note that, in taking this position, it means that Qld Health is determining that there is 
no way for emergency research that involves experimental treatments to take place (without 
consent of the patient). 
 
We note that this is actually consistent with the National Statement because the combination 
of paragraphs 4.4.6 – and 4.4.1 and 2.3.6 (now 2.3.10) to which it refers – creates a 
situation in which an HREC can only consider a waiver of consent if the emergency care 
research is low-risk, which experimental treatment in an emergency care research context is 
unlikely to be.  Some have argued that this outcome was not intentional and should be re-
considered. 
 
On this point, please note that NHMRC will be commencing with a full review of Section 4 of 
the National Statement in 2017. 
Preferable definitions of clinical equipoise might be: “where there is genuine uncertainty in 
the expert medical community over whether a treatment will be beneficial” or “where there is 
no decisive evidence that the intervention being tested will be superior to existing treatments 
or effective at all.” 
 
This phrasing suggests that clinical researchers would use an intervention in research that 
they already consider to be less effective than standard treatment, whereas, in reality, if they 
suspected that, they would (or should) not do the research.  Use of an intervention 
presumes that it is not known whether the intervention is as effective as or more or less 
effective than standard treatment. 
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2.1 Supplementary appendix - Medline search strategy 
 
1 epilep$.mp.  
2 seizure$.mp.  
3 convulsion$.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
4 exp Epilepsy/  
5 tonic clonic.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept 
word, unique identifier] 
6 status epilepticus.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
7 1 or 2 or 3 or 4 or 5 or 6  
8 Animals/  
9 Humans/  
10 8 not 9  
11 7 not 10  
12 (child: or adolescent or infan:).mp.  
13 11 and 12  
14 exp Emergency Medical Services/  
15 exp Military Medicine/  
16 exp Emergency Medicine/  
17 exp Emergency Treatment/  
18 exp First Aid/  
19 exp Emergency Medical Technicians/  
20 exp Ambulances/  
21 exp Air Ambulances/  
22 prehospital.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
23 pre-hospital.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
24 paramedic$.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
25 ambulance$.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
26 out of hospital.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
27 out-of-hospital.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
28 ems.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
29 emt.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
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30 emergency services.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
31 emergency medical service$.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
32 emergency technician.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
33 emergency practitioner$.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
34 emergency despatch$.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
35 first responder.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
36 public access defibrillation.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
37 emergency rescue.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
38 emergency resus$.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
39 emergency triage.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
40 advanced life support.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
41 community support co-ordinator.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
42 community support coordinator.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
43 emergency care practitioner.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
44 extended care practitioner$.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
45 physician assistant.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
46 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
47 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
48 13 and 46  
49 13 and 47  
50 limit 49 to yr="2014 -Current"  
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3.1 Supplementary appendix - Medline search strategy 
1. epilep$.mp. 
2. seizure$.mp. 
3. convulsion$.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
4. exp Epilepsy/ 
5. tonic clonic.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
6. status epilepticus.mp. [mp = title, abstract, original title, name of substance word, subject 
heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. Animals/ 
9. Humans/ 
10. 8 not 9 
11. 7 not 10 
12. (child: or adolescent or infan:).mp. 
13. 11 and 12 
14. exp Emergency Medical Services/ 
15. exp Military Medicine/ 
16. exp Emergency Medicine/ 
17. exp Emergency Treatment/ 
18. exp First Aid/ 
19. exp Emergency Medical Technicians/ 
20. exp Ambulances/ 7336 Advanced 
21. exp Air Ambulances/ 2146 Advanced 
22. prehospital.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
23. pre-hospital.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
24. paramedic$.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
25. ambulance$.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
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keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
26. out of hospital.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
27. out-of-hospital.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
28. ems.mp. [mp = title, abstract, original title, name of substance word, subject heading 
word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept 
word, 
unique identifier] 
29. emt.mp. [mp = title, abstract, original title, name of substance word, subject heading 
word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept 
word, 
unique identifier] 
30. emergency services.mp. [mp = title, abstract, original title, name of substance word, 
subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
31. emergency medical service$.mp. [mp = title, abstract, original title, name of substance 
word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
32. emergency technician.mp. [mp = title, abstract, original title, name of substance word, 
subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
33. emergency practitioner$.mp. [mp = title, abstract, original title, name of substance word, 
subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
34. emergency despatch$.mp. [mp = title, abstract, original title, name of substance word, 
subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
35. first responder.mp. [mp = title, abstract, original title, name of substance word, subject 
heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept 
word, unique identifier] 
36. public access defibrillation.mp. [mp = title, abstract, original title, name of substance 
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word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
37. emergency rescue.mp. [mp = title, abstract, original title, name of substance word, subject 
heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
38. emergency resus$.mp. [mp = title, abstract, original title, name of substance word, subject 
heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
39. emergency triage.mp. [mp = title, abstract, original title, name of substance word, subject 
heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
40. advanced life support.mp. [mp = title, abstract, original title, name of substance word, 
subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
41. community support co-ordinator.mp. [mp = title, abstract, original title, name of 
substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease 
supplementary concept word, unique identifier] 
42. community support coordinator.mp. [mp = title, abstract, original title, name of substance 
word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
43. emergency care practitioner.mp. [mp = title, abstract, original title, name of substance 
word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
44. extended care practitioner$.mp. [mp = title, abstract, original title, name of substance 
word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
45. physician assistant.mp. [mp = title, abstract, original title, name of substance word, 
subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary 
concept word, unique identifier] 
46. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
or 30 or 31 
or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
47. 13 and 46 
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4.1 Supplementary appendix (Delphi study)  
 
Table S5.1.1 Complete Delphi question rankings and scores. 
 
Question Round Two Round Three 
%  ≥ 4* Mean 
(SD) 
Median 
(IQR) 
% ≥ 4* Mean 
(SD) 
Median 
(QIR) 
1. In infants with convulsive SE, is levetiracetam superior to phenytoin (or phenobarbitone) 
for efficacy (seizure termination) and safety (adverse effects)? 
85% 5.3 
(1.1) 
5 (5-6)    
2. In children with convulsive SE, is levetiracetam superior to phenytoin for efficacy (seizure 
termination) and safety (adverse effects)? 
82% 5.5 
(1.3) 
6 (5-6)    
3. In children with convulsive SE is the early use of anaesthesia associated with more rapid 
seizure terminations, less complications and better long-term outcomes, compared to 
anticonvulsant treatment alone? 
82% 5.2 
(1.2) 
5 (5-6)    
4. In children with convulsive SE, is earlier administration of a second line agent (e.g. 
levetiracetam) more effective than standard protocols? 
74% 4.9 
(1.1) 
5 (4.25-
6) 
   
5. If EEG is not available, what are the most reliable clinical indicators of ongoing subtle SE? 73% 4.9 
(1.4) 
5 (4-6)    
6. In children with focal SE should the medical management proceed according to similar 
treatment pathways as for convulsive SE, and within the same time frames? 
72% 4.7 
(1.1) 
5 (4-5)    
7. In children with convulsive SE, what is the most appropriate dose of levetiracetam as a 
second line agent?  
68% 5.0 
(1.2) 
5 (4-6) 77% 4.9 
(1.2) 
5 (5-6) 
8. In children with convulsive SE who require intubation, what induction agent is most 
effective for seizure termination, long-term outcome and complications (e.g. ketamine, 
propofol, thipentone, other)?  
68% 4.8 
(1.1) 
5 (4-6) 81% 5.1 
(1.2) 
5 (5-6) 
9. In children with convulsive SE, Is third line medical anticonvulsant drugs compared with 
induction of anaesthesia and intubation associated with improved long-term outcomes? 
66% 4.9 
(1.2) 
5 (4-6) 81% 5.1 
(1.0) 
5 (5-
5.75) 
10. In children with recurrent convulsive SE, is home treatment with benzodiazepines 
associated less escalation of care? 
66% 4.9 
(1.3) 
5 (4-6) 60% 4.6 
(1.4) 
5 (3.25-
6) 
11. In children with convulsive SE, is seizure duration a predictor of long-term outcome 
independent of aetiology? 
65% 4.7 
(1.3) 
5 (4-5) 68% 4.7 
(1.3) 
5 (4-
5.75) 
12. In children with convulsive SE treated with benzodiazepines at home, how common is 
respiratory depression? 
63% 4.7 
(1.5) 
5 (4-6) 48% 4.3 
(1.4) 
4 (3-5) 
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13. In children with non-convulsive SE should the medical management proceed according to 
similar treatment pathways as for convulsive SE, and within the same time frames? 
61% 4.7 
(1.3) 
5 (4-
5.5) 
58% 4.2 
(1.5) 
5 (3-5) 
14. In children with convulsive SE after two doses of benzodiazepines, is pre-hospital 
administration of levetiracetam superior to phenytoin or levetiracetam administered in the 
emergency department (ED) to achieve termination of seizure? 
61% 4.5 
(1.4) 
5 (4-5) 56% 4.5 
(1.2) 
5 (4-5) 
15. Is recognition of subtle SE or non-convulsive SE in the ED associated with improved 
outcomes in children with SE? 
59% 4.7 
(1.2) 
5 (4-5) 60% 4.6 
(1.3) 
5 (4-5) 
16. In children with convulsive SE treated in the pre-hospital setting, what is the most 
effective benzodiazepine to achieve seizure termination? 
59% 4.6 
(1.4) 
5 (4-6) 37% 4.0 
(1.3) 
4 (3-5) 
17. In infants with convulsive SE, is phenobarbitone superior to phenytoin for efficacy 
(seizure termination) and safety (adverse effects)? 
55% 4.7 
(1.1) 
5 (4-5) 42% 4.3 
(1.5) 
4 (3-5) 
18. In children with convulsive SE, does access to EEG in the ED change decision-making 
and improve outcomes? 
54% 4.6 
(1.5) 
5 (4-6) 54% 4.4 
(1.4) 
5 (4-5) 
19. In children with convulsive SE, what factors are associated with a delay to administration 
of a second line agent? 
53% 4.7 
(1.2) 
5 (4-
5.75) 
55% 4.5 
(1.3) 
5 (4-5) 
20. In children with convulsive SE, is sodium valproate superior to phenytoin for efficacy 
(seizure termination) and safety (adverse effects)? 
53% 4.5 
(1.4) 
5 (4-5) 42% 4.2 
(1.5) 
4 (4-5) 
21. In children with convulsive SE, is the utility of MRI superior to CT in the acute setting for 
accurate diagnosis and prognostication? 
53% 4.3 
(1.7) 
5 (3-6) 39% 4.2 
(1.5) 
4 (3-5) 
22. In children with convulsive SE due to prolonged febrile seizure, what is the yield of 
neuroimaging in the acute setting?  
53% 4.2 
(1.6) 
5 (3-5) 47% 4.2 
(1.3) 
4 (3.25-
5) 
23. In children with prolonged febrile seizures, should the medical management proceed 
according to similar treatment pathways as for convulsive SE, and within the same time 
frames? 
50% 4.6 
(1.3) 
5 (4-6)    
24. In children with convulsive SE who fail to recover fully between seizures, what time 
needs to elapse, before a third dose of benzodiazepine is appropriate, without the risk of 
respiratory depression? 
47% 4.3 
(1.4) 
4 (3.25-
5) 
   
25. In children with convulsive SE is iv lorazepam superior to iv midazolam for efficacy 
(seizure termination) and safety (adverse effects)? 
46% 4.1 
(1.4) 
4 (3-5)    
26. In children with convulsive SE and a fever, does treatment with IV paracetamol, shorten 
the time to termination of seizure? 
42% 4.3 
(1.3) 
4 (4-5)    
27. In children presenting with presumed convulsive SE, does early Neurologist review 
(either in person or through review of transmitted video of the SE features) improve diagnosis 
of the form of SE, management of the SE and outcome? 
41% 4.2 
(1.4) 
4 (3-5)    
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28. In children with suspected pseudoseizures, what is the best way to confirm the diagnosis, 
without the need to escalate management? 
41% 4.2 
(1.4)  
4 (3-5)    
29. In children with convulsive SE, is there a role for the use of ketamine in the non-intubated 
patient? 
38% 4.2 
(1.1) 
4 (4-5)    
30. In children with convulsive SE treated at home, is IM midazolam more effective than IN / 
buccal administration for seizure termination? 
38% 3.9 
(1.4) 
4 (3-5)    
31. In children with convulsive SE, is IM fosphenytoin as effective to IV phenytoin for 
seizure termination? 
37% 3.8 
(1.4) 
4 (3-5)    
32. In children with convulsive SE, Is there utility in end tidal CO2 as a predictor of the need 
for induction of anaesthesia and intubation? 
32% 4.0 
(1.3) 
4 (3.25-
5) 
   
33. Is failure to achieve IV access, associated with delay in second line drug administration? 32% 3.8 
(1.5) 
4 (3-5)    
34. In children with convulsive SE, are doses of benzodiazepines outside of published 
guidelines associated with better or worse outcomes, than children who are managed within 
current guidelines. 
28% 3.9 
(1.3) 
4 (3-5)    
35. In children with convulsive SE, is there a role for the use of propofol in the non-intubated 
patient? 
24% 4.0 
(1.0) 
4 (4-4)    
36. In children with convulsive SE, does the use of steroids decrease the rate of long-term 
complications? 
19% 3.9 
(1.1) 
4 (3-4)    
37. In children with convulsive SE, does paradehyde still have a place in the management 
algorithm?  
18% 3.5 
(1.8) 
4 (3-4)    
*Denotes proportion of respondents who ranked question fairly high priority (4 on scale) or higher. SD standard deviation.  
 denotes questions achieving consensus high 
priority 
 denotes questions that did not reach 
consensus (or intermediate priority). 
 denotes consensus low priority 
 
 Table S5.1.2 Expert text comments on consensus High Priority questions in round 2 and 3.  
 
1. In infants with convulsive SE, is levetiracetam superior to phenytoin (or phenobarbitone) for 
efficacy (seizure termination) and safety (adverse effects)? 
“Three arm study feasible? PHT, PB, LEV” 
“PHB is now known to be very toxic for infant brains and this study therefore has ethical 
concerns” 
“in neonates this is an important question” 
“Use of phenobarbitone is generally unethical given the impact on development/cognition and is 
therefore avoided” 
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2. In children with convulsive SE, is levetiracetam superior to phenytoin for efficacy (seizure 
termination) and safety (adverse effects)? 
“Practice currently ahead of evidence which always concerns me” 
“Currently being undertaken in at least three countries. May need post marketing surveillance for 
true safety data” 
“Important, but happening now” 
“Current study needs completing before new one is planned” 
“Levetiracetam is rapidly becoming the standard second line agent in the absence of independent 
studies supporting this in either adults or children” 
3. In children with convulsive SE is the early use of anaesthesia associated with more rapid 
seizure terminations, less complications and better long-term outcomes, compared to 
anticonvulsant treatment alone? 
“Would be important to clarify RSI agents and on-going sedatives/antiepileptics (e.g. midaz 
infusion) used” 
“this is concerning as a question and unethical” 
“Trend to use anaesthesia without EEG and without understanding the consequences” 
“increased aggressive treatment earlier may result in over treatment of many children” 
“unlikely to get ethics approval” 
“Noting that some participants considered this an unethical question, it should be mentioned that 
there is a heterogeneity in practice and some vocal individuals promote intubation at 15 minutes, 
while others are extremely reluctant to intubate.  So with such polarised opinion clearly this 
question is ethical and important.” 
4. In children with convulsive SE, is earlier administration of a second line agent (e.g. 
levetiracetam) more effective than standard protocols? 
“would be interesting to know if should be given earlier if already had a prolonged period of SE 
prehospital” 
“No rigorous studies exist” 
“This could be a pre-hospital study – our ambulance service is already keen to use levetiracetam 
for SE” 
“Levetiracetam holds promise to be safer and more practical than PHT” 
5. If EEG is not available, what are the most reliable clinical indicators of ongoing subtle SE? 
“There are no reliable clinical indicators, even for a neurologist” 
“EEG will probably never be widely available so this is important” 
“The utility of EEG has to be assessed prior to this PICO” 
“the rate of over diagnosis of seizures and movement disorders as CSE is high” 
“video capture of presenting seizures might be very valuable to subsequent diagnosis” 
6. In children with focal SE should the medical management proceed according to similar 
treatment pathways as for convulsive SE, and within the same time frames? 
“Focal seizures are potentially more injurious than generalised ones” 
“most focal seizures you will be targeting will tend to settle or secondarily generalise anyway” 
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“will include a heterogeneous group” 
“Often focal SE may be associated with nasty underlying causes” 
“important to be incorporated into guidelines, as there is an ongoing belief in some places that 
focal seizures don’t matter” 
7. In children with convulsive SE, what is the most appropriate dose of levetiracetam as a second 
line agent? 
“wide safety range. Neurology tends to use lower doses than ED” 
“current trials should help answer that question” 
“20 mg/kg” 
8. In children with convulsive SE who require intubation, what induction agent is most effective 
for seizure termination, long-term outcome and complications (e.g. ketamine, propofol, 
thiopentone, other)? 
“Anaethetists can do this bit” 
“This mandates EEG before and after intubation/induction agent.” 
9. In children with convulsive SE, Is third line medical anticonvulsant drugs compared with 
induction of anaesthesia and intubation associated with improved long-term outcomes? 
“Multicentre observational study/retrospective study in first instance may be of interest” 
“Rigorous studies are not available for this PICO” 
“Low dose propofol for SE?” 
“Would not ketamine, which preserves the airways and is not likely to increase intubation rate due 
to dosing issues in a heterogenous population be a better agent to consider at this point?” 
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7.1 Supplementary appendix 
 
Appendix 1. Medline (Ovid) Search 
 
1.  exp Emergency Medical Services/  
2.  exp Emergency Medicine/  
3.  exp Emergency Treatment/  
4.  ems.mp.  
5.  emt.mp.  
6.  emergency services.mp.  
7.  emergency medical service$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading           word, 
protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
8.  emergency practitioner$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
9.  emergency triage.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
10.  emergency care practitioner.mp. 
11.  exp Physician Assistants/  
12.  exp Emergencies/  
13.  emergenc$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
14.  exp Resuscitation/ or exp Resuscitation Orders/  
15.  1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  
16.  Pediatrics/  
17. pediatric*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
18.  paediatric*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
19.  peadiatric*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
20.  exp Minors/  
21.  minor*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
22.  boy.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
23. boys.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
24.  boyfriend.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
25.  boyhood.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
26.  girl*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
27.  kid.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier] 
28.  kids.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
29.  child.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
30.  child*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
31.  children*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
32.  schoolchild*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
33.  school child.ab,ti.  
34.  "school child*".ab,ti.  
35.  adolescen*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
36.  juvenil*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
37.  youth*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
38.  teen*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
39.  under*age*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
40.  pubescen*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
41.  school.ab,ti.  
42.  "school*".ab,ti.  
43. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 
41 or 42 
44. exp Informed Consent/  
45.  deferred.ab,ti.  
46. delayed.ab,ti.  
47. waiver.ab,ti.  
48. exception.ab,ti.  
49. retrospective.ab,ti.  
50. alternative.ab,ti.  
51. 45 or 46 or 47 or 48 or 49 or 50  
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52. 44 and 51  
53. (deferred adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
54. (delayed adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
55. (waiver adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
56. (exception adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
57. (retrospective adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
58. (alternative adj3 consent).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
59. 53 or 54 or 55 or 56 or 57 or 58  
60. 52 or 59  
61. 15 and 43 and 60 
 
8.1 Supplementary appendix - EMA publication 
 
Consent Social Survey – Manuscript - Appendices 
 
Appendix 1.  
Informed consent in hospital emergency room research 
[READ STATEMENT IN FULL] 
The following questions are about your opinion regarding research that is undertaken in hospital emergency 
departments and the issue of consent. Before ANY research happens within an emergency department, the 
research plan is reviewed and approved by a Human Research Ethics Committee and the hospital also 
reviews the research plan and monitors the research. It is also usual to get the patient's permission to include 
them in the research - this is known as consent. However, in certain emergency situations, treatment needs 
to be started immediately with no time for discussion with the patient or their family. This type of situation 
may also involve the need for the doctor to enrol the patient in a research study before a family member can 
be found or contacted.  Examples include: patients requiring urgent treatment for severe head injury, stroke, 
and cardiac arrest.   
 
QRF1: Would you support emergency research which has been approved by an ethics committee but 
involves starting treatment before consent can be obtained?  
 
[READ OPTIONS 1-3] 
 
1. Yes, I would support this 
2. I might support this depending on the circumstances 
3. No, I would not support this 
DO NOT READ 
4. Don't know/Unsure 
5. No response 
 
If (ans=1) skp QRF2 
If (ans>2) skp QRF2 
 
QRF1b: What types of circumstances or factors would influence your decision? 
[PROBE FOR A RESPONSE - ENTER COMMENTS] 
 
[READ STATEMENT IN FULL] 
There are two main types of clinical research that occur in hospital emergency departments. The first type 
involves comparing a standard treatment that a patient would usually receive, with a newly developed 
treatment, in order to examine if the new treatment is as good as or better than the standard treatment. The 
second type involves comparing two treatments that are already used as standard practice to examine if one 
is better than the other.   
 
For the purposes of the next few questions, please imagine that you are seriously injured or unconscious, 
and you and your relatives are unable to provide consent. 
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QRF2: What type of clinical research study would be acceptable for you to be automatically included 
as a participant, without your prior consent? Remembering that the studies would have the approval 
of the hospital and ethics committee. 
  
[READ OPTIONS 1-4 IN FULL AND SELECT ONE RESPONSE] 
 
1. Any type of research study would be acceptable 
2. Only a study comparing two standard forms of treatment  
3. Only a study comparing a standard treatment with a new form of treatment 
4. None - Inclusion without consent would not be acceptable for any study 
DO NOT READ 
5. Don't know/Unsure 
6. No response 
 
QRF3: What type of clinical research study would be acceptable for YOUR CHILD to be 
automatically included as a participant, without your prior consent? (If you do not have children 
please answer hypothetically, as if you did have children). 
 
[READ OPTIONS 1-4 IN FULL AND SELECT ONE RESPONE] 
 
1. Any type of research study would be acceptable 
2. Only a study comparing two standard forms of treatment  
3. Only a study comparing a standard treatment with a new form of treatment 
4. None - Inclusion without consent would not be acceptable for any study 
DO NOT READ 
5. Don't know/Unsure 
6. No response 
 
[READ STATEMENT] 
We'd now like you to imagine that you were enrolled in a research study but you had been unable to give 
consent because of a condition such as a stroke or severe head injury. 
 
QRF4: In this situation, how important would it be to you that you are told about the study as soon as 
you were able to understand? For example, if you were unconscious and then later regained 
consciousness?  
 
[READ OPTIONS 1-4] 
 
1. Very important 
2. Important 
3. Not very important 
4. Not at all important 
DO NOT READ 
5. Don't know/Unsure 
6. No response 
 
[READ STATEMENT] 
In clinical trials it is important to include both good and bad patient outcomes in order to obtain reliable 
information about how well the treatment works. 
 
QRF5: If a patient who was part of a research study dies during their time in an emergency 
department and information about their treatment could be used in the study, do you think it would 
be acceptable to use the data without the families' consent?    
 
1. Yes 
2. No  
DO NOT READ 
3. Don't know/Unsure 
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4. No response 
 
If (ans=1) end section 
If (ans>2) end section 
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Q: QRF5b 
What do you think is the best time to approach the family in these circumstances to seek consent?  
 
1. Immediately 
2. After a suitable period of time has passed 
3. Never 
DO NOT READ 
4. Don't know/Unsure 
5. No response 
 
If (ans=1) end section 
If (ans>2) end section 
 
Q: QRF5c 
Could you describe when you think it would be most suitable?  
 
[PROBE FOR A RESPONSE - ENTER COMMENTS] 
 
Appendix 2. 
 
Table S1. Description of themes in qualitative analysis. 
 
Question: What types of circumstances or factors would influence your decision? 
(Support for research before consent) 
Theme Description 
1. Clinical factors Included qualifying statements from participants who were supportive of 
conducting emergency research without seeking prospective consent in the 
instance of a life-threatening event or in time-critical situations.  
2. Perceived Personal 
benefit 
Included statements from participants who indicated support on the 
expectation of personal benefit from research participation.  This theme also 
included statements addressing the relative risks and possible harms to 
participants.  
3. Patient factors  This theme included responses that indicated support for research without 
prospective consent, conditional on taking into consideration the patients’ 
personal beliefs, preferences and values. This included prior wishes if 
expressed, religious or cultural factors, e.g. blood product transfusions for 
Jehovah’s Witnesses.   
4. Trust in medical 
teams 
Support for research without prospective consent was associated for trust in 
medical teams, and concepts that medical judgment would protect their best 
interests.  
5. Surrogate decision 
makers (SDM) 
Included statement that highlighted the importance of SDM, and suggested that 
they should be involved in decisions if possible.   
6. Altruism Support for participation in research was associated with concepts of doing 
things for others, and for the benefit of society. 
7. Deferred consent Although the introductory stem included that consent would be sought later, 
respondents’ statements about the importance of this concept was highlighted 
by comments in this theme 
Question: In the case of a death as part of a research study, when is the best time to seek consent 
to use data already collected? 
Theme Description 
1. Depends on 
circumstances 
Responses classified in this theme related the problems with attempting to 
generalise, indicating that it would depend on many factors 
2. Time for grief This theme participants stressed the importance allowing sufficient time for 
families to grieve, prior to being approached for consent.  This was variably 
defined.   
 
